<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72034</article-id><article-id pub-id-type="doi">10.7554/eLife.72034</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-18336"><name><surname>Pohlkamp</surname><given-names>Theresa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3923-1917</contrib-id><email>ThePohlkamp@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-231237"><name><surname>Xian</surname><given-names>Xunde</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-118190"><name><surname>Wong</surname><given-names>Connie H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6452-7966</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-18337"><name><surname>Durakoglugil</surname><given-names>Murat S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4483-8166</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-245457"><name><surname>Werthmann</surname><given-names>Gordon Chandler</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-167858"><name><surname>Saido</surname><given-names>Takaomi C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-63608"><name><surname>Evers</surname><given-names>Bret M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5686-0315</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-63617"><name><surname>White</surname><given-names>Charles L</given-names><suffix>III</suffix></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3870-2804</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-231238"><name><surname>Connor</surname><given-names>Jade</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-2179"><name><surname>Hammer</surname><given-names>Robert E</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1351"><name><surname>Herz</surname><given-names>Joachim</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8506-3400</contrib-id><email>joachim.herz@utsouthwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Molecular Genetics, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Center for Translational Neurodegeneration Research</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Laboratory for Proteolytic Neuroscience, Riken Center for Brain Science</institution><addr-line><named-content content-type="city">Wako</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution>Pathology, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Biochemistry, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Neuroscience, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chin</surname><given-names>Jeannie</given-names></name><role>Reviewing Editor</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e72034</elocation-id><history><date date-type="received" iso-8601-date="2021-07-07"><day>07</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-19"><day>19</day><month>09</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-03-23"><day>23</day><month>03</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.03.22.436385"/></event></pub-history><permissions><copyright-statement>© 2021, Pohlkamp et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Pohlkamp et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72034-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72034-figures-v2.pdf"/><abstract><p>Apolipoprotein E4 (ApoE4) is the most important and prevalent risk factor for late-onset Alzheimer’s disease (AD). The isoelectric point of ApoE4 matches the pH of the early endosome (EE), causing its delayed dissociation from ApoE receptors and hence impaired endolysosomal trafficking, disruption of synaptic homeostasis, and reduced amyloid clearance. We have shown that enhancing endosomal acidification by inhibiting the EE-specific sodium-hydrogen exchanger 6 (NHE6) restores vesicular trafficking and normalizes synaptic homeostasis. Remarkably and unexpectedly, loss of NHE6 (encoded by the gene <italic>Slc9a6</italic>) in mice effectively suppressed amyloid deposition even in the absence of ApoE4, suggesting that accelerated acidification of EEs caused by the absence of NHE6 occludes the effect of ApoE on amyloid plaque formation. NHE6 suppression or inhibition may thus be a universal, ApoE-independent approach to prevent amyloid buildup in the brain. These findings suggest a novel therapeutic approach for the prevention of AD by which partial NHE6 inhibition reverses the ApoE4-induced endolysosomal trafficking defect and reduces plaque load.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ApoE</kwd><kwd>Alzheimer's</kwd><kwd>NHE6</kwd><kwd>neurodegeneration</kwd><kwd>endosome</kwd><kwd>trafficking</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL063762</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006312</institution-id><institution>BrightFocus Foundation</institution></institution-wrap></funding-source><award-id>A20135245</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>1F31AG067708-01</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Connie H</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Darrell K Royal Research Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Durakoglugil</surname><given-names>Murat S</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Harrington Discovery Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Circle of Friends Pilot Synergy</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Blue Field Project to Cure FTD</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NS093382</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NS108115</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AG053391</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006312</institution-id><institution>BrightFocus Foundation</institution></institution-wrap></funding-source><award-id>A2016396S</award-id><principal-award-recipient><name><surname>Herz</surname><given-names>Joachim</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic disruption of sodium-hydrogen exchanger 6 (NHE6) reduces amyloid plaques in humanized Alzheimer's disease mouse models and restores normal synaptic responses to neuromodulatory input in humanized ApoE4-expressing animals.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>ApoE is the principal lipid transport protein in the brain. Three different ApoE isoforms are common in humans: ApoE2 (ɛ2), ApoE3 (ɛ3), and ApoE4 (ɛ4). Each ApoE4 allele reduces the age of Alzheimer’s disease (AD) onset by approximately 3–5 years compared to ApoE3 homozygotes, which comprise ~80% of the human population (<xref ref-type="bibr" rid="bib70">Roses, 1994</xref>; <xref ref-type="bibr" rid="bib73">Sando et al., 2008</xref>). By contrast and by comparison, ApoE2 is protective against AD (<xref ref-type="bibr" rid="bib12">Corder et al., 1994</xref>; <xref ref-type="bibr" rid="bib61">Panza et al., 2000</xref>; <xref ref-type="bibr" rid="bib97">West et al., 1994</xref>). ApoE is an arginine-rich protein and a major component of very-low-density lipoproteins (<xref ref-type="bibr" rid="bib80">Shore and Shore, 1973</xref>). The number of positively charged arginine residues differs between the three human isoforms due to two single nucleotide polymorphisms in the ApoE gene. The most common isoform, ApoE3, has a charge neutral cysteine at amino acid position 112 and an arginine at position 158. The second most common isoform, ApoE4, has two arginines, while the less frequent ApoE2 has two cysteines at these respective positions. The positively charged arginines raise the net charge and thus the isoelectric point (IEP) of the protein (<xref ref-type="bibr" rid="bib18">Eto et al., 1985</xref>; <xref ref-type="bibr" rid="bib95">Warnick et al., 1979</xref>). The IEP of ApoE2 is the lowest (5.9), ApoE3 has an intermediate IEP of 6.1, and the IEP of ApoE4 is ~6.4 (<xref ref-type="bibr" rid="bib58">Ordovas et al., 1987</xref>).</p><p>For cargo delivery, ApoE binds to lipoprotein receptors and undergoes endocytosis and recycling. Endocytic subcompartments become progressively more acidic, and the pH of these compartments is regulated by the opposing functions of vesicular ATP-dependent proton pumps (vATPase) and proton leakage channels (Na<sup>+</sup>/H<sup>+</sup> exchangers, NHEs). Early endocytic vesicles are slightly acidic (pH, ~6.4), which facilitates ligand/receptor dissociation. Lysosomes are highly acidic (pH 4–5), which is required for the digestion of endocytosed biomolecules (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib8">Casey et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Naslavsky and Caplan, 2018</xref>). For maturation of the early endosomes (EEs) and entry into the next sorting stage, ligand/receptor dissociation is required. The pH-dependent release of ApoE from its receptor in the EE is important for endosomal maturation and cargo delivery (<xref ref-type="bibr" rid="bib103">Yamamoto et al., 2008</xref>) for the ability of endosomal content to rapidly recycle to the cell surface (<xref ref-type="bibr" rid="bib28">Heeren et al., 1999</xref>; <xref ref-type="bibr" rid="bib55">Nixon, 2017</xref>). The early endosomal pH, which triggers ligand-receptor dissociation, closely matches the IEP of ApoE4 (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). Loss of net surface charge at the IEP is accompanied by reduced solubility in an aqueous environment, leading to impaired dissociation of ApoE4 from its receptors (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>) and aided by a greater propensity of ApoE4 to form a molten globule configuration under acidic conditions (<xref ref-type="bibr" rid="bib52">Morrow et al., 2002</xref>). Dysregulation of endolysosomal trafficking by ApoE4 causes an age-dependent increase in EE number and size (<xref ref-type="bibr" rid="bib56">Nuriel et al., 2017</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>ApoE4 induces endolysosomal trafficking delay.</title><p>(<bold>A</bold>) pH regulation within the endolysosomal pathway. Upon receptor binding, ApoE is endocytosed along with glutamate receptors (AMPA and NMDA receptors). Cargo that has entered the early endosome (EE) can undergo recycling through a fast direct route without further acidification (fast recycling) or through slower sorting pathways that require further acidification (<xref ref-type="bibr" rid="bib8">Casey et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Naslavsky and Caplan, 2018</xref>). While lipid components are targeted to the lysosome, the majority of receptors, as well as ApoE, remain in endosomal compartments at the cellular periphery where they rapidly move back to the surface (<xref ref-type="bibr" rid="bib28">Heeren et al., 1999</xref>). The increasingly acidic luminal pH is illustrated as a color gradient and depicted on the left. (<bold>B</bold>) In the presence of ApoE4, early endosomal trafficking and fast recycling are delayed. At the pH of the EE, ApoE4 is near its isoelectric point where solubility is reduced (<xref ref-type="bibr" rid="bib98">Wintersteiner and Abramson, 1933</xref>), impairing receptor dissociation and resulting in delayed endosomal maturation with a concomitant entrapment of co-endocytosed glutamate receptors. Endosomal pH is regulated by the vesicular ATPase and the counterregulatory action of the proton leakage channel NHE6. NHE6 is an antiporter that exchanges a Na<sup>+</sup> or K<sup>+</sup> ion for each proton. As the pH decreases, ligands dissociate from their receptors allowing the EE to mature. If dissociation is delayed, as in case of ApoE4, endosomal trafficking is arrested, leading to progressive acidification as Na<sup>+</sup>, K<sup>+</sup>, and Cl<sup>-</sup> ions continue to enter the endosome to maintain charge neutrality while also drawing in water molecules due to osmotic pressure. We thus propose a model in which delayed ApoE4-receptor dissociation prevents early endosomal maturation and causes osmotic swelling while the pH continues to decrease until dissociation occurs. (<bold>C</bold>) Accelerated endosomal acidification by inhibition of the proton leak channel NHE6 resolves ApoE4 accumulation, promotes rapid receptor dissociation, and promotes the vesicle entry into the lysosomal delivery or recycling pathways.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig1-v2.tif"/></fig><p>Based on these observations, we have proposed a model in which destabilization of ApoE4 in the acidic EE environment, combined with a greater propensity for self-association, results in delayed detachment from its receptors (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Subsequent endosomal swelling through K<sup>+</sup>, Na<sup>+</sup>, and H<sub>2</sub>O influx further impairs cargo delivery, receptor recycling, and ligand re-secretion. Importantly, in neurons, ApoE and its receptor Apoer2 travel together with glutamate receptors through the endosomal recycling pathway (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). Rapid endocytosis and subsequent recycling of synaptic receptors is triggered by the synaptic homeostatic modulator and Apoer2 ligand Reelin (<xref ref-type="bibr" rid="bib29">Hiesberger et al., 1999</xref>; <xref ref-type="bibr" rid="bib87">Trommsdorff et al., 1999</xref>). We previously showed that ApoE4, in contrast to ApoE3 and ApoE2, prevents Reelin-mediated glutamate receptor insertion at the synapse, a state we refer to as ApoE4-mediated Reelin resistance (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib16">Durakoglugil et al., 2009</xref>; <xref ref-type="bibr" rid="bib42">Lane-Donovan and Herz, 2017</xref>; <xref ref-type="bibr" rid="bib40">Lane-Donovan et al., 2014</xref>; <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). Reduction of endosomal pH and increasing the differential to the ApoE4 IEP abolishes this effect in vitro (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>).</p><p>The pH of EE compartments is controlled by the vATPase-dependent proton pump and proton leakage through NHE6 (<xref ref-type="bibr" rid="bib53">Nakamura et al., 2005</xref>; <xref ref-type="bibr" rid="bib2">Basu et al., 1976</xref>; <xref ref-type="bibr" rid="bib13">Davis et al., 1987</xref>; <xref ref-type="bibr" rid="bib71">Rudenko et al., 2002</xref>). NHE6 is encoded by the gene <italic>Slc9a6</italic>. We showed that EE acidification by pharmaceutical pan-NHE inhibition or selective NHE6/<italic>Slc9a6</italic> knockdown in neurons prevents the ApoE4-caused trafficking delay of ApoE and glutamate receptors (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). NHE6 deficiency in humans causes neurodevelopmental defects, which result in Christianson syndrome, an X-linked genetic disorder characterized by cognitive dysfunction, autism, ataxia, and epilepsy. However, some <italic>Slc9a6</italic> mutant variants causing Christianson syndrome in humans do not significantly alter the ion exchange properties of NHE6 (<xref ref-type="bibr" rid="bib34">Ilie et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Ilie et al., 2019</xref>) suggesting that Christianson syndrome could be caused by loss of NHE6 scaffolding functions and not by loss of endosomal pH regulation. To investigate whether NHE6 depletion can reverse ApoE4 pathology in vivo, we generated a conditional <italic>Slc9a6</italic> knockout (KO) mouse line (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>) to avoid complications caused by neurodevelopmental defects by temporally and spatially controlling NHE6 ablation. We show that genetic NHE6 ablation attenuates both, the ApoE4-induced Reelin resistance and impaired synaptic plasticity in ApoE4 targeted replacement (<italic>Apoe<sup>APOE4</sup></italic>) mice using hippocampal field recordings.</p><p>The pathological hallmarks of AD are extracellular aggregates of the amyloid β (Aβ) peptide and intracellular tangles of hyperphosphorylated tau protein. Processing of the transmembrane amyloid precursor protein (APP) at the β- and γ-sites leads to Aβ production. Aβ forms neurotoxic oligomers and accumulates in plaques. The β-site amyloid precursor protein cleaving enzyme 1 (BACE1) cleaves APP in its extracellular juxtamembrane domain to create a membrane-anchored C-terminal fragment (β-CTF) and a soluble extracellular APP domain (sAPPβ). β-CTF is further cleaved by the γ-secretase complex, which leads to the release of the Aβ peptide. APP and its secretases co-localize in endosomal compartments where cleavage can occur (<xref ref-type="bibr" rid="bib94">Wang et al., 2018</xref>). It has further been reported that BACE1 activity is preferentially active in acidic environments (<xref ref-type="bibr" rid="bib79">Shimizu et al., 2008</xref>). We therefore investigated whether NHE6 depletion alters BACE1 activity in neurons and whether NHE6 deficiency leads to changes in plaque deposition in vivo. We found that NHE6 inhibition or knockdown did not alter BACE1 activity, as judged by unchanged Aβ generation. By contrast, NHE6 ablation led to glial activation and decreased plaque load in <italic>Apoe<sup>APOE4</sup></italic> (<xref ref-type="bibr" rid="bib85">Sullivan et al., 1997</xref>) and <italic>App<sup>NL-F</sup></italic> (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) double knockin mice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>NHE6 is required for postnatal Purkinje cell survival</title><p>NHE6 germline KO mice (<italic>Slc9a6<sup>-</sup></italic>) and tamoxifen-inducible conditional NHE6 KO mice (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>) were generated as described in Materials and methods and <xref ref-type="fig" rid="fig2">Figure 2A–C</xref>. To validate early endosomal pH acidification by NHE6 deficiency, we isolated mouse embryonic fibroblasts from the <italic>Slc9a6<sup>-</sup></italic> line and infected them with a Vamp3-pHluorin2 lentivirus expressing a fusion protein consisting of the endosomal Vamp3 protein and the ratiometric pH indicator pHluorin2 (<xref ref-type="bibr" rid="bib83">Stawicki et al., 2014</xref>). We found a significantly reduced number of vesicles with pH 6.4 and above in <italic>Slc9a6<sup>-</sup></italic> fibroblasts when compared to control (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Generation of <italic>Slc9a6<sup>fl</sup></italic> and <italic>Slc9a6<sup>-</sup></italic> mice.</title><p>(<bold>A</bold>) Gene targeting strategy. LoxP sites were introduced to flank the first exon (E1) of <italic>Slc9a6</italic> (located on the X-chromosome) by gene targeting in embryonic stem cells. The targeting construct contained a long arm of homology (LA, gray) upstream of the first loxP site and the first exon. An loxP/FRT-flanked neomycin resistance cassette was cloned downstream of the first exon, followed by a short arm of homology (SA, gray). The targeted locus is shown below. Targeted stem cells were used to generate chimeric <italic>Slc9a6<sup>fl</sup></italic> mice. Germline NHE6 knockout mice (NHE6<sup>-/-</sup> [female], NHE6<sup>y/-</sup> [male]; rec indicates recombined allele) were generated by breeding the <italic>Slc9a6<sup>fl</sup></italic> line with Meox-Cre mice. (<bold>B</bold>) Genotyping of wildtype (wt, +), floxed (fl), and recombined (rec, -) NHE6 alleles. The PCR amplified regions are indicated in panel A. The wildtype and floxed allele PCR products differ by 50 bp (270 for floxed, 220 for wildtype). (<bold>C</bold>) Western blot showing brain lysates (left) of different NHE6 genotypes after Meox-Cre-induced germline recombination. (<bold>D</bold>) Mouse embryonic fibroblasts from <italic>Slc9a6<sup>-</sup></italic> and control littermate were infected with Vamp3-pHluorin2 and excited at 408 and 488 nm with emission measured at 510 nm. (<bold>E</bold>) Vesicular pH measured using a standard curve was significantly decreased in <italic>Slc9a6<sup>-</sup></italic> fibroblasts. Data is expressed as mean ± SEM. Statistical analysis was performed using Student’s t-test. (**p &lt; 0.01) (<bold>F</bold>) The percent of vesicles with pH &gt;6.4 is significantly decreased in <italic>Slc9a6<sup>-</sup></italic> fibroblasts. (<bold>G</bold>) <italic>CAG-Cre<sup>ERT2</sup></italic> activity after tamoxifen application in a reporter mouse line expressing tdTomato. <italic>Cre<sup>ERT2</sup></italic> recombination activity without (left panel) or with (middle panel) tamoxifen application in the <italic>CAG-Cre<sup>ERT2</sup></italic> line bred with Rosa26<sup>floxStop-tdTomato</sup> line. After tamoxifen induction, CreERT2 activity led to a robust tdTomato signal in the hippocampus (middle panel). Pyramidal neurons in the CA1 pyramidal cell layer (PCL) (middle panel) are shown magnified in the right panel.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig2-v2.tif"/></fig><p>To induce the conditional KO (cKO) of <italic>Slc9a6</italic>, tamoxifen was administered to <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice at 2 months (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) and experiments were performed at the indicated time points. <italic>Slc9a6</italic> KO efficiency in the brains of tamoxifen-injected <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice was 65–82% and varied between brain regions (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To further investigate Cre<sup>ERT2</sup> activity upon tamoxifen injection, we bred the <italic>CAG-Cre<sup>ERT2</sup></italic> line with a stop-tdTomato reporter line in which a floxed stop-codon precedes the tdTomato start-codon. After tamoxifen injection, brains were examined for tdTomato expression. Without tamoxifen injection, tdTomato-expressing cells were almost absent in the hippocampus. Tamoxifen-induced recombination led to a broad expression of tdTomato in the hippocampus (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Long-term sodium-hydrogen exchanger 6 (NHE6) deficiency induced after Purkinje cell maturation causes Purkinje cell loss.</title><p>(<bold>A</bold>) Experimental timeline for B, mice were injected with tamoxifen at 2 months; after 1 month the brains were analyzed for NHE6 expression (Tam = tamoxifen, Exp. = experiment, mo. = months). (<bold>B</bold>) Western blot showing the efficiency of tamoxifen-induced NHE6 knockout in different brain regions (CA1, CA3, dentate gyrus, cortex, and cerebellum). The knockout efficiency differed between brain regions, it was 80% ± 2% in CA1, 82 ± 5.7% in the CA3, 67 ± 6.8% in the dentate gyrus, 65% ± 11.2% in the cortex, and 74% ± 4.7% in the cerebellum. A total of three brains in each group were examined. (<bold>C–F</bold>) NHE6 deficiency leads to cerebellar Purkinje cell loss in germline (<italic>Slc9a6<sup>-</sup></italic>, <bold>C</bold>) and conditional (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>, <bold>D–F</bold>) knockout mice. <italic>Slc9a6<sup>+</sup></italic> includes both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>) mice. <italic>Slc9a6<sup>-</sup></italic> includes both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>) mice. In addition, <italic>Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic>. The timeline shows that <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> and control mice were tamoxifen-injected at 2 months and analyzed 1 year after (<bold>D</bold>). Calbindin was fluorescently labeled to highlight Purkinje cells in the cerebellum. Massive loss of Purkinje cells was found in <italic>Slc9a6<sup>-</sup></italic> (C, lower panel), compared to wildtype <italic>Slc9a6<sup>+</sup></italic> control (C, upper panel). Long-term loss of NHE6, induced after Purkinje cell maturation at 2 months of age, also led to massive Purkinje cells loss when mice were examined 1 year after NHE6 ablation (E, lower panel). (<bold>F</bold>) Quantification of Purkinje cell loss in the cerebellum of <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice. Values are expressed as mean ± SEM from four independent experiments. Statistical analysis was performed using Student’s t-test. *p &lt; 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig3-v2.tif"/></fig><p>Individuals with Christianson syndrome and mice lacking NHE6 present with motor deficits due to a dramatic progressive loss of cerebellar Purkinje cells (<xref ref-type="bibr" rid="bib60">Ouyang et al., 2013</xref>). We have reproduced the Purkinje cell loss in our germline <italic>Slc9a6<sup>-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Next, we investigated whether Purkinje cell loss is the consequence of neurodevelopmental or neurodegenerative effects caused by loss of NHE6. <italic>Slc9a6</italic> deficiency was induced at 2 months, after Purkinje cells had developed and matured. One year after <italic>Slc9a6</italic> ablation, Purkinje cell loss was indistinguishable from that seen in the germline KO (<xref ref-type="fig" rid="fig3">Figure 3D–F</xref>). Therefore, Purkinje cell degeneration manifests itself postnatally and is not developmentally determined by the absence of NHE6. However, it is possible that loss of scaffolding functions and proper sorting, rather than dysregulation of endosomal pH, could be the main mechanism that causes Christianson syndrome, including Purkinje cell loss (<xref ref-type="bibr" rid="bib34">Ilie et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Ilie et al., 2019</xref>). If this could be substantiated by the development or discovery of <italic>Slc9a6</italic> mutants that selectively ablate its ion exchange capacity without affecting its subcellular sorting or interaction with cytoplasmic or luminal binding partners, this would further raise the potential of NHE6 as a novel drug target for neurodegenerative diseases.</p></sec><sec id="s2-2"><title>Genetic disruption of NHE6 restores trafficking of Apoer2, AMPA, and NMDA receptors in the presence of ApoE4</title><p>As we reported previously, ApoE4 impairs the trafficking of synaptic surface receptors (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>). To monitor receptor recycling in neurons, we made use of an assay where Reelin is used to modulate receptor surface expression. Reelin is applied to primary neurons for 30 min in the presence or absence of naturally secreted, receptor-binding competent ApoE (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Subsequently, surface biotinylation is performed and cells are harvested for immunoblotting to quantify the amount of Apoer2 and glutamate receptors expressed on the neuronal surface (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Sodium-hydrogen exchanger 6 (NHE6) deficiency alleviates ApoE4-impaired surface trafficking deficits of Apoer2 and glutamate receptors.</title><p>(<bold>A</bold>) Timeline for the receptor surface expression assay applied for the experiments shown in B–F. Primary neurons were treated with naturally secreted ApoE3 or ApoE4 and/or Reelin before they underwent surface biotinylation. (<bold>B–F</bold>) Wildtype and <italic>Slc9a6<sup>-</sup></italic> primary neurons were prepared from littermates and used in the receptor surface expression assay described in A. <italic>Slc9a6<sup>+</sup></italic> includes both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>) mice. <italic>Slc9a6<sup>-</sup></italic> includes both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>) mice. (<bold>B</bold>) NHE6 deficiency was confirmed via Western blot, β-actin was used as loading control. (<bold>C–F</bold>) ApoE-conditioned media treatment reduces the surface expression of Apoer2 and glutamate receptors in presence of Reelin in primary neurons. Receptor surface levels show a stronger reduction with ApoE4 than ApoE3. NHE6 depletion counteracts the ApoE4-induced reduction of receptor surface expression. Cell surface biotinylation assay was performed for Apoer2 (<bold>C</bold>), GluN2B (<bold>D</bold>), GluA1, (<bold>E</bold>) and GluA2/3 (<bold>F</bold>). Total levels were analyzed by immunoblotting of whole cell lysates against the same antibodies. β-Actin was used as loading control. Quantitative analysis of immunoblot signals is shown in the lower panels (<bold>C–F</bold>). All data are expressed as mean ± SEM from three independent experiments. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.005. Statistical analysis was performed using one-way analysis of variance (ANOVA) and Dunnett’s post hoc test (<bold>C–F</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig4-v2.tif"/></fig><p>We have shown previously that in the presence of ApoE4, Apoer2 and glutamate receptors recycle poorly to the neuronal surface. This recycling block could be resolved by endosomal acidification induced by shRNA knockdown of <italic>Slc9a6</italic> or by applying the NHE inhibitor EMD87580 (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). To further exclude a nonspecific effect caused by the inhibition of other NHE family members or by shRNA off-target effects, we applied this assay on neurons isolated from <italic>Slc9a6<sup>-</sup></italic> embryos (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Apoer2 recycling was completely restored in <italic>Slc9a6<sup>-</sup></italic> neurons treated with ApoE4 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We previously reported that the addition of ApoE3 to neurons also affects Apoer2 trafficking to a small, but reproducible extent. This was also abolished in <italic>Slc9a6<sup>-</sup></italic> neurons (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In addition, genetic loss of NHE6 equally restored the ApoE4-impaired surface expression of AMPA and NMDA receptor subunits (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>).</p></sec><sec id="s2-3"><title>Conditional disruption of NHE6 relieves synaptic Reelin resistance in <italic>Apoe<sup>APOE4</sup></italic> mice</title><p>Reelin can enhance long-term potentiation (LTP) in hippocampal field recordings of <italic>Apoe<sup>APOE3</sup></italic> but not <italic>Apoe<sup>APOE4</sup></italic> acute brain slices (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>). We previously showed that this Reelin resistance in <italic>Apoe<sup>APOE4</sup></italic> slices was attenuated by pharmacological NHE inhibition (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). To investigate if endogenous loss of NHE6 also restores synaptic plasticity in the presence of ApoE4, we performed hippocampal field recordings on <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice bred to <italic>Apoe<sup>APOE3</sup></italic> or <italic>Apoe<sup>APOE4</sup></italic> mice. To avoid potentially compounding effects of NHE6 deficiency during embryonic development (<xref ref-type="bibr" rid="bib60">Ouyang et al., 2013</xref>), NHE6/<italic>Slc9a6</italic> gene disruption was induced at 8 weeks by intraperitoneal tamoxifen injection (<xref ref-type="bibr" rid="bib41">Lane-Donovan et al., 2015</xref>). Electrophysiology was performed 3–4 weeks after NHE6 depletion in 3-month-old mice (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>, <xref ref-type="fig" rid="fig5">Figure 5B, D, F and H</xref>). Tamoxifen-injected <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>-negative mice expressing human ApoE3 or ApoE4 served as controls (<italic>Apoe<sup>APOE3</sup></italic> and <italic>Apoe<sup>APOE4</sup></italic>, <xref ref-type="fig" rid="fig5">Figure 5A, C, E and G</xref>). For field recordings, hippocampal slices were perfused with Reelin as described (<xref ref-type="bibr" rid="bib3">Beffert et al., 2005</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib16">Durakoglugil et al., 2009</xref>; <xref ref-type="bibr" rid="bib96">Weeber et al., 2002</xref>). Conditional genetic loss of NHE6 resulted in a moderate reduction of the ability of Reelin to enhance LTP in <italic>Apoe<sup>APOE3</sup></italic> mice (comparing <xref ref-type="fig" rid="fig5">Figure 5A and E</xref> to B and F). By contrast, as reported previously (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>), hippocampal slices from <italic>Apoe<sup>APOE4</sup></italic> mice were completely resistant to LTP enhancement by Reelin (<xref ref-type="fig" rid="fig5">Figure 5C and G</xref>). This resistance was abolished when NHE6 was genetically disrupted in <italic>Apoe<sup>APOE4</sup></italic> mice: Reelin application enhanced LTP (<xref ref-type="fig" rid="fig5">Figure 5D and H</xref>) in <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> to a comparable extent as in the <italic>Apoe<sup>APOE3</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Synaptic transmission was monitored and input-output curves were generated by plotting the fiber volley amplitude, measured at increasing stimulus intensities, against the fEPSP slope. No significant differences were found (<xref ref-type="fig" rid="fig5">Figure 5I and J</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effect of conditional sodium-hydrogen exchanger 6 (NHE6) knockout on Reelin-potentiated synaptic plasticity.</title><p>(<bold>A–H</bold>) Conditional knockout of NHE6 restores Reelin-enhanced long-term potentiation (LTP) in <italic>Apoe<sup>APOE4</sup></italic> mice. Reelin facilitated induction of LTP in <italic>Apoe<sup>APOE3</sup></italic> (<bold>A, E</bold>), but not <italic>Apoe<sup>APOE4</sup></italic> (<bold>C, G</bold>) control (<italic>Slc9a6<sup>fl</sup></italic>) mice. <italic>Slc9a6</italic> deficiency in <italic>Apoe<sup>APOE3</sup></italic> mice caused a reduction in Reelin-enhanced LTP, such that it is not significantly different from the control LTP (<bold>B, F</bold>). Importantly, in <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice Reelin was able to enhance theta burst-induced potentiation (<bold>D, H</bold>). Hippocampal slices were prepared from 3-month-old double mutant mice with either human <italic>Apoe<sup>APOE3</sup></italic> or <italic>Apoe<sup>APOE4</sup></italic> crossed with <italic>Slc9a6</italic> conditional knockout mice (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>, tamoxifen injections at 6–8 weeks). Extracellular field recordings were performed in slices treated with or without Reelin. Theta burst stimulation (TBS) was performed after 20 min of stable baseline. Representative traces are shown in each panel, before TBS induction (black) and 40 min after TBS (gray). (<bold>E–H</bold>) Quantitative analysis of normalized fEPSP slopes at time intervals as indicated. (<bold>I, J</bold>) Input output curves of <italic>Apoe<sup>APOE3</sup></italic> (<bold>I</bold>) and <italic>Apoe<sup>APOE4</sup></italic> (<bold>J</bold>) mice with or without <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>. Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic> mice. <italic>Apoe</italic> mice are homozygous for APOE3 or APOE4. All data are expressed as mean ± SEM. N-numbers for each genotype group and treatment are indicated in panels A–D. *p &lt; 0.05. Statistical analysis was performed using Student’s t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig5-v2.tif"/></fig></sec><sec id="s2-4"><title>NHE inhibition or NHE6 knockdown does not alter β-CTF generation in vitro</title><p>Cleavage of APP by γ-secretase and the BACE1 generates the short neurotoxic polypeptide Aβ. Cleavage by BACE1 results in a membrane anchored fragment called β-CTF, which is further processed by γ-secretase to yield the soluble Aβ peptide. BACE1 processing of APP occurs in the Golgi complex, on the cell membrane, and after endocytosis in endosomes (<xref ref-type="bibr" rid="bib7">Caporaso et al., 1994</xref>; <xref ref-type="bibr" rid="bib89">Vassar et al., 1999</xref>). It has been reported that BACE1 activity increases with lower pH (<xref ref-type="bibr" rid="bib30">Hook et al., 2002</xref>). In a recent in vitro study in an HEK293 cell line overexpressing APP and BACE1, NHE6 overexpression reportedly led to a reduction of Aβ production and conversely shRNA knockdown of NHE6/<italic>Slc9a6</italic> resulted in an increase in Aβ production (<xref ref-type="bibr" rid="bib66">Prasad and Rao, 2015</xref>). To investigate if NHE6/<italic>Slc9a6</italic> deficiency contributes to APP processing by BACE1 in neurons, we used primary neurons derived from <italic>AppSwe</italic> (<italic>Tg2576</italic>) mice, an Alzheimer’s disease (AD) mouse model that overexpresses human APP with the ‘Swedish’ mutation (<xref ref-type="bibr" rid="bib31">Hsiao et al., 1996</xref>). Neurons were treated with the NHE inhibitor EMD87580 or transduced with lentiviral shRNA directed against NHE6/<italic>Slc9a6</italic> in the presence or absence of the γ-secretase inhibitor L-685458. β-CTF was detected using the monoclonal antibody 6E10 directed against Aβ residues 1–16 (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Inhibition of γ-secretase in ApoE4-treated <italic>AppSwe</italic> neurons strongly enhanced β-CTF accumulation, however, additional treatment with EMD87580 did not alter the amount of β-CTF in the cell lysates (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). NHE6 knockdown using lentiviral shRNA also had no effect on the amount of β-CTF (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). We conclude that NHE6 inhibition is unlikely to increase Aβ production under near-physiological conditions.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) inhibition or sodium-hydrogen exchanger 6 (NHE6) knockdown does not alter β-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity in primary neurons.</title><p>(<bold>A, B</bold>) Pan-NHE inhibition by EMD87580 or lentiviral knockdown of <italic>Slc9a6</italic> (NHE6) did not alter BACE1 activity in primary neurons of <italic>AppSwe</italic> mice (Tg2576). (<bold>A</bold>) DIV10 primary neurons were treated with γ-secretase inhibitor L-685458, EMD87580, and/or ApoE4 (as indicated) and harvested for immunoblotting against Aβ-containing C-terminal fragment of APP (β-CTF). β-Actin was blotted as loading control. Bar graph shows the statistics of n = 3 experiments. (<bold>B</bold>) Primary neurons of <italic>AppSwe</italic> mice were infected with lentivirus for shRNA expression directed against <italic>Slc9a6</italic>(NHE6) (sh<italic>Slc9a6</italic>) or a scramble control sequence (-) at DIV7. At DIV13 neurons were treated with L-685458 overnight and harvested for immunoblotting against NHE6 and β-CTF on DIV14. RAP was blotted as loading control. Bar graph shows the statistics of n = 6 experiments. All data are expressed as mean ± SEM. Statistical analysis was performed using Student’s t-test. n.s. = not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig6-v2.tif"/></fig></sec><sec id="s2-5"><title>NHE6 deficiency reduces Aβ plaque load in human <italic>App</italic> knockin mice</title><p>To further study the effect of NHE6 deficiency on Aβ pathology in vivo, we bred humanized <italic>App<sup>NL-F</sup></italic> mice (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) to our germline NHE6 KO line (<italic>Slc9a6<sup>-</sup></italic>). In these <italic>App<sup>NL-F</sup></italic> mice, the Aβ sequence has been completely humanized and the early onset AD Swedish mutation (5’ located mutations encoding K670N and M671L = NL) and the Beyreuther/Iberian mutation (3’ flanking mutation encoding I716<italic>F</italic> = F) were also introduced, resulting in increased Aβ production, but physiological regulation of APP expression. This allowed us to determine the effect of Aβ overproduction while keeping APP expression under the control of the endogenous promoter. <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> and control <italic>App<sup>NL-F</sup></italic> littermates were aged to 1 year. Perfusion-fixed brains were harvested and analyzed by hematoxylin and eosin (H&amp;E) staining, Thioflavin S staining to visualize plaque load, and Aβ immunohistochemistry. H&amp;E staining did not reveal any obvious anatomical structural differences between genotypes, but brain size, cortical thickness, hippocampal area, and CA1 thickness were reduced, as described previously (<xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Plaques were more frequent in <italic>Slc9a6 wildtype</italic> than <italic>Slc9a6<sup>-</sup></italic> mice. To further investigate and quantify plaque load, we analyzed the same brains after Thioflavin S staining (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). We found an approximate 80% reduction of plaques in <italic>Slc9a6<sup>-</sup></italic> mice when compared to littermate controls (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Immunohistochemistry against Aβ showed the same reduction (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A,B</xref>). In addition, we analyzed soluble (TBS fraction) and insoluble (GuHCl and 70 % FA fractions) Aβ in cortical brain lysates of 1.5-year-old <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> mice and their control littermates. The amount of insoluble Aβ (GuHCl and 70% FA fractions) was reduced in NHE6-depleted mice by approximately 71%, when compared to their control littermates (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3C-E</xref>). The ~50% reduction in soluble Aβ was statistically not significant in <italic>Slc9a6<sup>-</sup></italic> lysates (TBS fraction).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Sodium-hydrogen exchanger 6 (NHE6) deficiency decreases plaque formation in both <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice.</title><p>(<bold>A, B</bold>) NHE6-deficient <italic>App<sup>NL-F</sup></italic> and control <italic>App<sup>NL-F</sup></italic> mice were analyzed for plaque deposition at an age of 12 months. Thioflavin S staining was performed to visualize plaques. Plaques were found more frequently in the control <italic>App<sup>NL-F</sup></italic> mice (left panel in <bold>A</bold>), magnifications of the boxed areas are shown in the two middle panels. The plaque load between <italic>Slc9a6<sup>-</sup></italic> mice and control littermates (all <italic>App<sup>NL-F</sup></italic>) was compared and analyzed. (<bold>B</bold>) In the <italic>Slc9a6<sup>-</sup></italic> littermates, the plaque number was reduced, when compared to controls. (<bold>C–D</bold>) <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice were analyzed for plaque deposition. NHE6 was ablated at 2 months and brains were analyzed at 13.5–16 months. 4G8-immunolabeling against Aβ was performed to visualize plaques. In <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice conditional <italic>Slc9a6</italic> knockout caused a reduction in plaque load compared to the <italic>Slc9a6<sup>fl</sup></italic> control littermates. (<bold>C</bold>) Magnifications of the boxed areas in C are shown in the middle. (<bold>D</bold>) Plaque load was analyzed and compared between <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice and floxed control littermates. (<bold>I</bold>) Hematoxylin and eosin (H&amp;E) staining was performed to investigate for gross anatomic abnormalities in the <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice. (<bold>F–I</bold>) Brain area (<bold>F</bold>), cortical thickness (<bold>G</bold>), hippocampal (HC) area (<bold>H</bold>), and CA1 thickness (<bold>I</bold>) were analyzed. Student’s t-test did not reveal a significant difference. Plaques were differentiated by size or staining density as described in detail in the supplements (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Labeled plaques were analyzed by a blinded observer. All data are expressed as mean ± SEM. (<bold>B</bold>) <italic>Slc9a6<sup>-</sup></italic> n = 5, control n = 8, (<bold>C</bold>) <italic>Slc9a6<sup>fl</sup></italic> n = 8 (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> n = 8), in (<bold>F–I</bold>) derived from n = 5 (<italic>Slc9a6<sup>fl</sup></italic>) and n = 6 (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>) animals. *p &lt; 0.05. **p &lt; 0.01, ***p &lt; 0.005. <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). In addition, <italic>Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic> mice. <italic>Apoe</italic> mice are homozygous for APOE4 (<italic>Apoe<sup>APOE4</sup></italic>). <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>). Statistical analysis was performed using two-way analysis of variance (ANOVA) with Sidak’s post hoc test (<bold>B and D</bold>) and Student’s t-test (<bold>F–I</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Gross anatomical brain structure in <italic>Slc9a6<sup>-</sup></italic> mice.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H&amp;E) staining was performed to investigate for gross anatomic abnormalities in the <italic>Slc9a6<sup>-</sup>;App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup></italic> mice. Structures representing plaques were found in the <italic>App<sup>NL-F</sup></italic> control groups (magnified example is shown in the middle panel). (<bold>B–E</bold>) Brain area (<bold>B</bold>), cortical thickness (<bold>C</bold>), hippocampal (HC) area (<bold>D</bold>), and CA1 thickness (<bold>E</bold>) were analyzed. All data are expressed as mean ± SEM. Student’s t-test did not reveal significant differences, n = 3 (control) and n = 4 (<italic>Slc9a6<sup>-</sup></italic>). <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Example of Thioflavin S stained plaques for quantification.</title><p>Different types of Thioflavin S stained plaques and 4G8-immunoreactive accumulations in <italic>App<sup>NL-F</sup></italic> brains are shown. Different sizes of plaques were grouped together for quantification Thioflavin S-labeled plaques (<xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>). Plaques bigger in diameter than 20 µm with a dense core were defined as big. Medium sized plaques had a diameter between 10 and 20 µm with a dense core. Small plaques were smaller than 10 µm and often represented individual cells. 4G8-labeled plaques were differentiated by diffuse or dense appearance as depicted in the examples.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig7-figsupp2-v2.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Sodium-hydrogen exchanger 6 (NHE6) deficiency decreases plaque formation in both <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice.</title><p>(<bold>A–B</bold>) NHE6-deficient <italic>App<sup>NL-F</sup></italic> and control <italic>App<sup>NL-F</sup></italic> mice were analyzed for plaque deposition at an age of 12 months. 4G8-immunolabeling against Aβ (<bold>A</bold>) visualized more plaques in the control <italic>App<sup>NL-F</sup></italic> mice. The plaque load between <italic>Slc9a6<sup>-</sup></italic> mice and control littermates (all <italic>App<sup>NL-F</sup></italic>) was compared and analyzed. (<bold>B</bold>) In the <italic>Slc9a6<sup>-</sup></italic> littermates the plaque number was reduced, when compared to controls. (<bold>C–E</bold>) Soluble (TBS) and insoluble (GuHCl and 70% FA) Aβ fractions of cortical lysates were analyzed by commercial ELISA; 1.5-year-old <italic>Slc9a6<sup>-</sup></italic> mice showed less insoluble Aβ than their control littermates (all <italic>App<sup>NL-F</sup></italic>). (<bold>F–G</bold>) <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice were analyzed for plaque deposition. NHE6 was ablated at 2 months and brains were analyzed at 13.5–16 months. Thioflavin S staining was performed to visualize plaques. With <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> background, the <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice had a reduced plaque load compared to the <italic>Slc9a6<sup>fl</sup></italic> control mice (left panel in <bold>F</bold>). Magnifications of the boxed areas in left panel are shown in the middle. (<bold>G</bold>) Plaque load was analyzed and compared between <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice and floxed control littermates. Plaques were differentiated by size or staining density as described in detail in the supplements (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Labeled plaques were analyzed by a blinded observer (<bold>B, G</bold>). All data (immunohistochemistry: <italic>Slc9a6<sup>-</sup></italic> n = 5, control n = 4, <italic>Slc9a6<sup>fl</sup></italic> n = 10, <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> n = 12; biochemistry: <italic>Slc9a6<sup>-</sup></italic> n = 11, control n = 7) are expressed as mean ± SEM. *p &lt; 0.05. **p &lt; 0.01, ***p &lt; 0.005. <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). In addition, <italic>Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic> mice. <italic>Apoe</italic> mice are homozygous for APOE4. <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>). Statistical analysis was performed using two-way analysis of variance (ANOVA) with Sidak’s post hoc test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig7-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>NHE6/<italic>Slc9a6</italic> deficiency reduces plaque load in <italic>App<sup>NL-F</sup></italic>;<italic>Apoe<sup>APOE4</sup></italic></title><p>To further investigate whether <italic>Slc9a6</italic> deficiency also protects the brain from plaques in the presence of human ApoE4 instead of murine ApoE, we bred <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>; Apoe<sup>APOE4</sup></italic> with <italic>App<sup>NL-F</sup></italic> mice. At 2 months of age, we induced <italic>Slc9a6</italic> ablation with tamoxifen and aged the mice to 14–16 months. <italic>Slc9a6</italic> deficiency on the background of human ApoE4 reduced plaque deposition, as shown by Thioflavin S staining (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3F, G</xref>) and 4G8 immunoreactivity (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). The age-dependent increase in plaque load in <italic>Apoe<sup>APOE4</sup>;App<sup>NL-F</sup></italic> mice was abolished or delayed when <italic>Slc9a6</italic> was depleted after 2 months of age (<xref ref-type="fig" rid="fig8">Figure 8</xref>). <italic>App<sup>NL-F</sup></italic> mice expressing murine ApoE developed plaques at 12 months (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), compared to <italic>Apoe<sup>APOE4</sup>;App<sup>NL-F</sup></italic> which showed a similar number of plaques at 15–16 months (<xref ref-type="fig" rid="fig7">Figures 7C–D</xref>–<xref ref-type="fig" rid="fig8">8</xref>, and <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3F-G</xref>). This delay of plaque deposition caused by the presence of human ApoE4 as opposed to murine ApoE is consistent with earlier findings by the Holtzman group (<xref ref-type="bibr" rid="bib46">Liao et al., 2015</xref>). Importantly, NHE6/<italic>Slc9a6</italic> ablation induced at 2 months showed a comparable reduction of plaque load as germline NHE6/<italic>Slc9a6</italic> depletion. We conclude that plaque deposition is modulated by the presence of NHE6 postnatally and is not affected by NHE6 activity during development.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Age-dependent increase in plaque load is abolished in <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice.</title><p>(<bold>A–E</bold>) <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice were analyzed for plaque deposition. Sodium-hydrogen exchanger 6 (NHE6) was ablated at 2 months and brains were analyzed at 13.5–16 months. 4G8-immunolabeling against Aβ (<bold>A,B</bold>) and Thioflavin S staining (<bold>C–E</bold>) were performed to visualize plaques (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3F</xref>). Plaque load was analyzed and compared between <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice and floxed control littermates. Plaques were differentiated by staining intensity (<bold>A, B</bold>) or size (<bold>C–E</bold>) as described in the supplements (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). In the time range analyzed, plaque load increased by age in control, but not in <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice. Plaques were analyzed by a blinded observer. Plaque count (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> n = 8, <italic>Slc9a6<sup>fl</sup></italic> n = 8 for <bold>A</bold>) (<bold>B</bold>); <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> n = 12; <italic>Slc9a6<sup>fl</sup></italic> n = 10 in (<bold>C–E</bold>) is pis plotted against age of mice. <italic>Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic> mice. <italic>Apoe</italic> mice are homozygous for APOE4. <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig8-v2.tif"/></fig></sec><sec id="s2-7"><title>NHE6/<italic>Slc9a6</italic> deficiency does not affect cortical thickness and hippocampus size in <italic>App<sup>NL-F</sup></italic>;<italic>Apoe<sup>APOE4</sup></italic> cortices</title><p><xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>, reported reduced cortex thickness and hippocampus volume in <italic>Slc9a6<sup>-</sup></italic> mice, which we were able to reproduce in our germline <italic>Slc9a6<sup>-</sup></italic> model (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). In addition, based on their findings <xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>, concluded that the difference in brain size was a combined result of both neurodevelopmental and neurodegenerative effects caused by NHE6/<italic>Slc9a6</italic> deficiency. Since both germline deficiency and adult-onset deficiency of NHE6 causes massive Purkinje cell loss in the cerebellum (<xref ref-type="fig" rid="fig3">Figure 3C–E</xref>), we next investigated the effect of conditional NHE6/<italic>Slc9a6</italic> loss on hippocampal and cortical neuronal loss in our <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> model (<xref ref-type="fig" rid="fig7">Figure 7E–I</xref>). We measured brain size, cortical thickness, hippocampal area, and CA1 thickness. In contrast to germline <italic>Slc9a6<sup>-</sup></italic> mice (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), none of the analyzed parameters differed significantly between <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> and controls (<xref ref-type="fig" rid="fig7">Figure 7E–I</xref>), and we specifically did not detect any reduction in brain size compared to <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> littermate controls. This is consistent with the undergrowth model proposed by <xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>, as we induced conditional disruption of NHE6/<italic>Slc9a6</italic> in the adult after postnatal brain growth was completed.</p></sec><sec id="s2-8"><title>NHE6 deficiency increases Iba1 and GFAP expression in the brain</title><p>Neuroprotective astrocytes and microglia have been described to reduce Aβ deposition in early stages of AD (<xref ref-type="bibr" rid="bib74">Sarlus and Heneka, 2017</xref>). It has been reported that NHE6 deficiency leads to increased glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule (Iba1) immunoreactivity in different brain regions (<xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>). To validate if plaque load correlated with Iba1 and/or GFAP immunoreactivity, we performed DAB immunostaining for both marker proteins. We found that Iba1 and GFAP immunoreactivity is increased in the white matter and to a lesser extent in the cortex of <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A, C, D</xref>, C, and D) and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B, E, F</xref>) mice compared to their littermate controls. There was a non-significant trend toward increased immunoreactivity for both markers in the hippocampus of the <italic>Slc9a6<sup>-</sup></italic> group. Taken together, these data are consistent with the findings of the Morrow group in germline <italic>Slc9a6<sup>-</sup></italic> mice (<xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>). Neurodegeneration can be a trigger for glial activation (<xref ref-type="bibr" rid="bib106">Yanuck, 2019</xref>). However, our data on glial activation and cerebral volume in cKO mice, where NHE6/<italic>Slc9a6</italic> was disrupted postnatally, suggest that neurodegeneration induced by NHE6/<italic>Slc9a6</italic> deficiency is unlikely to be the trigger for the glial activation we observe.</p></sec><sec id="s2-9"><title>Microglia and astrocytes surround plaques in both <italic>slc9a6<sup>-</sup></italic> and control <italic>App<sup>NL-F</sup></italic> mice</title><p>Conditional and germline <italic>Slc9a6</italic> deficient <italic>App<sup>NL-F</sup></italic> mice have a reduced number of plaques in the brain and an increase of Iba1 and GFAP labeled glia. Others have shown that Aβ plaques levels are reduced with increased plaque-associated microglia detected with a co-stain for Iba1 and Aβ (<xref ref-type="bibr" rid="bib62">Parhizkar et al., 2019</xref>; <xref ref-type="bibr" rid="bib108">Zhong et al., 2019</xref>). In order to investigate the contribution of microglia and astrocytes to the observed plaque reduction, we analyzed brain slices by co-staining for Aβ using the 6E10 antibody (<xref ref-type="fig" rid="fig9">Figure 9</xref> and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref>). Whereas the total amount of plaques labeled by 6E10 was reduced in <italic>Slc9a6<sup>-</sup></italic> as compared to control mice (<xref ref-type="fig" rid="fig9">Figure 9C</xref>), the amount of microglia and astrocytes surrounding plaques did not differ between genotypes (<xref ref-type="fig" rid="fig9">Figure 9D and G</xref>). In addition, there was no difference between genotypes in the amount of microglia co-labeled with 6E10 (<xref ref-type="fig" rid="fig9">Figure 9E</xref>) or the intensity of immunoreactivity for 6E10 within microglia (<xref ref-type="fig" rid="fig9">Figure 9F</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Microglia and astrocytes surround plaques in both <italic>App<sup>NL-F</sup></italic> control and <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> brains.</title><p>(<bold>A–B</bold>) Co-labeling of microglia (Iba1, green, <bold>A</bold>) or astrocytes (GFAP, green, <bold>B</bold>) with Aβ (6E10, red) in brain slices of <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> mice. (<bold>C</bold>) Quantification of plaques in control and <italic>Slc9a6<sup>-</sup></italic> brain slices. (<bold>D</bold>) Bar graph showing the intensity density of Iba1/6E10 as quantitative measure of microglia surrounding plaques. (<bold>E</bold>) Statistical analysis of 6E10 positive microglia and (<bold>F</bold>) the intensity of 6E10 signal within microglia. (<bold>G</bold>) Bar graph showing the intensity density of GFAP/Aβ as quantitative measure of astrocytes surrounding plaques. Data were analyzed by a blinded observer. All data are expressed as mean ± SEM. Data were obtained from n = 4 (control) and n = 5 (<italic>Slc9a6<sup>-</sup></italic>) mice (<bold>A–G</bold>).(<bold>D</bold>) n = 33 (control) and n = 23 (<italic>Slc9a6<sup>-</sup></italic>) plaques were analyzed, in (<bold>E</bold>) n = 22 (control) and n = 24 (<italic>Slc9a6<sup>-</sup></italic>) microscopical pictures were analyzed, in (<bold>F</bold>) n = 31 (control) and n = 38 (<italic>Slc9a6<sup>-</sup></italic>) 6E10 positive (defined as signal intensity above 500) microglia were analyzed, in (<bold>G</bold>) n = 33 (control) and n = 18 (<italic>Slc9a6<sup>-</sup></italic>) plaques were analyzed. Student’s t-test revealed a difference in <bold>C</bold> (**p &lt; 0.01) and did not reveal significant differences in (<bold>D–G</bold>). <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Sodium-hydrogen exchanger 6 (NHE6) deficiency causes an increase in Iba1 and glial fibrillary acidic protein (GFAP) immunoreactivity in both <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice.</title><p>(<bold>A</bold>) Immunohistochemistry against GFAP and ionized calcium-binding adapter molecule (Iba1) was performed on brain slices obtained from 1-year-old <italic>App<sup>NL-F</sup></italic> mice deficient for NHE6 (<italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic>) and control littermates (<italic>App<sup>NL-F</sup></italic>). GFAP (upper panels) and Iba1 (lower panels) immunoreactivity was increased in NHE6-deficient <italic>App<sup>NL-F</sup></italic> mice when compared to NHE6 expressing controls. (<bold>B</bold>) <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice were analyzed for immunoreactivity GFAP and Iba1. Mice were injected with tamoxifen at 2 months and brain slices obtained from 13.5- to 16-month-old mice. GFAP (upper panels) and Iba1 (lower panels) immunoreactivity was increased in NHE6-deficient <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice when compared to NHE6-expressing controls. (<bold>C–F</bold>) Intensity of the staining in various areas was compared for GFAP (<bold>C</bold>) and Iba1 (<bold>D</bold>) in <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> and <italic>App<sup>NL-F</sup></italic> mice. Intensity of the staining for GFAP (<bold>E</bold>) and Iba1 (<bold>F</bold>) in <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> and <italic>Slc9a6<sup>fl</sup>;App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice. Analysis was performed by a blinded observer. ‘White matter’ comprises corpus callosum, cingulum, and external capsule. All data (<italic>Slc9a6<sup>-</sup></italic> n = 5; control n = 4; <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> n = 6; <italic>Slc9a6<sup>fl</sup></italic> n = 8) are expressed as mean ± SEM. *p &lt; 0.05. **p &lt; 0.01, ***p &lt; 0.005. <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). In addition, <italic>Slc9a6<sup>fl</sup></italic> mice includes both female <italic>Slc9a6<sup>fl/fl</sup></italic> and male <italic>Slc9a6<sup>y/fl</sup></italic> mice. For the <italic>Cag-Cre<sup>ERT2</sup></italic>, <italic>Cre<sup>+</sup></italic> + the absence of Cre (<italic>Slc9a6<sup>fl</sup></italic> alone) and <italic>Cag-Cre<sup>ERT2</sup></italic> indicates the presence of Cre (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>), which are both injected with Tamoxifen at 2 months of age. <italic>Apoe</italic> mice are homozygous for APOE4. <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>). Statistical analysis was performed using Student’s t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>Examples of plaques surrounded by microglia and astrocytes.</title><p>(<bold>A</bold>) Co-labeling of microglia (Iba1, green) and Aβ (6E10, red) in brain slices of <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> mice. (<bold>B</bold>) Co-labeling of astrocytes (glial fibrillary acidic protein [GFAP], green) and Aβ (6E10, red) in brain slices of <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>; Slc9a6<sup>-</sup></italic> mice. <italic>Slc9a6<sup>+</sup></italic> represents both female wildtypes (<italic>Slc9a6<sup>+/+</sup></italic>) and male wildtypes (<italic>Slc9a6<sup>y/+</sup></italic>). <italic>Slc9a6<sup>-</sup></italic> represents both female knockouts (<italic>Slc9a6<sup>-/-</sup></italic>) and male knockouts (<italic>Slc9a6<sup>y/-</sup></italic>). <italic>App<sup>NL-F</sup></italic> mice are homozygous for human NL-F knockin mutation (<italic>App<sup>NL-F/NL-F</sup></italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-fig9-figsupp2-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The prevalence of AD is increasing with life expectancy in all human populations. ApoE4 is the most important genetic risk factor. This makes it of paramount importance to understand the underlying mechanisms by which ApoE4 contributes to the pathology of the disease in order to devise effective targeted therapies that can be deployed on a global scale. Only small molecule drug therapies or, alternatively, immunization approaches can satisfy this requirement. Biologics, including monoclonal antibodies and potential viral gene therapy approaches, are unlikely to be sufficiently scalable. We have previously reported a novel small molecule intervention that has the potential to neutralize ApoE4 risk (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>) through prevention of the ApoE4-induced endosomal trafficking delay of synaptic receptors by the early endosomal sorting machinery. The mechanistic basis of this conceptually novel intervention is the acidification of the early endosomal compartment through inhibition of NHE6. Remarkably and unexpectedly, loss of NHE6/<italic>Slc9a6</italic> effectively reduced Aβ accumulation even in the absence of ApoE4, suggesting that hyperacidification of EEs prevents amyloid plaque formation independently of ApoE4. NHE6/<italic>Slc9a6</italic> suppression or inhibition may thus be a universal approach to prevent amyloid buildup in the brain, irrespective of ApoE genotype. Our previous (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>) and current studies thus suggest a novel mechanism to prevent ApoE4-risk for AD and delay plaque formation. In addition, genome-wide association studies (GWAS) in conjunction with studies on cell culture and mouse models of AD show that various AD risk factors enhance endolysosomal dysfunction (<xref ref-type="bibr" rid="bib36">Knopman et al., 2021</xref>; <xref ref-type="bibr" rid="bib82">Small et al., 2017</xref>; <xref ref-type="bibr" rid="bib90">Verheijen and Sleegers, 2018</xref>), which potentially could be corrected by NHE6 inhibition.</p><p>Upon endocytosis, endosomes undergo gradual acidification controlled by vATPases which actively pump protons into the vesicular lumen, and by the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE6 which functions as a regulatable proton leak channel. NHE6 depletion acidifies early and recycling endosomes (<xref ref-type="bibr" rid="bib47">Lucien et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Ohgaki et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Ouyang et al., 2013</xref>; <xref ref-type="bibr" rid="bib101">Xinhan et al., 2011</xref>). pH is an important regulator of the endolysosomal sorting machinery in which vesicles undergo multiple rounds of fusion. EEs undergo fusion and fission events in close proximity to the cell membrane. Recycling endosomes originate from EEs while they undergo early-to-late endosomal maturation. In contrast to late endosomes, recycling endosomes do not undergo further acidification (<xref ref-type="bibr" rid="bib35">Jovic et al., 2010</xref>; <xref ref-type="bibr" rid="bib75">Schmid, 2017</xref>). The pH of EEs and recycling endosomes is ∼6.4–6.5 (<xref ref-type="bibr" rid="bib8">Casey et al., 2010</xref>). This is normally sufficient to induce ligand receptor dissociation and enable cargo sorting. Our data, however, suggest that ApoE4 dramatically delays this fast recycling step in neurons, where ApoE, Apoer2, and glutamate receptors co-traffic through fast recycling compartments upon Reelin stimulation (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). We have proposed that ApoE4 impairs vesicle recycling due to isoelectric precipitation and structural unfolding at the physiological pH of the EE environment. This delays the dissociation of ApoE4 from its receptors, which in turn prolongs the entry of ApoE4 – along with Apoer2 and glutamate receptors in the same vesicle – into the recycling pathway (illustrated in <xref ref-type="fig" rid="fig1">Figure 1</xref>). We conclude that ApoE4 net charge affects its endosomal trafficking. This is further supported by recent findings by Arboleda-Velasquez and colleagues (<xref ref-type="bibr" rid="bib1">Arboleda-Velasquez et al., 2019</xref>), who reported the presence of the ‘Christchurch’ R136S mutation in an E3/E3 PS1 mutation carrier without dementia. By neutralizing the positive charge of Arg136 in ApoE3, the IEP of this ApoE3 isoform is predicted to match that of ApoE2, which is protective against AD (<xref ref-type="bibr" rid="bib12">Corder et al., 1994</xref>). ApoE2 homozygous carriers have an exceptionally low likelihood of developing AD (<xref ref-type="bibr" rid="bib69">Reiman et al., 2020</xref>). Moreover, the Christchurch mutation is located within the heparin-binding domain of ApoE, which reduces its affinity for cell surface heparan sulfate proteoglycans. That in turn would result in decreased uptake and thus depletion of ApoE in EEs. The net effect would be unimpeded trafficking of EE vesicles through the fast recycling compartment.</p><p>In dendritic spines, NHE6 co-localizes with markers of early and recycling endosomes and with the glutamate receptor subunit GluA1. In the hippocampus, NHE6 is highly expressed in the pyramidal cells of the CA and the granule cells of the dentate gyrus (<xref ref-type="bibr" rid="bib84">Strømme et al., 2011</xref>). Apoer2 is present at the postsynaptic density of CA1 neurons (<xref ref-type="bibr" rid="bib3">Beffert et al., 2005</xref>). During LTP induction, translocation of NHE6-containing vesicles to dendritic spine heads is enhanced (<xref ref-type="bibr" rid="bib15">Deane et al., 2013</xref>) and glutamate receptors are recruited to the synaptic surface through fast recycling (<xref ref-type="bibr" rid="bib20">Fernández-Monreal et al., 2016</xref>). Our findings are consistent with a model where NHE6 serves as a pH regulator of Reelin-controlled fast recycling endosomes containing Apoer2 and glutamate receptors. This mechanism possibly translates to other cell types and other ApoE receptors.</p><p>We previously showed that ApoE4 impairs Reelin-mediated receptor recruitment to the neuronal surface and this can be reversed by functionally disabling NHE6 in primary neurons, which results in the increased acidification of EEs to a level sufficiently different from the IEP of ApoE4, which then allows its efficient dissociation from its receptors. Conditional <italic>Slc9a6</italic> deletion accordingly alleviates the ApoE4-mediated resistance to Reelin-enhanced synaptic plasticity in hippocampal field recordings (<xref ref-type="bibr" rid="bib24">Gao et al., 2019</xref>; <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>).</p><p>Aβ and tau, forming amyloid plaques and neurofibrillary tangles, are the defining features of AD pathology. As of today, it remains controversial how ApoE isoforms interfere with Aβ and tau pathology. ApoE, which is primarily expressed by astrocytes, is the major lipid transporter in the brain and in an isoform-dependent manner affects inflammatory, endolysosomal, and lipid-metabolic pathways (<xref ref-type="bibr" rid="bib23">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Minett et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Van Acker et al., 2019</xref>; <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). Most risk factors identified by GWAS, including but not limited to APOE, ABCA7, CLU, BIN1, TREM2, SORL1, PICALM, CR1, are members of one or more of these pathways (<xref ref-type="bibr" rid="bib38">Kunkle et al., 2019</xref>). In recent years, endosomal dysfunction has increasingly gained acceptance as a causal mechanism for late-onset AD. Our findings now provide a mechanistic explanation how ApoE4 impairs endolysosomal trafficking and recycling, by interfering with vesicular sorting and maturation at a crucial bottleneck juncture of the endosomal trafficking machinery. This has far-reaching consequences for neuronal function, synaptic plasticity, and tau phosphorylation (<xref ref-type="bibr" rid="bib6">Brich et al., 2003</xref>; <xref ref-type="bibr" rid="bib9">Cataldo et al., 2000</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib56">Nuriel et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Pensalfini et al., 2020</xref>). More specifically, ApoE4 causes abnormalities of Rab5-positive endosomes (<xref ref-type="bibr" rid="bib56">Nuriel et al., 2017</xref>). Intriguingly, over-activation of the small guanosine triphosphatase (GTPase) Rab5, recapitulates neurodegenerative features of AD (<xref ref-type="bibr" rid="bib63">Pensalfini et al., 2020</xref>).</p><p>ApoE4 alters APP processing and Aβ degradation (reviewed in <xref ref-type="bibr" rid="bib4">Benilova et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Haass et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Huynh et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Lane-Donovan and Herz, 2017</xref>; <xref ref-type="bibr" rid="bib65">Pohlkamp et al., 2017</xref>; <xref ref-type="bibr" rid="bib104">Yamazaki et al., 2019</xref>), and the ability of Reelin to protect the synapse from Aβ toxicity is impaired by ApoE4 (<xref ref-type="bibr" rid="bib16">Durakoglugil et al., 2009</xref>). Aβ oligomerization followed by plaque formation is one hallmark of AD. NHE6 controls endosomal pH, which can affect BACE1 activity, one of the two enzymes required to process APP to release the Aβ peptide. <xref ref-type="bibr" rid="bib66">Prasad and Rao, 2015</xref>, reported that overexpression of NHE6 and full-length APP in HEK293 cells, rather than its inhibition or knockdown, reduced Aβ generation, which conflicts with our findings in primary cortical neurons (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Although the cause of this discrepancy remains currently unresolved, it is possible that it is the result of the two fundamentally different experimental systems that were used in the respective studies, that is, overexpression in immortalized kidney cells on one hand and primary cortical neuronal cultures on the other. Using a humanized <italic>App<sup>NL-F</sup></italic> knockin mouse model, we show that NHE6/<italic>Slc9a6</italic> deficiency in 1-year-old animals reduces plaque deposition by ∼80%. In <italic>App<sup>NL-F</sup></italic> mice, plaques can be identified as early as 9 months of age. Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>). Importantly, the reduction in plaque deposition by <italic>Slc9a6</italic> deficiency persists from early (12 months) to later stages (18 months) of AD, as <italic>Slc9a6</italic>-deficient <italic>App<sup>NL-F</sup></italic> animals aged 18 months had a reduction in insoluble Aβ by approximately 71%. NHE6/<italic>Slc9a6</italic> depletion in <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice showed a comparable reduction in plaque load (<xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>). Our data are consistent with previous findings by the Holtzman group (<xref ref-type="bibr" rid="bib19">Fagan et al., 2002</xref>) that showed that mouse ApoE promotes plaque deposition more potently than human ApoE4.</p><p>Prevention of plaque formation in our <italic>Slc9a6</italic>-deficient model was likely caused by increased microglial activation and plaque phagocytosis (<xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>, <xref ref-type="fig" rid="fig8">8</xref>,<xref ref-type="fig" rid="fig9">9</xref><xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref>). In the brains of AD patients and APP-overexpressing mice, plaques are surrounded by reactive microglia and astrocytes (<xref ref-type="bibr" rid="bib50">Meyer-Luehmann et al., 2008</xref>; <xref ref-type="bibr" rid="bib76">Serrano-Pozo et al., 2013</xref>), but the pathological significance of this is incompletely understood. Beneficial or detrimental roles of reactive microglia and astrocytes in the degradation of Aβ have been reported, depending on the activation state of these cells (<xref ref-type="bibr" rid="bib50">Meyer-Luehmann et al., 2008</xref>; <xref ref-type="bibr" rid="bib109">Ziegler-Waldkirch and Meyer-Luehmann, 2018</xref>). We observed an increase in reactive microglia and astrocytes resulting from NHE6/<italic>Slc9a6</italic> depletion, which correlated with reduced plaque deposition in <italic>App<sup>NL-F</sup></italic> mice, irrespective of the presence of either murine ApoE or human ApoE4. As murine ApoE exacerbates plaque deposition even more than ApoE4, the comparable plaque reduction in <italic>Slc9a6</italic>-deficient mice with murine <italic>Apoe</italic> or <italic>Apoe<sup>APOE4</sup></italic> might be the result of a maximally accelerated early endosomal maturation and cargo transport in the absence of NHE6. When compared to control <italic>App<sup>NL-F</sup></italic> mice, <italic>Slc9a6</italic>-deficient <italic>App<sup>NL-F</sup></italic> mice show an increase in Iba1 (microglia) and GFAP (astrocytes) immunoreactivity, but reduced Aβ immunoreactivity. Surprisingly, the intensity of GFAP and Iba1 in plaque areas was comparable between the groups. Moreover, even though Aβ is reduced and Iba1 is increased in the <italic>Slc9a6<sup>-</sup></italic>, the proportion of microglial structures containing Aβ (6E10 antibody) was comparable between <italic>Slc9a6</italic>-deficient and control <italic>App<sup>NL-F</sup></italic> mice, as was the intensity signal for 6E10. This suggests that microglia in the <italic>Slc9a6<sup>-</sup></italic> may be more efficient in taking up and degrading Aβ. Whether the reduction in plaques is due to the presence of an increased number of microglia and astrocytes that actively phagocytose nascent plaques, or whether endosomal acidification in microglia and astrocytes improves their ability to degrade or export Aβ from the brain remains to be determined. It is tempting to speculate that the mechanism that leads to reduced plaque load in <italic>Slc9a6</italic>-deficient <italic>App<sup>NL-F</sup></italic> mice may involve an increased catabolic rate (<xref ref-type="bibr" rid="bib78">Shi et al., 2021</xref>), brought about by the accelerated acidification and vesicular trafficking of EEs.</p><p>It is also possible that <italic>Slc9a6</italic> deficiency alters the efficiency of astrocytes to lipidate ApoE. In a mouse model, improved ApoE lipidation by the overexpression of ATP-binding cassette transporter family member A1 (ABCA1) decreased plaque deposition (<xref ref-type="bibr" rid="bib92">Wahrle et al., 2005</xref>; <xref ref-type="bibr" rid="bib93">Wahrle et al., 2008</xref>; <xref ref-type="bibr" rid="bib91">Wahrle et al., 2004</xref>). During HDL assembly, ABCA1 shuttles between EE and the plasma membrane, a process also referred to as retroendocytosis (<xref ref-type="bibr" rid="bib59">Ouimet et al., 2019</xref>). Moreover, membrane trafficking of ABCA1 is altered by ApoE in an isoform-dependent fashion (<xref ref-type="bibr" rid="bib68">Rawat et al., 2019</xref>). The <italic>App<sup>NL-F</sup></italic> mouse model used in our study develops plaques at 12 months (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) in the presence of murine ApoE. However, the onset of plaque deposition in human <italic>Apoe<sup>APOE4</sup></italic> mice was delayed by ∼3 months. The effect of germline <italic>Slc9a6</italic> deficiency and conditional <italic>Slc9a6</italic> deficiency induced at 2 months had a comparable effect on plaque reduction in <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice.</p><p><italic>Slc9a6<sup>-</sup></italic> and <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> both show progressive Purkinje cell loss in the cerebellum, indicating that NHE6 requirement is cell-autonomous and not developmentally determined. <italic>Slc9a6<sup>-</sup></italic> and <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> show a comparable increase in immunoreactivity against Iba1 and GFAP. Increased glia reactivity can be a direct cell-autonomous effect of NHE6 loss or an indirect effect caused by NHE6 deficiency-related neurodegeneration. As germline <italic>Slc9a6<sup>-</sup></italic> mice present with a reduction in cortical thickness and hippocampal volume caused by both neurodevelopmental and neurodegenerative effects (<xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), it is possible that neurodegeneration gives rise to glia activation. However, the tamoxifen-induced <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice do not present with a reduction in cortical or hippocampal volume (<xref ref-type="fig" rid="fig7">Figure 7</xref>), yet have comparable immunoreactivity for markers of glial activation. Our study supports a temporally distinct function of NHE6 in the adult brain where the cerebrum requires NHE6 for development, but not for postnatal neuronal survival, whereas Purkinje cells in the cerebellum do. A similar dual function for NHE6 has been described previously by <xref ref-type="bibr" rid="bib102">Xu et al., 2017</xref>. Moreover, this further indicates that reduced plaque load is also not an effect of neuronal loss. Therefore, our two mouse models together suggest that the observed increased glial activation is not caused by neuronal cell loss, but rather is likely a direct cell-autonomous effect of NHE6 loss of function. It thus remains to be determined whether endosomal acidification in NHE6-deficient microglia alone is sufficient to induce Aβ degradation and plaque reduction.</p><p>NHE6 is ubiquitously expressed in all cells of the body, however, in the CNS it is highly expressed in neurons where abundant synaptic vesicles and neurotransmitter receptors recycle in synapses (<xref ref-type="bibr" rid="bib44">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Lee et al., 2021</xref>) and to a lesser extent in glial cells (<xref ref-type="bibr" rid="bib107">Zhang et al., 2014</xref>). Neuronal NHE6 plays a direct role in both synaptic development and plasticity, potentially through BDNF/TrkB (<xref ref-type="bibr" rid="bib15">Deane et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Ouyang et al., 2013</xref>) and other pathways. The impact of NHE6 loss in microglia and astrocytes is still unknown. Global <italic>Slc9a6</italic> deficiency causes glial activation in vivo, which could be mediated through either a primary cell-autonomous mechanism or a secondary mechanism induced by damaged neurons. In ApoE4-expressing astrocytes, others have shown that overexpression of NHE6 increases LRP1 on the surface, which correlated with an increase in Aβ uptake (<xref ref-type="bibr" rid="bib67">Prasad and Rao, 2018</xref>). Microglia are the primary glial cells that degrade Aβ; thus, it will be imperative to determine how NHE6 levels alter Aβ degradation selectively in astrocytes and microglia, respectively.</p><p>Early endosomal pH balance in phagocytic cells plays an important role in viral and bacterial infection response. In phagocytic cells, the deacidification of endosomes using pharmacological inhibitors like chloroquine has been shown to reduce endosomal toll-like receptor (TLR) response (<xref ref-type="bibr" rid="bib14">de Bouteiller et al., 2005</xref>; <xref ref-type="bibr" rid="bib22">Fox, 2019</xref>; <xref ref-type="bibr" rid="bib39">Kuznik et al., 2011</xref>; <xref ref-type="bibr" rid="bib99">Wozniacka et al., 2006</xref>; <xref ref-type="bibr" rid="bib105">Yang et al., 2016</xref>), suggesting that NHE6 depletion in microglia might conversely augment TLR response.</p><p>It would also be intriguing to test whether <italic>Slc9a6</italic> deficiency increases cognitive performance in AD mouse models. In the current study we used <italic>App<sup>NL-F</sup></italic> and <italic>App<sup>NL-F</sup>;Apoe<sup>APOE4</sup></italic> mice as the most physiological currently available mouse models of AD that do not rely on excessive amyloid overproduction. These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) (own unpublished observations). Other neurobehavioral phenotypes have been described for <italic>Slc9a6<sup>-</sup></italic> mice, which also recapitulate symptoms in Christianson syndrome patients, for example, hyposensitivity to pain (<xref ref-type="bibr" rid="bib64">Petitjean et al., 2020</xref>). Future studies on our novel tamoxifen-inducible <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> line will help to understand whether these symptoms are based on neurodevelopmental deficits caused by germline <italic>Slc9a6</italic> deficiency or whether they can be reproduced by induced loss of NHE6 postnatally.</p><p>In conclusion, we have shown that both the endosomal trafficking defect induced by ApoE4 in neurons and increased plaque deposition irrespective of ApoE genotype can be corrected by inhibition or genetic deletion of NHE6/<italic>Slc9a6</italic>, a key regulator of early endosomal pH. Accelerated acidification of EEs abolishes the ApoE4-induced Reelin resistance and restores normal synaptic plasticity in ApoE4-targeted replacement mice. The first FDA-approved drug for AD treatment in 18 years is aducanumab (<xref ref-type="bibr" rid="bib77">Sevigny et al., 2016</xref>), an antibody directed against Aβ, which clears amyloid from the brain. However, amyloid removal in individuals already afflicted with AD provides at best marginal benefits at this stage. Moreover, in excess of 1 billion people worldwide are ApoE4 carriers, making early treatment with a complex biologic such as aducanumab impractical on the global scale. Here, we have presented a potential alternative approach which should be adaptable to large-scale prevention treatment using blood-brain barrier penetrant NHE6-specific inhibitors. Taken together, our combined data suggest that endosomal acidification has considerable potential as a novel therapeutic approach for AD prevention and possibly also for the prevention of disease progression.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/<italic>Slc9a6</italic><sup><italic>fl</italic></sup></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">Refer to Materials and methods section for detailed description of mouse model production</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/<italic>Slc9a6</italic><sup><italic>-</italic></sup></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">Refer to Materials and methods section for detailed description of mouse model production</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/<italic>Apoe</italic><sup><italic>APOE3</italic></sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib85">Sullivan et al., 1997</xref></td><td align="left" valign="bottom">IMSR_TAC:2,542</td><td align="left" valign="bottom"><italic>Apoe</italic><sup><italic>APOE3</italic></sup></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/<italic>Apoe</italic><sup><italic>APOE4</italic></sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib37">Knouff et al., 1999</xref></td><td align="left" valign="bottom">IMSR_TAC:3,518</td><td align="left" valign="bottom"><italic>Apoe</italic><sup><italic>APOE4</italic></sup></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J</td><td align="left" valign="bottom">The Jackson Laboratory <xref ref-type="bibr" rid="bib49">Madisen et al., 2010</xref></td><td align="left" valign="bottom">JAX #007909</td><td align="left" valign="bottom"><italic>ROSA</italic><sup><italic>floxedStop-tdTomato</italic></sup></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/CAG-cre/Esr15Amc/J</td><td align="left" valign="bottom">The Jackson Laboratory <xref ref-type="bibr" rid="bib27">Hayashi and McMahon, 2002</xref></td><td align="left" valign="bottom">JAX #004682</td><td align="left" valign="bottom"><italic>CAG-Cre</italic><sup><italic>ERT2</italic></sup></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse/B6.129S4-Meox2tm1(cre)Sor/J</td><td align="left" valign="bottom">The Jackson Laboratory <xref ref-type="bibr" rid="bib86">Tallquist and Soriano, 2000</xref></td><td align="left" valign="bottom">JAX 003755</td><td align="left" valign="bottom"><italic>Meox-Cre</italic></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>App</italic><sup><italic>NL-F</italic></sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref></td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom"><italic>App</italic><sup><italic>NL-F</italic></sup></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Tg2576</td><td align="left" valign="bottom">Charles River <xref ref-type="bibr" rid="bib31">Hsiao et al., 1996</xref></td><td align="left" valign="bottom">Charles River Tg2576</td><td align="left" valign="bottom">Tg2576, <italic>APPSwe</italic></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom">SD rat</td><td align="left" valign="bottom">Charles River</td><td align="left" valign="bottom">SC:400</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">R70507, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0045">CVCL_0045</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293-T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Neuro-2a</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-131</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">NHE6-KO (<italic>Slc9a6</italic><sup><italic>-</italic></sup>) mouse embryonic fibroblasts (MEFs)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">Refer to Materials and methods section for detailed description of MEF production</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Slc9a6</italic><sup><italic>+</italic></sup> MEFs (<italic>Slc9a6</italic><sup><italic>-</italic></sup> littermate)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">Refer to Materials and methods section for detailed description of MEF production</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Aβ (clone 6E10) (mouse monoclonal)</td><td align="left" valign="bottom">Covance</td><td align="left" valign="bottom">SIG-39320 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_662798">AB_662798</ext-link></td><td align="left" valign="bottom">WB and IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Aβ (clone 4 G8) (mouse monoclonal)</td><td align="left" valign="bottom">Covance</td><td align="left" valign="bottom">SIG-39220 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10175152">AB_10175152</ext-link></td><td align="left" valign="bottom">IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho tyrosine (clone 4 G10) (mouse monoclonal)</td><td align="left" valign="bottom">EMD Millipore</td><td align="left" valign="bottom">Millipore Cat# 05–321, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_309678">AB_309678</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Apoer2 (rabbit polyclonal)</td><td align="left" valign="bottom">Herz Lab, #2561, <xref ref-type="bibr" rid="bib87">Trommsdorff et al., 1999</xref></td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-Actin (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab8227, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_23051">AB_23051</ext-link> 86</td><td align="left" valign="bottom">WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Calbindin D-28k (mouse monoclonal)</td><td align="left" valign="bottom">Swant</td><td align="left" valign="bottom">Swant Cat# 300, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10000347">AB_10000347</ext-link></td><td align="left" valign="bottom">IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFAP (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Abcam Cat# ab7260, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305808">AB_305808</ext-link></td><td align="left" valign="bottom">IHC (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GluA1 (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab31232, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2113447">AB_2113447</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GluA2/3 (rabbit polyclonal)</td><td align="left" valign="bottom">EMD Millipore</td><td align="left" valign="bottom">07–598, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_31074">AB_31074</ext-link> 1</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GluN2B (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">4,207 S, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_12642">AB_12642</ext-link> 23</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Iba1 (rabbit polyclonal)</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">019–19741, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_839504">AB_839504</ext-link></td><td align="left" valign="bottom">IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NHE6 (C-terminus) (rabbit polyclonal)</td><td align="left" valign="bottom">Herz Lab, <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref></td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse-IgG AF594 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">A-11032, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534091">AB_2534091</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rabbit-IgG AF488 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">A-11034, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2576217">AB_2576217</ext-link></td><td align="left" valign="bottom">IHC (1:500)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-mouse-IgG staining kit</td><td align="left" valign="bottom">Vector</td><td align="left" valign="bottom">MP-7602, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2336532">AB_2336532</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-rabbit-IgG staining kit</td><td align="left" valign="bottom">Vector</td><td align="left" valign="bottom">MP-7601, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2336533">AB_2336533</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Antigen retrieval citrate buffer</td><td align="left" valign="bottom">BioGenex, Cat</td><td align="left" valign="bottom">HK086-9K</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">B-27 Supplement (50×), serum free</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">17504044</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cytoseal 60</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">8310</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMEM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">D6046</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FuGENE</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">E2311</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HBSS (1×)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">14175</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-Glutamic acid (glutamate)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">G1251</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">γ-Secretase inhibitor L-685458</td><td align="left" valign="bottom">Tocris Bioscience</td><td align="left" valign="bottom">2627</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin-streptomycin solution, 100×</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">30–002 CI</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Neurobasal Medium (1×) liquid without Phenol Red</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">12348017</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NeutrAvidin Agarose</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">29201</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nonidet P-40 Alternative</td><td align="left" valign="bottom">EMD Millipore</td><td align="left" valign="bottom">492016</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">32% Paraformaldehyde AQ solution</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">15714 S</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PBS (1×)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">D8537</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penisillin-streptomycin</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">30–002 CI</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatase inhibitor cocktail</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">78420</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Poly-D-lysine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A-003-M</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protein A-Sepharose 4B</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">101042</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Proteinase Inhibitor Cocktail</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P8340</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sulfo-NHS-SS-biotin</td><td align="left" valign="bottom">Pierce</td><td align="left" valign="bottom">21331</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Triton X-100</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAS9002-93-1</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tween 20</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">P1379</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Vectashield with DAPI</td><td align="left" valign="bottom">Vector Labs</td><td align="left" valign="bottom">H-1200</td><td align="left" valign="bottom">(DAPI 1.5 µg/ml)</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">pCrl, Reelin expression vector</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">D’Arcangelo et al., 1997</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">pcDNA3.1-ApoE3</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Progenitor pcDNA3.1-Zeo</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">pcDNA3.1-ApoE4</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Progenitor pcDNA3.1-Zeo</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">pLKO.1 scramble shRNA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">pLKO.1 shNHE6</td><td align="left" valign="bottom">Open Biosystem <break/><xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref></td><td align="left" valign="bottom">TRCN0000068828</td><td align="left" valign="bottom">Refer to shNHE6-a</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">psPAX2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">12260</td><td align="left" valign="bottom">Plasmid was a gift <break/>from Didier Trono</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">pMD2.G</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">12259</td><td align="left" valign="bottom">Plasmid was a gift <break/>from Didier Trono</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">pJB-NHE6 <break/>targeting vector</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Refer to Materials and methods <break/>section for detailed <break/>description</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pJB1 (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">Braybrooke et al., 2000</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCR4-TOPO (plasmid)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">K457502</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLVCMVfull (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pME (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib83">Stawicki et al., 2014</xref></td><td align="left" valign="bottom">Addgene <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:addgene_73794">#73794</ext-link></td><td align="left" valign="bottom">Plasmid was a gift <break/>from David Raible</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLVCMV Vamp3pHluorin2 (plasmid)</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Refer to Materials and methods <break/>section for detailed <break/>description</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">BAC containing murine NHE6 sequence <break/>(bacterial artificial chromosome)</td><td align="left" valign="bottom">BACPAC <break/>Resources Center</td><td align="left" valign="bottom">RP23 364 F14</td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Adobe Creative Cloud</td><td align="left" valign="bottom">Adobe</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010279">SCR_010279</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 7.0</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji/ImageJ</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">LabView7.0</td><td align="left" valign="bottom">National Instruments</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014325">SCR_014325</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NDP.view2</td><td align="left" valign="bottom">Hamamatsu Photonics</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Odyssey <break/>Imaging System</td><td align="left" valign="bottom">LI-COR</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014579">SCR_014579</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Clustal Omega</td><td align="left" valign="bottom">EMBL-EBI</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001591">SCR_001591</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Leica TCS SPE</td><td align="left" valign="bottom">Leica</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002140">SCR_002140</ext-link></td><td align="left" valign="bottom"><break/></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SA forward</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GGATCCGTGT<break/>GTGTGTTGGG<break/>GGAGGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SA reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CTCGAGCTCAC<break/>AATCAGCCCTTT<break/>AAATATGCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAP repair US forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">AAGCTTGCGGCC<break/>GCTTCAATTTCTG<break/>TCCTTGCTACTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAP repair <break/>US reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">AGATCTCAAGAA<break/>AGTTAGCTAGA<break/>AGTGTGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAP repair <break/>DS forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">AGATCTGTAGA<break/>GGATGTGGGA<break/>AAGAGAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAP repair <break/>DS reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GTCGACGCGG<break/>CCGACACACA<break/>CAGATAAATAA<break/>CCTCAAAAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5’ flanking 1st LoxP fragment forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GCTTCTCTCG<break/>AGCAAGAGTCAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5’ flanking 1st LoxP fragment reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GATATCAGCA<break/>GGTACCACCAA<break/>GATCTCAACCT<break/>TATTGTCCTATA<break/>TGCACAAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3’ flanking 1<sup>st</sup> LoxP fragment forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GTCTTGTTGGTA<break/>CCTGATGAAATG<break/>GACTACCTCCACTTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3’ flanking 1st LoxP fragment reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">ATCGATCTTCA<break/>TAACCCATCTGGATA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">LoxP Oligo forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GATCTGCTCAGC<break/>ATAACTTCGTATAG<break/>CATACATTATACG<break/>AAGTTATGGTAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">LoxP Oligo reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CATAACTTCGTA<break/>TAATGTATGCTAT<break/>ACGAAGTTATGC<break/>TGAGCAGATC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Genotyping NHE6-floxed and wt forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GAGGAAGC<break/>AAAGTGTCA<break/>GCTCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Genotyping NHE6-floxed and wt reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CTAATCCCCTC<break/>GGATGCTGCTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Genotyping NHE6-KO forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GAGGAAGC<break/>AAAGTGTCA<break/>GCTCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Genotyping NHE6-KO reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CCTCACAAGACT<break/>AGAGAAATGGTTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Vamp3 forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">TTCAAGCTTCAC<break/>CATGTCTACAGG<break/>TGTGCCTTCGGGGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Vamp3 reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CATTGTCATCAT<break/>CATCATCGTGTG<break/>GTGTGTCTCTAA<break/>GCTGAGCAACAG<break/>CGCCGTGGACGGC<break/>ACCGCCGGCCCCG<break/>GCAGCATCGCCAC<break/>CAAGCTTAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">pHluorin2 forward</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">CCGGTCCCAAGCTT<break/>ATGGTGAGCAAGG<break/>GCGAGGAGCTGTTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">pHluorin2 reverse</td><td align="left" valign="bottom">Integrated DNA Technology</td><td align="left" valign="bottom"><break/></td><td align="left" valign="bottom">GCCCTCTTCTAGAG<break/>AATTCACTTGTACAG<break/>CTCGTCCATGCCGTG</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All animal procedures were performed according to the approved guidelines (Animal Welfare Assurance Number D16-00296) for Institutional Animal Care and Use Committee (IACUC) at the University of Texas Southwestern Medical Center at Dallas.</p><p>The mouse lines Rosa-stop-tdTomato <italic>B6.Cg-Gt(ROSA)26Sor<sup>tm9(CAG-tdTomato)Hze</sup>/J</italic> (<xref ref-type="bibr" rid="bib49">Madisen et al., 2010</xref>) (JAX #007909) and CAG-Cre<sup>ERT2</sup> <italic>B6.Cg-Tg(CAG-cre/Esr1)5Amc/J</italic> mice (<xref ref-type="bibr" rid="bib27">Hayashi and McMahon, 2002</xref>) (JAX #004682) were obtained from The Jackson Laboratories (Bar Harbor, ME). ApoE3 and ApoE4 targeted replacement mice (<italic>Apoe<sup>APOE3</sup></italic>, <italic>Apoe<sup>APOE4</sup></italic>) (<xref ref-type="bibr" rid="bib37">Knouff et al., 1999</xref>; <xref ref-type="bibr" rid="bib85">Sullivan et al., 1997</xref>) were kind gifts of Dr Nobuyo Maeda. <italic>AppSwe</italic> (<italic>Tg2576</italic>) were generated by <xref ref-type="bibr" rid="bib31">Hsiao et al., 1996</xref>. The Meox-Cre <italic>B6.129S4-Meox2tm1(cre)Sor/J</italic> mice (JAX 003755) were provided by Drs M Tallquist and P Soriano (<xref ref-type="bibr" rid="bib86">Tallquist and Soriano, 2000</xref>). Conditional NHE6 KO (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>) and germline NHE6 KO (<italic>Slc9a6<sup>-</sup></italic>) mice were generated as described below. The human APP knockin line (<italic>App<sup>NL-F</sup></italic>) (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) has been described earlier. Pregnant female SD (Sprague Dawley) rats were obtained from Charles River (SC:400). Mice were group-housed in a standard 12 hr light/dark cycle and fed ad libitum standard mouse chow (Envigo, Teklad 2016 diet as standard and Teklad 2018 diet for breeding cages).</p><p>To generate <italic>Slc9a6</italic>-floxed (<italic>Slc9a6<sup>fl</sup></italic>) mice, the first exon of NHE6 was flanked with loxP sites (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). A loxP site was inserted 2 kb upstream of the first exon of the X-chromosomal NHE6 gene and a Neo-cassette (flanked with loxP and FRT sites) was inserted 1 kb downstream of the first exon. Insertion sites were chosen based on low conservation (mVISTA) between mammalian species (rat, human, mouse). To create the targeting vector for the <italic>Slc9a6<sup>fl</sup></italic> mouse line, pJB1 (<xref ref-type="bibr" rid="bib5">Braybrooke et al., 2000</xref>) was used as backbone. Murine C57Bl/6 J embryonic stem (ES) cell DNA was used as template to amplify the short arm of homology (SA; 0.88 kb of the first intron starting 1 kb 3’ downstream of exon 1), which was inserted between the Neo and HSVTK selection marker genes of pJB1 (BamHI and XhoI sites) to create an intermediate plasmid referred to as pJB1-NHE6SA. To create the intermediate plasmid pNHE6-LA for the long homology arm, a fragment spanning from 13 kb 5’ upstream to 1 kb 3’ downstream of the first <italic>Slc9a6</italic> (NHE6) exon was integrated into pCR4-TOPO (Thermo Fisher) by using a bacterial artificial chromosome (RP23 364F14, Children’s Hospital Oakland Research Institute [CHORI]) and the GAP repair technique (<xref ref-type="bibr" rid="bib43">Lee et al., 2001</xref>) (primers to amplify the upstream (US) and downstream (DS) homology boxes are listed in the Key resources table). In a parallel cloning step, a 2.4 kb XhoI-EcoRV <italic>Slc9a6</italic> promoter region fragment spanning from 2.7 to 0.4 kp 5’ upstream of the <italic>Slc9a6</italic> start-codon was modified with the 1st loxP site to generate pLoxP: three fragments (1) 0.7 kb 5’ loxP flanking <italic>Slc9a6</italic>-fragment, (2) 1.7 kb 3’ loxP flanking <italic>Slc9a6</italic> fragment, and (3) 100 bp loxP oligo (primers/oligos for each fragment are listed in the Key resources table) were cloned into pCR4-TOPO. The 2.5 kb loxP-modified XhoI-EcoRV <italic>Slc9a6</italic>-promoter fragment of pLoxP was cloned into pNHE6-LA to create pNHE6-LA-LoxP. To obtain the final targeting construct pJB-NHE6-TV, the NotI-EagI fragment of pNHE6-LA-LoxP containing the long arm (11 kb 5’ upstream of the 1st LoxP) and the 1st loxP site was cloned into the NotI-site of pJB1-NHE6SA and checked for orientation (pJB1-NHE6 targeting vector). pJB-NHE6-TV was linearized with NotI and electroporated into C57Bl/6 J ES cells. Gene targeting-positive C57Bl/6 J ES cells (PCR screen) were injected into albino C57Bl/6 J blastocysts, resulting in chimeric mice. The chimeras were crossed to C57Bl/6 J mice, resulting in <italic>Slc9a6<sup>fl/+</sup></italic> females. Genotyping: The <italic>Slc9a6<sup>fl</sup></italic> PCR amplifies a 250 bp of the wildtype and 270 bp of the floxed allele, primers are listed in the Key resources table.</p><p>To generate <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>, <italic>Slc9a6<sup>fl/+</sup></italic> females were crossed to <italic>CAG-Cre<sup>ERT2</sup></italic> mice to obtain <italic>Slc9a6<sup>fl/fl</sup>;CAG-Cre<sup>ERT2</sup></italic> and <italic>Slc9a6<sup>y/fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice (<italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>) and <italic>CAG-Cre<sup>ERT2</sup></italic> negative control littermates (<italic>Slc9a6<sup>fl</sup></italic>). <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice were backcrossed to <italic>Apoe<sup>APOE3</sup></italic> or <italic>Apoe<sup>APOE4</sup></italic> mice. Breeding pairs were set up in which only one parent was <italic>CAG-Cre<sup>ERT2</sup></italic> positive. The following genotypes were used for hippocampal field recordings: (1) <italic>Apoe<sup>APOE3</sup>;SLC9a6<sup>y/fl</sup></italic> (short:<italic>Apoe<sup>APOE3</sup></italic>), (2) <italic>Apoe<sup>APOE3</sup>;Slc9a6<sup>y/fl</sup>;Cre<sup>ERT2</sup></italic> (short: <italic>Apoe<sup>APOE3</sup>; Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>), (3) <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>y/fl</sup></italic> (short: <italic>Apoe<sup>APOE4</sup></italic>), and (4) <italic>Apoe<sup>APOE4</sup>;SLc9a6<sup>y/fl</sup>;Cre<sup>ERT2</sup></italic> (short: <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic>). The <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> line was further crossed with the <italic>App<sup>NL-F</sup></italic> line to generate <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup>;App<sup>NL-F</sup></italic> and <italic>Apoe<sup>APOE4</sup>;Slc9a6<sup>fl</sup>;App<sup>NL-F</sup></italic> control littermates. To induce genetic depletion of NHE6, tamoxifen (120 mg/kg) was intraperitoneally injected at 6–8 weeks of age. Injections were applied for 5 consecutive days. Tamoxifen was dissolved in sunflower oil (Sigma, W530285) and 10% EtOH.</p><p>To generate the germline NHE6 KO line (<italic>Slc9a6<sup>-</sup></italic>), heterozygous <italic>Slc9a6<sup>fl/+</sup></italic> females were crossed to <italic>Meox-Cre</italic> to yield germline mutant <italic>Slc9a6<sup>-/-</sup></italic> females and <italic>Slc9a6<sup>y/-</sup></italic> males (<italic>Slc9a6<sup>-</sup></italic>). Genotyping: The <italic>Slc9a6<sup>fl</sup></italic> PCR amplifies 250 bp of the wildtype, 270 bp of the floxed, and no fragment in the KO alleles. Recombination was verified with the NHE6-rec PCR, which amplifies 400 bp if recombination has occurred. PCR primers are listed in the Key resources table. <italic>Slc9a6<sup>-</sup></italic> animals were further crossed with <italic>App<sup>NL-F</sup></italic> (<xref ref-type="bibr" rid="bib72">Saito et al., 2014</xref>) mice. <italic>App<sup>NL-F</sup>;Slc9a6<sup>-</sup></italic> (<italic>App<sup>NL-F/NL-F</sup>;Slc9a6<sup>y/-</sup></italic> or <italic>App<sup>NL-F/NL-F</sup>;Slc9a6<sup>-/-</sup></italic>) and control (<italic>App<sup>NL-F</sup> = AppNL<sup>NL-F/NL-F</sup>;Slc9a6<sup>y/+</sup></italic> or <italic>App<sup>NL-F/NL-F</sup>;Slc9a6<sup>+/+</sup></italic>) littermates were obtained by crossing <italic>Slc9a6<sup>+/-</sup>;App<sup>NL-F/NL-F</sup></italic> females with either <italic>Slc9a6<sup>y/+</sup>;App<sup>NL-F/NL-F</sup></italic> or <italic>Slc9a6<sup>y/-</sup>;App<sup>NL-F/NL-F</sup></italic> males.</p></sec><sec id="s4-2"><title>DNA constructs, recombinant proteins, lentivirus production</title><p>Lentiviral plasmids with shRNA directed against NHE6/<italic>Slc9a6</italic> and the scrambled control have been described in <xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>. Plasmids encoding ApoE3 and ApoE4 (<xref ref-type="bibr" rid="bib11">Chen et al., 2010</xref>), and Reelin <xref ref-type="bibr" rid="bib17">D’Arcangelo et al., 1997</xref> have been described before. The lentiviral plasmid encoding the Vamp3-pHluorin2 fusion protein was cloned by inserting mouse Vamp3 cDNA, a linker and pHluorin2 (pME, <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene%20#73794">Addgene #73794</ext-link>) (<xref ref-type="bibr" rid="bib83">Stawicki et al., 2014</xref>) into pLVCMVfull (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>). For Vamp3 the forward primer (5’- <named-content content-type="sequence">TTCAAGCTTCACCATGTCTACAGGTGTGCCTTCGGGGTC</named-content>-3’) contains a Kozak sequence, the reverse primer encodes a KLSNSAVDGTAGPGSIAT linker (<xref ref-type="bibr" rid="bib53">Nakamura et al., 2005</xref>) (5’ <named-content content-type="sequence">CATTGTCATCATCATCATCGTGTGGTGTGTCTCTAAGCTGAGCAACAGCGCCGTGGACGGCACCGCCGGCCCCGGCAGCATCGCCACCAAGCTTAAC</named-content>-3'). The pHluorin2 primers were forward 5’-<named-content content-type="sequence">CCGGTCCCAAGCTTATGGTGAGCAAGGGCGAGGAGCTGTTC</named-content>-3’ and reverse 5’- <named-content content-type="sequence">GCCCTCTTCTAGAGAATTCACTTGTACAGCTCGTCCATGCCGTG</named-content>-3’. The fragments were sequentially cloned into pcDNA3.1 and the fusion protein was then transferred with NheI and EcoRI into pLVCMVfull. Lentiviral plasmids psPAX2 and pMD2.g were a kind gift from Dr D Trono and obtained from Addgene.</p><p>Recombinant Reelin and ApoE were generated in HEK293 cells. Reelin was purified as described before (<xref ref-type="bibr" rid="bib96">Weeber et al., 2002</xref>). ApoE-conditioned medium was collected from HEK293 cell cultures transiently transfected with pcDNA3.1-ApoE constructs or empty control vector (pcDNA3.1-Zeo). ApoE concentration was measured as described before (<xref ref-type="bibr" rid="bib100">Xian et al., 2018</xref>).</p><p>For lentivirus production HEK 293 T cells were co-transfected with psPAX2, pMD2.g, and the individual shRNA encoding transfer or Vamp3-pHluorin2 constructs. Media was replaced after 12–16 hr. Viral particle containing media was collected after centrifuging cellular debris. The viral particles were 10× concentrated by ultra-centrifugation and resuspended in Neurobasal medium. To infect neurons on DIV7 1/10th of the culture medium was replaced by concentrated virus. After 24 hr, the virus was removed.</p></sec><sec id="s4-3"><title>Histochemistry</title><p>Mice were euthanized with isoflurane and perfused with PBS followed by 4% paraformaldehyde (PFA) in PBS. Brains were removed and post-fixed for 24 hr in 4 % PFA. Fresh fixed brains were immobilized in 5 % agarose in PBS and 50 μm thick sections were sliced on a vibratome (Leica, Wetzlar, Germany). Vibratome slices of Rosa26<sup>floxedStop-tdTomato</sup>;CAGCre<sup>ERT2</sup> mice, with or without tamoxifen injection at 8 weeks of age were mounted with Antifade Mounting medium containing DAPI (Vectashield). For immunofluorescence, vibratome slices were labeled for Calbindin after permeabilization with 0.3 % Triton X in PBS and blocking for 1 hr in blocking buffer (10 % normal goat serum, 3 % BSA, and 0.3 % Triton X in PBS). The primary antibody mouse anti-Calbindin (Swant CB300) was diluted in blocking buffer (1:1000) and added to the slices for 24–48 hr at 4°C. Slices were subsequently washed 4 × 15 min with PBS containing 0.3 % Triton X. Slices were incubated with anti-mouse IgG coupled to Alexa594 (1:500 in blocking buffer) for 2 hr at room temperature. After washing, slices were mounted with Antifade Mounting medium with DAPI (Vectashield). Images were taken with an Axioplan two microscope (Zeiss).</p><p>For immunohistochemistry staining, PFA-fixed brains were block-sectioned into coronal slabs, paraffin-embedded, and serially sectioned on a rotating microtome (Leica) at 5 μm. Deparaffinized sections were stained with Thioflavin S as described before (<xref ref-type="bibr" rid="bib25">Guntern et al., 1992</xref>). Briefly, deparaffinized slices were oxidized in 0.25 % KMnO<sub>4</sub> for 20 min. After washing with water, slices were bleached with 1 % K<sub>2</sub>S<sub>2</sub>O<sub>5</sub> / C<sub>2</sub>H<sub>2</sub>O<sub>4</sub> for 2 min, washed in water, and treated with 2 % NaOH/H<sub>2</sub>O<sub>2</sub> for 20 min. After washing with water, slices were acidified in 0.25 % CH<sub>3</sub>COOH for 1 min, washed with water and equilibrated in 50 % EtOH for 2 min, and stained in Thioflavin S solution for 7 min. Reaction was stopped by washing in 50 % EtOH. Slices were dehydrated with 95 % EtOH, followed by 100 % EtOH and xylene. Slices were mounted with Cytoseal 60 (Thermo Scientific). Deparaffinized sections were labeled using antibodies raised against GFAP (Abcam AB5804, Rabbit, 1:2000), Iba1 (Wako 019–19741, Rabbit, 1:1000), and Aβ (4G8, Covance or 6E10, Biolegend, both mouse, 1:1000). Briefly, 5 μm sections were deparaffinized, subjected to microwave antigen retrieval (citrate buffer, pH 6.0), permeabilized with 0.3 % (vol/vol) Triton X, endogenous peroxidases activity was quenched for diaminobenzidine (DAB) staining. Slices were blocked with goat serum (2.5%) prior to overnight incubation with primary antibodies at 4°C. Primary antibodies were detected by either fluorescent secondary antibodies (goat-anti-mouse Alexa594, goat-anti-rabbit Alexa488) or sequential incubation with biotinylated secondary antisera and streptavidin-peroxidase for DAB staining. DAB chromagen was used to detect the immunoperoxidase signal (<xref ref-type="bibr" rid="bib81">Sinclair et al., 1981</xref>) (Vector; anti-mouse and anti-rabbit IgG kits). Fluorescence-labeled slices were counterstained with DAPI (mounting media with DAPI, Vectashield). Standard protocols were utilized for staining of paraffin sections with H&amp;E (Leica) (<xref ref-type="bibr" rid="bib21">Fischer et al., 2008</xref>). Microscopy was performed on a high-throughput microscope (NanoZoomer 2.0-HT, Hamamatsu) for DAB-stained tissue or with an Axioplan two microscope (Zeiss) for immunofluorescence analysis. The analysis of DAB-labeled antibodies was performed after exporting the images with NDP.view2 software with ImageJ. For Thioflavin S staining and Aβ labeling plaques were quantified by categorizing them as small, medium, and large (Thioflavin S) or dense and diffuse (4G8) as depicted in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>. Co-localization analysis of microglia (Iba1) and astrocytes (GFAP) with plaques (6E10) was performed with ImageJ. A blind observer selected the area of plaques with circles of 20, 40, or 80 µm diameter and analyzed the intensity of 6E10 and Iba1 or GFAP by using the ImageJ plugin RGB_measure. 6E10-positive microglia (Iba1) were quantified by a blind observer by first identifying microglia structures/cells in the green channel (Iba1), and then analyzing the proportion of 6E10-positive structures and signal intensity (red channel).</p></sec><sec id="s4-4"><title>Primary cortical neuronal cultures</title><p>Primary cortical neuronal cultures were prepared from rat (SD, Charles River) or various mouse lines (<italic>wildtype, Slc9a6<sup>-</sup>, AppSwe</italic>) (E18) as described previously (<xref ref-type="bibr" rid="bib10">Chen et al., 2005</xref>). Neurons were cultured in poly-D-lysine coated six-well plates (1 million/9 cm<sup>2</sup>) or on coverslips (30,000 neurons/1.1 cm<sup>2</sup>) in presence of Neurobasal medium supplemented with B27, glutamine, and penicillin-streptomycin at 37°C and 5% CO<sub>2</sub>. At indicated days in vitro (DIV) primary neurons were used for experiments.</p></sec><sec id="s4-5"><title>Mouse embryonic fibroblasts</title><p>Fibroblasts were isolated from <italic>Slc9a6<sup>-</sup></italic> and wildtype littermate control embryos (E13.5). After removing the head and the liver, the tissue was trypsinized (0.05% trypsin-EDTA) at 4°C overnight, followed by 30 min at 37°C. Suspended cells were cultivated in DMEM high glucose with 15% FCS, 2 mM L-glutamine, and Pen/Strep. Fibroblasts were serially passaged until proliferation slowed down. Immortalization was achieved by keeping fibroblasts in culture under high confluency until they overcame their growth crisis.</p></sec><sec id="s4-6"><title>pH measurements</title><p>Mouse embryonic fibroblasts derived from either <italic>Slc9a6<sup>-</sup></italic> or wildtype littermate embryos were infected with Vamp3-pHluorin2 lentivirus; 24–48 hr post-infection, vesicular pH was measured on a Zeiss LSM880 Airyscan confocal microscope as described in <xref ref-type="bibr" rid="bib48">Ma et al., 2017</xref>. For the standard calibration curve, cells were washed and incubated with pH standard curve buffer (125 mM KCl, 25 mM NaCl, 10 μM monensin, 25 mM HEPES for pH &gt;7.0 or 25 mM MES for pH &lt;7.0; pH adjusted with NaOH and HCl) and imaged in 5% CO<sub>2</sub> at 37°C. For vesicular pH measurements, cells were washed and imaged with pH standard curve at pH 7 without monensin. Samples were excited at 405 and 488 nm with an emission of 510 nm. For quantification, six fields of view were imaged for <italic>Slc9a6<sup>+</sup></italic> and four fields of view for <italic>Slc9a6<sup>-</sup></italic> fibroblast. Between 4 and 10 pHluorin-positive vesicles were measured per field of view which resulted in n = 32 wildtype vesicle and n = 28 <italic>Slc9a6<sup>-</sup></italic> vesicles. The same settings were used for every image, and images were analyzed using ImageJ software. The intensity of excitations with 405 and 488 nm was measured, individual vesicles were marked as regions of interest, and the 405/488 ratio was calculated and plotted against pH for the standard curve.</p></sec><sec id="s4-7"><title>Biochemistry</title><p>To analyze receptor recycling, cell surface biotinylation was performed. At DIV10–14, primary neurons were pre-treated for 30 min with ApoE-conditioned medium (5 μg/ml) and incubated with Reelin (2 μg/ml) for an additional 30 min (see timeline in <xref ref-type="fig" rid="fig4">Figure 4A</xref>). After treatment, cells were washed with cold PBS and incubated in PBS containing sulfo-NHS-SS-biotin for 30 min at 4°C. Subsequently excess reagent was quenched by rinsing the neurons with cold PBS containing 100 mM glycine. Neurons were lysed in 160 µl/9 cm<sup>2</sup> lysis buffer (PBS with 0.1% SDS, 1% Triton X-100, and protease inhibitors) at 4°C for 20 min. Cell debris were pelleted at 14,000 rpm for 10 min at 4°C. The protein concentration was measured using the Bradford Protein Assay (Bio-Rad). One hundred µg of total proteins were incubated with 50 µl of NeutrAvidin agarose at 4°C for 1 hr. Agarose beads were washed three times using washing buffer (500 mM NaCl; 15 mM Tris-HCl, pH 8.0; 0.5% Triton X-100), biotinylated surface proteins were eluted from agarose beads by boiling in 2× SDS sample loading buffer and loaded on an SDS-PAGE gel for Western blot analysis. GST-control and GST-RAP (50 μg/ml) pre-treatment of neurons was performed for 1 hr.</p><p>To analyze BACE1 activity, β-CTF was detected by immunoblotting. BACE1 activity was examined after pharmacological NHE inhibition or genetic <italic>Slc9a6</italic> knockdown in primary neurons of <italic>AppSwe</italic> mice. For NHE inhibition DIV10 neurons were treated with 5 µg/ml ApoE4, 3 µM EMD87580 (Merck), and/or 1 µM γ-secretase inhibitor L-685458 (Merck) for 5 hr. For knockdown of NHE6/<italic>Slc9a6</italic> DIV7 neurons of <italic>AppSwe</italic> mice were infected with lentivirus encoding shRNA against NHE6 or a scrambled control shRNA. On DIV13 neurons were treated with γ-secretase inhibitor for 12 hr. Proteins were extracted for Western blot analysis: Cells were washed three times with cold PBS and lysed for 20 min on ice in RIPA buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% Nonidet P-40; phosphatase and proteinase inhibitors). Cell debris were pelleted at 14,000 rpm for 10 min at 4°C. Protein concentration was measured using the Bradford Protein Assay (Bio-Rad). After adding 4× SDS loading buffer (0.1 M Tris-HCl, pH 6.8, 2% SDS, 5% β-mercaptoethanol, 10% glycerol, and 0.05% bromophenol blue), samples were denatured at 80°C for 10 min. Proteins were separated via SDS-PAGE and transferred to a nitrocellulose membrane for Western blotting using different antibodies listed in the Key resources table.</p><p>Brain tissue was dissected and prepared for immunoblotting as follows: After removal, brains were placed in ice-cold PBS containing proteinase inhibitors. Anatomical sectioning was performed under a microscope. The hippocampus was dissected out and transversal slices were further separated into cornu ammonis (CA) 1, CA3, and dentate gyrus. Respective pieces of the same anatomical regions of one brain were pooled, shock-frozen in liquid nitrogen, and stored at –80C. Frozen tissue was homogenized in 10× volume of RIPA buffer and incubated on ice for 30 min. Cell debris were pelleted for 10 min with 14,000 rpm at 4°C. After adding 4× SDS loading buffer, the samples were denatured at 80°C for 10 min and used for immunoblotting.</p><p>To measure soluble and insoluble Aβ species, a sequential homogenization procedure was employed. After removal of the brains from PBS perfused mice, cortical tissue was dissected and flash-frozen. Frozen cortical tissue was homogenized in TBS supplemented with phosphatase and proteinase inhibitors at 100 mg protein/ml using a glass dounce homogenizer. Crude lysate was centrifuged at 800 <italic>× g</italic> for 5 min at 4°C. The supernatant was further centrifuged at 100,000 <italic>× g</italic> for 30 min at 4°C and collected as TBS-soluble lysate (Aβ-soluble). The TBS pellet was further homogenized in 1% Triton-TBS containing phosphatase and proteinase inhibitors, centrifuged at 100,000 <italic>× g</italic> for 30 min at 4°C and collected as 1% Triton-soluble lysate. The Triton-pellet was incubated with 5 M guanidine-HCl rotating at RT for 1 hr. Guanidine-soluble lysate (Aβ-insoluble) was collected after centrifugation at 21,000 <italic>× g</italic> for 15 min at 4°C. The guanidine-pellet was further solubilized in 1/20th volume with 70% formic acid (Aβ-insoluble) and centrifuged at 21,000 <italic>× g</italic> for 15 min at 4°C. Soluble and insoluble Aβ levels were measured in duplicates using a commercial Aβ42 ELISA kit (Thermo Fisher, KHB3441) following the manufacturer’s instructions.</p></sec><sec id="s4-8"><title>Extracellular field recordings</title><p>Hippocampal slices were prepared from 3-month-old mice (tamoxifen-injected at 8 weeks). Slices of mice were obtained from four different genotypes; <italic>Slc9a6<sup>fl</sup>;CAG-Cre<sup>ERT2</sup></italic> mice or <italic>Slc9a6<sup>fl</sup></italic> mice with <italic>Apoe<sup>APOE3</sup></italic> or <italic>Apoe<sup>APOE4</sup></italic>. The brains were quickly removed and placed in ice-cold high sucrose cutting solution (in mM: 110 sucrose, 60 NaCl, 3 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 28 NaHCO<sub>3</sub>, 0.5 CaCl<sub>2</sub>, 5 glucose, 0.6 ascorbic acid, 7 MgSO<sub>4</sub>), bubbled with a gas mixture of 95% O<sub>2</sub> and 5% CO<sub>2</sub> for oxygenation. 350 µm transverse sections were cut using a vibratome (Leica). Slices were transferred into an incubation chamber containing 50% artificial cerebrospinal fluid (aCSF, in mM: 124 NaCl, 3 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 26 NaHCO<sub>3</sub>, 10 D-glucose, 2 CaCl<sub>2</sub>, 1 MgSO<sub>4</sub>) and 50% sucrose cutting solution, oxygenated with 95% O<sub>2</sub>/5% CO<sub>2</sub>. Slices were transferred into an oxygenated interface chamber and perfused with aCSF with or without Reelin (2 μg/ml). The stimulating electrode was placed on the Schaffer-collateral of the CA1-pyramidal neurons and the recording electrode on the dendrites of the CA3-pyramidal neurons. Once baseline was stably recorded for 20 min, theta burst was applied, and traces collected for an hour. For stimulation concentric bipolar electrodes (FHC, catalog no CBBRC75) were placed into the stratum radiatum. Stimulus intensity was set at 40–60% of maximum response and delivered at 33 mHz through an Isolated Pulse Stimulator (A-M Systems, Model 2100). A custom written program in LabView 7.0 was used for recording and analysis of LTP experiments. A theta burst (TBS; train of four pulses at 100 Hz repeated 10 times with 200 ms intervals; repeated five times at 10 s intervals) was used as a conditioning stimulus.</p></sec><sec id="s4-9"><title>Statistical methods</title><p>Data were expressed as the mean ± SEM and evaluated using two-tailed Student’s t-test for two groups with one variable tested and equal variances, one-way analysis of variance (ANOVA) with Dunnett’s post hoc or Tukey’s post hoc for multiple groups with only variable tested, or two-way ANOVA with Sidak’s post hoc for plaque quantification (two independent variables of NHE6 genotype and plaque classification). The differences were considered to be significant at p &lt; 0.05 (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). Software used for data analysis was ImageJ (NIH), LabView7.0 (National Instruments), Odyssey Imaging Systems (Li-Cor), Prism7.0 (GraphPad Software).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Inventor of Patent: https://patents.google.com/patent/US20110136832A1/en</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Resources, Validation, Visualization</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology, Resources, Validation, Visualization</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology, Validation</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were performed according to the approved guidelines (Animal Welfare Assurance Number D16-00296) for Institutional Animal Care and Use Committee (IACUC) at the University of Texas Southwestern Medical Center at Dallas.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-72034-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All relevant data are included in the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by NIH grants R37 HL063762, R01 NS093382, R01 NS108115, and RF1 AG053391 to JH and 1F31 AG067708-01 to CHW as well as funding from the Darrell K Royal Research Fund to MD. While this work was ongoing, JH was further supported by the Bright Focus Foundation (A20135245) and (A2016396S); Harrington Discovery Institute; and Circle of Friends Pilot Synergy Grant; and the Blue Field Project to Cure FTD. We are indebted Rebekah Hewitt, Barsha Subbha, Huichuan Reyna, Issac Rocha, Tamara Terrones, Emily Boyle, Alisa Gilloon, Travis Wolff, and Eric Hall for their excellent technical assistance. We thank Dr Yuan Yang for creating the NHE6-FLAG plasmid and the UTSW Whole Brain Microscopy Facility (WBMF) in the Department of Neurology and Neurotherapeutics for assistance with slide scanning. The WBMF is supported by the Texas Institute for Brain Injury and Repair (TIBIR). John Shelton and the UT Southwestern’s Histopathology Core provided help with paraffin sectioning as well as H&amp;E and Thioflavin S staining. We thank Wolfgang Scholz for providing EMD87580.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arboleda-Velasquez</surname><given-names>JF</given-names></name><name><surname>Lopera</surname><given-names>F</given-names></name><name><surname>O’Hare</surname><given-names>M</given-names></name><name><surname>Delgado-Tirado</surname><given-names>S</given-names></name><name><surname>Marino</surname><given-names>C</given-names></name><name><surname>Chmielewska</surname><given-names>N</given-names></name><name><surname>Saez-Torres</surname><given-names>KL</given-names></name><name><surname>Amarnani</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>AP</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Leyton-Cifuentes</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Baena</surname><given-names>A</given-names></name><name><surname>Aguillon</surname><given-names>D</given-names></name><name><surname>Rios-Romenets</surname><given-names>S</given-names></name><name><surname>Giraldo</surname><given-names>M</given-names></name><name><surname>Guzmán-Vélez</surname><given-names>E</given-names></name><name><surname>Norton</surname><given-names>DJ</given-names></name><name><surname>Pardilla-Delgado</surname><given-names>E</given-names></name><name><surname>Artola</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>JS</given-names></name><name><surname>Acosta-Uribe</surname><given-names>J</given-names></name><name><surname>Lalli</surname><given-names>M</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name><name><surname>Huentelman</surname><given-names>MJ</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Reiman</surname><given-names>RA</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Thiyyagura</surname><given-names>P</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Jun</surname><given-names>GR</given-names></name><name><surname>Naymik</surname><given-names>M</given-names></name><name><surname>Gai</surname><given-names>X</given-names></name><name><surname>Bootwalla</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JB</given-names></name><name><surname>Kim</surname><given-names>LA</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Quiroz</surname><given-names>YT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report</article-title><source>Nature Medicine</source><volume>25</volume><fpage>1680</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0611-3</pub-id><pub-id pub-id-type="pmid">31686034</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>SK</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Anderson</surname><given-names>GW</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts</article-title><source>PNAS</source><volume>73</volume><fpage>3178</fpage><lpage>3182</lpage><pub-id pub-id-type="doi">10.1073/pnas.73.9.3178</pub-id><pub-id pub-id-type="pmid">184464</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beffert</surname><given-names>U</given-names></name><name><surname>Weeber</surname><given-names>EJ</given-names></name><name><surname>Durudas</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>S</given-names></name><name><surname>Masiulis</surname><given-names>I</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>W-P</given-names></name><name><surname>Adelmann</surname><given-names>G</given-names></name><name><surname>Frotscher</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2</article-title><source>Neuron</source><volume>47</volume><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2005.07.007</pub-id><pub-id pub-id-type="pmid">16102539</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benilova</surname><given-names>I</given-names></name><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes</article-title><source>Nature Neuroscience</source><volume>15</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nn.3028</pub-id><pub-id pub-id-type="pmid">22286176</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braybrooke</surname><given-names>JP</given-names></name><name><surname>Spink</surname><given-names>KG</given-names></name><name><surname>Thacker</surname><given-names>J</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>29100</fpage><lpage>29106</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002075200</pub-id><pub-id pub-id-type="pmid">10871607</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brich</surname><given-names>J</given-names></name><name><surname>Shie</surname><given-names>F-S</given-names></name><name><surname>Howell</surname><given-names>BW</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Tus</surname><given-names>K</given-names></name><name><surname>Wakeland</surname><given-names>EK</given-names></name><name><surname>Jin</surname><given-names>L-W</given-names></name><name><surname>Mumby</surname><given-names>M</given-names></name><name><surname>Churchill</surname><given-names>G</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Genetic modulation of tau phosphorylation in the mouse</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-01-00187.2003</pub-id><pub-id pub-id-type="pmid">12514215</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caporaso</surname><given-names>GL</given-names></name><name><surname>Takei</surname><given-names>K</given-names></name><name><surname>Gandy</surname><given-names>SE</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name><name><surname>Mundigl</surname><given-names>O</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>De Camilli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein</article-title><source>The Journal of Neuroscience</source><volume>14</volume><fpage>3122</fpage><lpage>3138</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.14-05-03122.1994</pub-id><pub-id pub-id-type="pmid">8182461</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>JR</given-names></name><name><surname>Grinstein</surname><given-names>S</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sensors and regulators of intracellular pH</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>11</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nrm2820</pub-id><pub-id pub-id-type="pmid">19997129</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataldo</surname><given-names>AM</given-names></name><name><surname>Peterhoff</surname><given-names>CM</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Nixon</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations</article-title><source>The American Journal of Pathology</source><volume>157</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/s0002-9440(10)64538-5</pub-id><pub-id pub-id-type="pmid">10880397</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Beffert</surname><given-names>U</given-names></name><name><surname>Ertunc</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>TS</given-names></name><name><surname>Kavalali</surname><given-names>ET</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Reelin modulates NMDA receptor activity in cortical neurons</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>8209</fpage><lpage>8216</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1951-05.2005</pub-id><pub-id pub-id-type="pmid">16148228</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Durakoglugil</surname><given-names>MS</given-names></name><name><surname>Xian</surname><given-names>X</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling</article-title><source>PNAS</source><volume>107</volume><fpage>12011</fpage><lpage>12016</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914984107</pub-id><pub-id pub-id-type="pmid">20547867</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corder</surname><given-names>EH</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Risch</surname><given-names>NJ</given-names></name><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Schmechel</surname><given-names>DE</given-names></name><name><surname>Gaskell</surname><given-names>PC</given-names></name><name><surname>Rimmler</surname><given-names>JB</given-names></name><name><surname>Locke</surname><given-names>PA</given-names></name><name><surname>Conneally</surname><given-names>PM</given-names></name><name><surname>Schmader</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease</article-title><source>Nature Genetics</source><volume>7</volume><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/ng0694-180</pub-id><pub-id pub-id-type="pmid">7920638</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>CG</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Anderson</surname><given-names>RG</given-names></name><name><surname>Russell</surname><given-names>DW</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region</article-title><source>Nature</source><volume>326</volume><fpage>760</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1038/326760a0</pub-id><pub-id pub-id-type="pmid">3494949</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bouteiller</surname><given-names>O</given-names></name><name><surname>Merck</surname><given-names>E</given-names></name><name><surname>Hasan</surname><given-names>UA</given-names></name><name><surname>Hubac</surname><given-names>S</given-names></name><name><surname>Benguigui</surname><given-names>B</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Bates</surname><given-names>EEM</given-names></name><name><surname>Caux</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>38133</fpage><lpage>38145</lpage><pub-id pub-id-type="doi">10.1074/jbc.M507163200</pub-id><pub-id pub-id-type="pmid">16144834</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>EC</given-names></name><name><surname>Ilie</surname><given-names>AE</given-names></name><name><surname>Sizdahkhani</surname><given-names>S</given-names></name><name><surname>Das Gupta</surname><given-names>M</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name><name><surname>McKinney</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enhanced recruitment of endosomal Na+/H+ exchanger NHE6 into Dendritic spines of hippocampal pyramidal neurons during NMDA receptor-dependent long-term potentiation</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>595</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2583-12.2013</pub-id><pub-id pub-id-type="pmid">23303939</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durakoglugil</surname><given-names>MS</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Kavalali</surname><given-names>ET</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Reelin signaling antagonizes beta-amyloid at the synapse</article-title><source>PNAS</source><volume>106</volume><fpage>15938</fpage><lpage>15943</lpage><pub-id pub-id-type="doi">10.1073/pnas.0908176106</pub-id><pub-id pub-id-type="pmid">19805234</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Arcangelo</surname><given-names>G</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Mikoshiba</surname><given-names>K</given-names></name><name><surname>Curran</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody</article-title><source>The Journal of Neuroscience</source><volume>17</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8987733</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>149</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(85)90269-4</pub-id><pub-id pub-id-type="pmid">4028432</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease</article-title><source>Neurobiology of Disease</source><volume>9</volume><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1006/nbdi.2002.0483</pub-id><pub-id pub-id-type="pmid">11950276</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Monreal</surname><given-names>M</given-names></name><name><surname>Sánchez-Castillo</surname><given-names>C</given-names></name><name><surname>Esteban</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>APPL1 gates long-term potentiation through its plekstrin homology domain</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>2793</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1242/jcs.183475</pub-id><pub-id pub-id-type="pmid">27257087</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>AH</given-names></name><name><surname>Jacobson</surname><given-names>KA</given-names></name><name><surname>Rose</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hematoxylin and eosin staining of tissue and cell sections</article-title><source>Cold Spring Harbor Protocols</source><volume>2008</volume><elocation-id>prot4986</elocation-id><pub-id pub-id-type="doi">10.1101/pdb.prot4986</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development</article-title><source>Lupus</source><volume>5</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1177/0961203396005001031</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Casey</surname><given-names>AE</given-names></name><name><surname>Sargeant</surname><given-names>TJ</given-names></name><name><surname>Mäkinen</surname><given-names>V-P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic variation within endolysosomal system is associated with late-onset Alzheimer’s disease</article-title><source>Brain</source><volume>141</volume><fpage>2711</fpage><lpage>2720</lpage><pub-id pub-id-type="doi">10.1093/brain/awy197</pub-id><pub-id pub-id-type="pmid">30124770</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>AYL</given-names></name><name><surname>Ilie</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>PKY</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name><name><surname>McKinney</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Christianson syndrome-linked deletion mutation (Δ287ES288) in SLC9A6 impairs hippocampal neuronal plasticity</article-title><source>Neurobiology of Disease</source><volume>130</volume><elocation-id>104490</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2019.104490</pub-id><pub-id pub-id-type="pmid">31175985</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guntern</surname><given-names>R</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Vallet</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer’s disease</article-title><source>Experientia</source><volume>48</volume><fpage>8</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/BF01923594</pub-id><pub-id pub-id-type="pmid">1371102</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Kaether</surname><given-names>C</given-names></name><name><surname>Thinakaran</surname><given-names>G</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Trafficking and proteolytic processing of APP</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>2</volume><elocation-id>a006270</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006270</pub-id><pub-id pub-id-type="pmid">22553493</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse</article-title><source>Developmental Biology</source><volume>244</volume><fpage>305</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1006/dbio.2002.0597</pub-id><pub-id pub-id-type="pmid">11944939</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>W</given-names></name><name><surname>Beisiegel</surname><given-names>U</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>tracellular processing of endocytosed triglyceride-rich lipoproteins comprises both recycling and degradation</article-title><source>Journal of Cell Science</source><volume>112</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1242/jcs.112.3.349</pub-id><pub-id pub-id-type="pmid">9885288</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiesberger</surname><given-names>T</given-names></name><name><surname>Trommsdorff</surname><given-names>M</given-names></name><name><surname>Howell</surname><given-names>BW</given-names></name><name><surname>Goffinet</surname><given-names>A</given-names></name><name><surname>Mumby</surname><given-names>MC</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation</article-title><source>Neuron</source><volume>24</volume><fpage>481</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)80861-2</pub-id><pub-id pub-id-type="pmid">10571241</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hook</surname><given-names>VYH</given-names></name><name><surname>Toneff</surname><given-names>T</given-names></name><name><surname>Aaron</surname><given-names>W</given-names></name><name><surname>Yasothornsrikul</surname><given-names>S</given-names></name><name><surname>Bundey</surname><given-names>R</given-names></name><name><surname>Reisine</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles</article-title><source>Journal of Neurochemistry</source><volume>81</volume><fpage>237</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00794.x</pub-id><pub-id pub-id-type="pmid">12064471</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>P</given-names></name><name><surname>Nilsen</surname><given-names>S</given-names></name><name><surname>Eckman</surname><given-names>C</given-names></name><name><surname>Harigaya</surname><given-names>Y</given-names></name><name><surname>Younkin</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Cole</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice</article-title><source>Science</source><volume>274</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1126/science.274.5284.99</pub-id><pub-id pub-id-type="pmid">8810256</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>T-PV</given-names></name><name><surname>Davis</surname><given-names>AA</given-names></name><name><surname>Ulrich</surname><given-names>JD</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins</article-title><source>Journal of Lipid Research</source><volume>58</volume><fpage>824</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1194/jlr.R075481</pub-id><pub-id pub-id-type="pmid">28246336</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilie</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>AYL</given-names></name><name><surname>Boucher</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Berghuis</surname><given-names>AM</given-names></name><name><surname>Hoffer</surname><given-names>MJV</given-names></name><name><surname>Hilhorst-Hofstee</surname><given-names>Y</given-names></name><name><surname>McKinney</surname><given-names>RA</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome</article-title><source>Neurobiology of Disease</source><volume>121</volume><fpage>187</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.10.002</pub-id><pub-id pub-id-type="pmid">30296617</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilie</surname><given-names>A</given-names></name><name><surname>Boucher</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Berghuis</surname><given-names>AM</given-names></name><name><surname>McKinney</surname><given-names>RA</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assorted dysfunctions of endosomal alkali cation/proton exchanger SLC9A6 variants linked to Christianson syndrome</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>7075</fpage><lpage>7095</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.012614</pub-id><pub-id pub-id-type="pmid">32277048</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jovic</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Rahajeng</surname><given-names>J</given-names></name><name><surname>Caplan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The early endosome: a busy sorting station for proteins at the crossroads</article-title><source>Histology and Histopathology</source><volume>25</volume><fpage>99</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.14670/HH-25.99</pub-id><pub-id pub-id-type="pmid">19924646</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Amieva</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Chételat</surname><given-names>G</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Nixon</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Alzheimer disease</article-title><source>Nature Reviews. Disease Primers</source><volume>7</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knouff</surname><given-names>C</given-names></name><name><surname>Hinsdale</surname><given-names>ME</given-names></name><name><surname>Mezdour</surname><given-names>H</given-names></name><name><surname>Altenburg</surname><given-names>MK</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Quarfordt</surname><given-names>SH</given-names></name><name><surname>Sullivan</surname><given-names>PM</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Apo E structure determines VLDL clearance and atherosclerosis risk in mice</article-title><source>The Journal of Clinical Investigation</source><volume>103</volume><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1172/JCI6172</pub-id><pub-id pub-id-type="pmid">10359567</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkle</surname><given-names>BW</given-names></name><name><surname>Grenier-Boley</surname><given-names>B</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Damotte</surname><given-names>V</given-names></name><name><surname>Naj</surname><given-names>AC</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Vronskaya</surname><given-names>M</given-names></name><name><surname>van der Lee</surname><given-names>SJ</given-names></name><name><surname>Amlie-Wolf</surname><given-names>A</given-names></name><name><surname>Bellenguez</surname><given-names>C</given-names></name><name><surname>Frizatti</surname><given-names>A</given-names></name><name><surname>Chouraki</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Badarinarayan</surname><given-names>N</given-names></name><name><surname>Jakobsdottir</surname><given-names>J</given-names></name><name><surname>Hamilton-Nelson</surname><given-names>KL</given-names></name><name><surname>Moreno-Grau</surname><given-names>S</given-names></name><name><surname>Olaso</surname><given-names>R</given-names></name><name><surname>Raybould</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kuzma</surname><given-names>AB</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Vardarajan</surname><given-names>BN</given-names></name><name><surname>Epelbaum</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Boada</surname><given-names>M</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Garnier</surname><given-names>J-G</given-names></name><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Moutet</surname><given-names>M-L</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Bacq</surname><given-names>D</given-names></name><name><surname>Denning</surname><given-names>N</given-names></name><name><surname>Jian</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Del Zompo</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Choi</surname><given-names>S-H</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Hughes</surname><given-names>JT</given-names></name><name><surname>Adams</surname><given-names>HH</given-names></name><name><surname>Malamon</surname><given-names>J</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>Y</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Dombroski</surname><given-names>BA</given-names></name><name><surname>Naranjo</surname><given-names>MCD</given-names></name><name><surname>Daniilidou</surname><given-names>M</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Wallon</surname><given-names>D</given-names></name><name><surname>Uphill</surname><given-names>J</given-names></name><name><surname>Aspelund</surname><given-names>T</given-names></name><name><surname>Cantwell</surname><given-names>LB</given-names></name><name><surname>Garzia</surname><given-names>F</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Hofer</surname><given-names>E</given-names></name><name><surname>Butkiewicz</surname><given-names>M</given-names></name><name><surname>Fin</surname><given-names>B</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Sarnowski</surname><given-names>C</given-names></name><name><surname>Bush</surname><given-names>WS</given-names></name><name><surname>Meslage</surname><given-names>S</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>CC</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Barber</surname><given-names>RC</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Sordon</surname><given-names>S</given-names></name><name><surname>Voijnovic</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>PM</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Mayhaus</surname><given-names>M</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Himali</surname><given-names>JJ</given-names></name><name><surname>Beekly</surname><given-names>D</given-names></name><name><surname>Squassina</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>AM</given-names></name><name><surname>Orellana</surname><given-names>A</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Rodriguez-Rodriguez</surname><given-names>E</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>ME</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Munoz-Fernadez</surname><given-names>C</given-names></name><name><surname>Sussams</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Fairchild</surname><given-names>TJ</given-names></name><name><surname>Benito</surname><given-names>YA</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Karamujić-Čomić</surname><given-names>H</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Thonberg</surname><given-names>H</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Roshchupkin</surname><given-names>G</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>Kawalia</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huebinger</surname><given-names>RM</given-names></name><name><surname>Kilander</surname><given-names>L</given-names></name><name><surname>Moebus</surname><given-names>S</given-names></name><name><surname>Hernández</surname><given-names>I</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Brundin</surname><given-names>R</given-names></name><name><surname>Turton</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Katz</surname><given-names>MJ</given-names></name><name><surname>Concari</surname><given-names>L</given-names></name><name><surname>Lord</surname><given-names>J</given-names></name><name><surname>Beiser</surname><given-names>AS</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Kloszewska</surname><given-names>I</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Koivisto</surname><given-names>AM</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Tarraga</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Haapasalo</surname><given-names>A</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Solfrizzi</surname><given-names>V</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Longstreth</surname><given-names>WT</given-names><suffix>Jr</suffix></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Frisardi</surname><given-names>V</given-names></name><name><surname>Diez-Fairen</surname><given-names>M</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Alvarez</surname><given-names>I</given-names></name><name><surname>Salani</surname><given-names>F</given-names></name><name><surname>Ciaramella</surname><given-names>A</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Fievet</surname><given-names>N</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Reisch</surname><given-names>JS</given-names></name><name><surname>Hanon</surname><given-names>O</given-names></name><name><surname>Cupidi</surname><given-names>C</given-names></name><name><surname>Andre Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Royall</surname><given-names>DR</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Maletta</surname><given-names>RG</given-names></name><name><surname>de Rojas</surname><given-names>I</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Cecchetti</surname><given-names>R</given-names></name><name><surname>George-Hyslop</surname><given-names>PS</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>C-K</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Avramidou</surname><given-names>D</given-names></name><name><surname>Albin</surname><given-names>RL</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><name><surname>Germanou</surname><given-names>A</given-names></name><name><surname>Apostolova</surname><given-names>LG</given-names></name><name><surname>Keller</surname><given-names>L</given-names></name><name><surname>Koutroumani</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Gkatzima</surname><given-names>O</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Whitehead</surname><given-names>P</given-names></name><name><surname>Atwood</surname><given-names>CS</given-names></name><name><surname>Caffarra</surname><given-names>P</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Quintela</surname><given-names>I</given-names></name><name><surname>Carracedo</surname><given-names>Á</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Barnes</surname><given-names>LL</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Frölich</surname><given-names>L</given-names></name><name><surname>Barral</surname><given-names>S</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Johnston</surname><given-names>JA</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Passmore</surname><given-names>P</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Boxer</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name><name><surname>Burke</surname><given-names>JR</given-names></name><name><surname>Kauwe</surname><given-names>JSK</given-names></name><name><surname>Burns</surname><given-names>JM</given-names></name><name><surname>Mancuso</surname><given-names>M</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Bonuccelli</surname><given-names>U</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Livingston</surname><given-names>G</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Bass</surname><given-names>NJ</given-names></name><name><surname>Carlsson</surname><given-names>CM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Carney</surname><given-names>RM</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Guerreiro</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Masullo</surname><given-names>C</given-names></name><name><surname>Crocco</surname><given-names>EA</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Bisceglio</surname><given-names>G</given-names></name><name><surname>Dick</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Hodges</surname><given-names>A</given-names></name><name><surname>Faber</surname><given-names>KM</given-names></name><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>KB</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Fardo</surname><given-names>DW</given-names></name><name><surname>Heun</surname><given-names>R</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Kölsch</surname><given-names>H</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Leber</surname><given-names>M</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Heuser</surname><given-names>I</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Hüll</surname><given-names>M</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Feulner</surname><given-names>T</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Harrell</surname><given-names>LE</given-names></name><name><surname>Drichel</surname><given-names>D</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Cushion</surname><given-names>TD</given-names></name><name><surname>Huentelman</surname><given-names>MJ</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Marshall</surname><given-names>R</given-names></name><name><surname>Jarvik</surname><given-names>GP</given-names></name><name><surname>Meggy</surname><given-names>A</given-names></name><name><surname>Abner</surname><given-names>E</given-names></name><name><surname>Menzies</surname><given-names>GE</given-names></name><name><surname>Jin</surname><given-names>L-W</given-names></name><name><surname>Leonenko</surname><given-names>G</given-names></name><name><surname>Real</surname><given-names>LM</given-names></name><name><surname>Jun</surname><given-names>GR</given-names></name><name><surname>Baldwin</surname><given-names>CT</given-names></name><name><surname>Grozeva</surname><given-names>D</given-names></name><name><surname>Karydas</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Vardy</surname><given-names>E</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name><name><surname>Jöckel</surname><given-names>K-H</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Pickering-Brown</surname><given-names>S</given-names></name><name><surname>Lieberman</surname><given-names>AP</given-names></name><name><surname>Klopp</surname><given-names>N</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Marson</surname><given-names>DC</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Martiniuk</surname><given-names>F</given-names></name><name><surname>Medway</surname><given-names>C</given-names></name><name><surname>Mash</surname><given-names>DC</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>Daniele</surname><given-names>A</given-names></name><name><surname>McCurry</surname><given-names>SM</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>McDavid</surname><given-names>AN</given-names></name><name><surname>Gallacher</surname><given-names>J</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>van den Bussche</surname><given-names>H</given-names></name><name><surname>Mesulam</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Riedel-Heller</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>O’Bryant</surname><given-names>S</given-names></name><name><surname>Olichney</surname><given-names>JM</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Paulson</surname><given-names>HL</given-names></name><name><surname>Collinge</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>WR</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>NS</given-names></name><name><surname>Poon</surname><given-names>WW</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Potter</surname><given-names>H</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Sacchinelli</surname><given-names>E</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Bossù</surname><given-names>P</given-names></name><name><surname>Orfei</surname><given-names>MD</given-names></name><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Warden</surname><given-names>D</given-names></name><name><surname>Roberson</surname><given-names>ED</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Bruni</surname><given-names>AC</given-names></name><name><surname>Rosen</surname><given-names>HJ</given-names></name><name><surname>Gallo</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>RN</given-names></name><name><surname>Ben-Shlomo</surname><given-names>Y</given-names></name><name><surname>Sager</surname><given-names>MA</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Cuccaro</surname><given-names>ML</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Slifer</surname><given-names>S</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Smith</surname><given-names>AG</given-names></name><name><surname>Sonnen</surname><given-names>JA</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Swerdlow</surname><given-names>RH</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Van Eldik</surname><given-names>LJ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Vonsattel</surname><given-names>JP</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><name><surname>Wilhelmsen</surname><given-names>KC</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Wingo</surname><given-names>TS</given-names></name><name><surname>Woltjer</surname><given-names>RL</given-names></name><name><surname>Wright</surname><given-names>CB</given-names></name><name><surname>Yu</surname><given-names>C-E</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Saba</surname><given-names>Y</given-names></name><name><surname>Pilotto</surname><given-names>A</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Peters</surname><given-names>O</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Boccardi</surname><given-names>V</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Warner</surname><given-names>N</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Sanchez-Juan</surname><given-names>P</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Ertekin-Taner</surname><given-names>N</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Debette</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Dartigues</surname><given-names>J-F</given-names></name><name><surname>Corcoran</surname><given-names>C</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Tschanz</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Munger</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>C O’Donovan</surname><given-names>M</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Escott-Price</surname><given-names>V</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Ramirez</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L-S</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Lambert</surname><given-names>J-C</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><collab>Alzheimer Disease Genetics Consortium (ADGC)</collab><collab>European Alzheimer’s Disease Initiative (EADI)</collab><collab>Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE)</collab><collab>Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES)</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing</article-title><source>Nature Genetics</source><volume>51</volume><fpage>414</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmid">30820047</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznik</surname><given-names>A</given-names></name><name><surname>Bencina</surname><given-names>M</given-names></name><name><surname>Svajger</surname><given-names>U</given-names></name><name><surname>Jeras</surname><given-names>M</given-names></name><name><surname>Rozman</surname><given-names>B</given-names></name><name><surname>Jerala</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines</article-title><source>Journal of Immunology</source><volume>186</volume><fpage>4794</fpage><lpage>4804</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000702</pub-id><pub-id pub-id-type="pmid">21398612</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane-Donovan</surname><given-names>C</given-names></name><name><surname>Philips</surname><given-names>GT</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration</article-title><source>Neuron</source><volume>83</volume><fpage>771</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.08.005</pub-id><pub-id pub-id-type="pmid">25144875</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane-Donovan</surname><given-names>C</given-names></name><name><surname>Philips</surname><given-names>GT</given-names></name><name><surname>Wasser</surname><given-names>CR</given-names></name><name><surname>Durakoglugil</surname><given-names>MS</given-names></name><name><surname>Masiulis</surname><given-names>I</given-names></name><name><surname>Upadhaya</surname><given-names>A</given-names></name><name><surname>Pohlkamp</surname><given-names>T</given-names></name><name><surname>Coskun</surname><given-names>C</given-names></name><name><surname>Kotti</surname><given-names>T</given-names></name><name><surname>Steller</surname><given-names>L</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Frotscher</surname><given-names>M</given-names></name><name><surname>Bock</surname><given-names>HH</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reelin protects against amyloid β toxicity in vivo</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra67</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaa6674</pub-id><pub-id pub-id-type="pmid">26152694</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane-Donovan</surname><given-names>C</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ApoE, ApoE Receptors, and the Synapse in Alzheimer’s Disease</article-title><source>Trends in Endocrinology and Metabolism</source><volume>28</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2016.12.001</pub-id><pub-id pub-id-type="pmid">28057414</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EC</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Martinez de Velasco</surname><given-names>J</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Swing</surname><given-names>DA</given-names></name><name><surname>Court</surname><given-names>DL</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A highly efficient <italic>Escherichia coli</italic>-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA</article-title><source>Genomics</source><volume>73</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1006/geno.2000.6451</pub-id><pub-id pub-id-type="pmid">11352566</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>U</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SCAMP5 plays a critical role in axonal trafficking and synaptic localization of NHE6 to adjust quantal size at glutamatergic synapses</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2011371118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2011371118</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>U</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SCAMP5 mediates activity-dependent enhancement of NHE6 recruitment to synaptic vesicles during synaptic plasticity</article-title><source>Molecular Brain</source><volume>14</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.1186/s13041-021-00763-0</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>TJ</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Lefton</surname><given-names>KB</given-names></name><name><surname>Robinson</surname><given-names>GO</given-names></name><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Sullivan</surname><given-names>PM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models</article-title><source>Acta Neuropathologica Communications</source><volume>3</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-015-0250-y</pub-id><pub-id pub-id-type="pmid">26556230</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucien</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>PP</given-names></name><name><surname>Lavoie</surname><given-names>RR</given-names></name><name><surname>Lacroix</surname><given-names>JM</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Parent</surname><given-names>JL</given-names></name><name><surname>Arsenault</surname><given-names>D</given-names></name><name><surname>Harper</surname><given-names>K</given-names></name><name><surname>Dubois</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15884</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15884</pub-id><pub-id pub-id-type="pmid">28635961</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Werthmann</surname><given-names>GC</given-names></name><name><surname>Thompson</surname><given-names>HM</given-names></name><name><surname>Morrow</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Live-cell Microscopy and Fluorescence-based Measurement of Luminal pH in Intracellular Organelles</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>5</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2017.00071</pub-id><pub-id pub-id-type="pmid">28871281</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madisen</surname><given-names>L</given-names></name><name><surname>Zwingman</surname><given-names>TA</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Zariwala</surname><given-names>HA</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A robust and high-throughput Cre reporting and characterization system for the whole mouse brain</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/nn.2467</pub-id><pub-id pub-id-type="pmid">20023653</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Luehmann</surname><given-names>M</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Prada</surname><given-names>C</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>de Calignon</surname><given-names>A</given-names></name><name><surname>Rozkalne</surname><given-names>A</given-names></name><name><surname>Koenigsknecht-Talboo</surname><given-names>J</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Bacskai</surname><given-names>BJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease</article-title><source>Nature</source><volume>451</volume><fpage>720</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nature06616</pub-id><pub-id pub-id-type="pmid">18256671</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minett</surname><given-names>T</given-names></name><name><surname>Classey</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Fahrenhold</surname><given-names>M</given-names></name><name><surname>Taga</surname><given-names>M</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Nicoll</surname><given-names>JAR</given-names></name><name><surname>Boche</surname><given-names>D</given-names></name><collab>MRC CFAS</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Microglial immunophenotype in dementia with Alzheimer’s pathology</article-title><source>Journal of Neuroinflammation</source><volume>13</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-016-0601-z</pub-id><pub-id pub-id-type="pmid">27256292</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>JA</given-names></name><name><surname>Hatters</surname><given-names>DM</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Hochtl</surname><given-names>P</given-names></name><name><surname>Oberg</surname><given-names>KA</given-names></name><name><surname>Rupp</surname><given-names>B</given-names></name><name><surname>Weisgraber</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>50380</fpage><lpage>50385</lpage><pub-id pub-id-type="doi">10.1074/jbc.M204898200</pub-id><pub-id pub-id-type="pmid">12393895</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Teko</surname><given-names>Y</given-names></name><name><surname>Mitsui</surname><given-names>K</given-names></name><name><surname>Kanazawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>1561</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1074/jbc.M410041200</pub-id><pub-id pub-id-type="pmid">15522866</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naslavsky</surname><given-names>N</given-names></name><name><surname>Caplan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The enigmatic endosome - sorting the ins and outs of endocytic trafficking</article-title><source>Journal of Cell Science</source><volume>131</volume><elocation-id>jcs216499</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.216499</pub-id><pub-id pub-id-type="pmid">29980602</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease</article-title><source>FASEB Journal</source><volume>31</volume><fpage>2729</fpage><lpage>2743</lpage><pub-id pub-id-type="doi">10.1096/fj.201700359</pub-id><pub-id pub-id-type="pmid">28663518</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuriel</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>KY</given-names></name><name><surname>Ashok</surname><given-names>A</given-names></name><name><surname>Dillman</surname><given-names>AA</given-names></name><name><surname>Figueroa</surname><given-names>HY</given-names></name><name><surname>Apuzzo</surname><given-names>J</given-names></name><name><surname>Ambat</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>E</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Mathews</surname><given-names>PM</given-names></name><name><surname>Duff</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Endosomal-Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo</article-title><source>Frontiers in Neuroscience</source><volume>11</volume><elocation-id>702</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2017.00702</pub-id><pub-id pub-id-type="pmid">29311783</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohgaki</surname><given-names>R</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Kanazawa</surname><given-names>H</given-names></name><name><surname>Ogihara</surname><given-names>S</given-names></name><name><surname>Hoekstra</surname><given-names>D</given-names></name><name><surname>van Ijzendoorn</surname><given-names>SCD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Na+/H+ exchanger NHE6 in the endosomal recycling system is involved in the development of apical bile canalicular surface domains in HepG2 cells</article-title><source>Molecular Biology of the Cell</source><volume>21</volume><fpage>1293</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1091/mbc.E09-09-0767</pub-id><pub-id pub-id-type="pmid">20130086</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Litwack-Klein</surname><given-names>L</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Schaefer</surname><given-names>MM</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms</article-title><source>Journal of Lipid Research</source><volume>28</volume><fpage>371</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">3585172</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouimet</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>TJ</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HDL and Reverse Cholesterol Transport</article-title><source>Circulation Research</source><volume>124</volume><fpage>1505</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.312617</pub-id><pub-id pub-id-type="pmid">31071007</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Lizarraga</surname><given-names>SB</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>U</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Ellisor</surname><given-names>D</given-names></name><name><surname>Kauer</surname><given-names>JA</given-names></name><name><surname>Morrow</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Christianson syndrome protein NHE6 modulates TrkB endosomal signaling required for neuronal circuit development</article-title><source>Neuron</source><volume>80</volume><fpage>97</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.07.043</pub-id><pub-id pub-id-type="pmid">24035762</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panza</surname><given-names>F</given-names></name><name><surname>Solfrizzi</surname><given-names>V</given-names></name><name><surname>Torres</surname><given-names>F</given-names></name><name><surname>Mastroianni</surname><given-names>F</given-names></name><name><surname>Colacicco</surname><given-names>AM</given-names></name><name><surname>Basile</surname><given-names>AM</given-names></name><name><surname>Capurso</surname><given-names>C</given-names></name><name><surname>D’Introno</surname><given-names>A</given-names></name><name><surname>Del Parigi</surname><given-names>A</given-names></name><name><surname>Capurso</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early- and late-onset sporadic Alzheimer’s disease</article-title><source>Neuroscience Letters</source><volume>292</volume><fpage>79</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/s0304-3940(00)01447-6</pub-id><pub-id pub-id-type="pmid">10998553</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parhizkar</surname><given-names>S</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Brendel</surname><given-names>M</given-names></name><name><surname>Kleinberger</surname><given-names>G</given-names></name><name><surname>Deussing</surname><given-names>M</given-names></name><name><surname>Focke</surname><given-names>C</given-names></name><name><surname>Nuscher</surname><given-names>B</given-names></name><name><surname>Xiong</surname><given-names>M</given-names></name><name><surname>Ghasemigharagoz</surname><given-names>A</given-names></name><name><surname>Katzmarski</surname><given-names>N</given-names></name><name><surname>Krasemann</surname><given-names>S</given-names></name><name><surname>Lichtenthaler</surname><given-names>SF</given-names></name><name><surname>Müller</surname><given-names>SA</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Monasor</surname><given-names>LS</given-names></name><name><surname>Tahirovic</surname><given-names>S</given-names></name><name><surname>Herms</surname><given-names>J</given-names></name><name><surname>Willem</surname><given-names>M</given-names></name><name><surname>Pettkus</surname><given-names>N</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Bartenstein</surname><given-names>P</given-names></name><name><surname>Edbauer</surname><given-names>D</given-names></name><name><surname>Rominger</surname><given-names>A</given-names></name><name><surname>Ertürk</surname><given-names>A</given-names></name><name><surname>Grathwohl</surname><given-names>SA</given-names></name><name><surname>Neher</surname><given-names>JJ</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Meyer-Luehmann</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>191</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0296-9</pub-id><pub-id pub-id-type="pmid">30617257</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pensalfini</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Subbanna</surname><given-names>S</given-names></name><name><surname>Bleiwas</surname><given-names>C</given-names></name><name><surname>Goulbourne</surname><given-names>CN</given-names></name><name><surname>Stavrides</surname><given-names>PH</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Darji</surname><given-names>S</given-names></name><name><surname>Pawlik</surname><given-names>M</given-names></name><name><surname>Huo</surname><given-names>C</given-names></name><name><surname>Peddy</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>MJ</given-names></name><name><surname>Smiley</surname><given-names>JF</given-names></name><name><surname>Basavarajappa</surname><given-names>BS</given-names></name><name><surname>Nixon</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer’s Disease</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108420</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108420</pub-id><pub-id pub-id-type="pmid">33238112</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petitjean</surname><given-names>H</given-names></name><name><surname>Fatima</surname><given-names>T</given-names></name><name><surname>Mouchbahani-Constance</surname><given-names>S</given-names></name><name><surname>Davidova</surname><given-names>A</given-names></name><name><surname>Ferland</surname><given-names>CE</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name><name><surname>Sharif-Naeini</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of SLC9A6/NHE6 impairs nociception in a mouse model of Christianson syndrome</article-title><source>Pain</source><volume>161</volume><fpage>2619</fpage><lpage>2628</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001961</pub-id><pub-id pub-id-type="pmid">32569089</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohlkamp</surname><given-names>T</given-names></name><name><surname>Wasser</surname><given-names>CR</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional Roles of the Interaction of APP and Lipoprotein Receptors</article-title><source>Frontiers in Molecular Neuroscience</source><volume>10</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2017.00054</pub-id><pub-id pub-id-type="pmid">28298885</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>5311</fpage><lpage>5327</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.602219</pub-id><pub-id pub-id-type="pmid">25561733</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH</article-title><source>PNAS</source><volume>115</volume><fpage>E6640</fpage><lpage>E6649</lpage><pub-id pub-id-type="doi">10.1073/pnas.1801612115</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawat</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sima</surname><given-names>J</given-names></name><name><surname>Bar</surname><given-names>R</given-names></name><name><surname>Liraz</surname><given-names>O</given-names></name><name><surname>Gundimeda</surname><given-names>U</given-names></name><name><surname>Parekh</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>JO</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Harrington</surname><given-names>MG</given-names></name><name><surname>Michaelson</surname><given-names>DM</given-names></name><name><surname>Yassine</surname><given-names>HN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes</article-title><source>The Journal of Neuroscience</source><volume>39</volume><fpage>9611</fpage><lpage>9622</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1400-19.2019</pub-id><pub-id pub-id-type="pmid">31641056</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Arboleda-Velasquez</surname><given-names>JF</given-names></name><name><surname>Quiroz</surname><given-names>YT</given-names></name><name><surname>Huentelman</surname><given-names>MJ</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Caselli</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Paul Vonsattel</surname><given-names>J</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Kofler</surname><given-names>JK</given-names></name><name><surname>Duque</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Gwirtsman</surname><given-names>HE</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Ghetti</surname><given-names>BF</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>L-S</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Mayeux</surname><given-names>RP</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Jun</surname><given-names>GR</given-names></name><collab>Alzheimer’s Disease Genetics Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>667</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-14279-8</pub-id><pub-id pub-id-type="pmid">32015339</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roses</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>53</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1097/00005072-199409000-00002</pub-id><pub-id pub-id-type="pmid">8083686</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudenko</surname><given-names>G</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>K</given-names></name><name><surname>Ichtchenko</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Deisenhofer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structure of the LDL receptor extracellular domain at endosomal pH</article-title><source>Science</source><volume>298</volume><fpage>2353</fpage><lpage>2358</lpage><pub-id pub-id-type="doi">10.1126/science.1078124</pub-id><pub-id pub-id-type="pmid">12459547</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Matsuba</surname><given-names>Y</given-names></name><name><surname>Mihira</surname><given-names>N</given-names></name><name><surname>Takano</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Itohara</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Single App knock-in mouse models of Alzheimer’s disease</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>661</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/nn.3697</pub-id><pub-id pub-id-type="pmid">24728269</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>Melquist</surname><given-names>S</given-names></name><name><surname>Cannon</surname><given-names>A</given-names></name><name><surname>Hutton</surname><given-names>ML</given-names></name><name><surname>Sletvold</surname><given-names>O</given-names></name><name><surname>Saltvedt</surname><given-names>I</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Lydersen</surname><given-names>S</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer’s disease; a case control study from central Norway</article-title><source>BMC Neurology</source><volume>8</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-8-9</pub-id><pub-id pub-id-type="pmid">18416843</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarlus</surname><given-names>H</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microglia in Alzheimer’s disease</article-title><source>The Journal of Clinical Investigation</source><volume>127</volume><fpage>3240</fpage><lpage>3249</lpage><pub-id pub-id-type="doi">10.1172/JCI90606</pub-id><pub-id pub-id-type="pmid">28862638</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Reciprocal regulation of signaling and endocytosis: Implications for the evolving cancer cell</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>2623</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1083/jcb.201705017</pub-id><pub-id pub-id-type="pmid">28674108</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Muzikansky</surname><given-names>A</given-names></name><name><surname>Gómez-Isla</surname><given-names>T</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Betensky</surname><given-names>RA</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>72</volume><fpage>462</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3182933788</pub-id><pub-id pub-id-type="pmid">23656989</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevigny</surname><given-names>J</given-names></name><name><surname>Chiao</surname><given-names>P</given-names></name><name><surname>Bussière</surname><given-names>T</given-names></name><name><surname>Weinreb</surname><given-names>PH</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Maier</surname><given-names>M</given-names></name><name><surname>Dunstan</surname><given-names>R</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>O’Gorman</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Arastu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chollate</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>MS</given-names></name><name><surname>Quintero-Monzon</surname><given-names>O</given-names></name><name><surname>Scannevin</surname><given-names>RH</given-names></name><name><surname>Arnold</surname><given-names>HM</given-names></name><name><surname>Engber</surname><given-names>T</given-names></name><name><surname>Rhodes</surname><given-names>K</given-names></name><name><surname>Ferrero</surname><given-names>J</given-names></name><name><surname>Hang</surname><given-names>Y</given-names></name><name><surname>Mikulskis</surname><given-names>A</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Nitsch</surname><given-names>RM</given-names></name><name><surname>Sandrock</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease</article-title><source>Nature</source><volume>537</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nature19323</pub-id><pub-id pub-id-type="pmid">27582220</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Andhey</surname><given-names>PS</given-names></name><name><surname>Ising</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Snipes</surname><given-names>LL</given-names></name><name><surname>Boyer</surname><given-names>K</given-names></name><name><surname>Lawson</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><name><surname>Manis</surname><given-names>M</given-names></name><name><surname>Serrano</surname><given-names>JR</given-names></name><name><surname>Benitez</surname><given-names>BA</given-names></name><name><surname>Schmidt</surname><given-names>RE</given-names></name><name><surname>Artyomov</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>JD</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms</article-title><source>Neuron</source><volume>109</volume><fpage>2413</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.05.034</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Tosaki</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Hisano</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Nukina</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>3663</fpage><lpage>3671</lpage><pub-id pub-id-type="doi">10.1128/MCB.02185-07</pub-id><pub-id pub-id-type="pmid">18378702</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>VG</given-names></name><name><surname>Shore</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components</article-title><source>Biochemistry</source><volume>12</volume><fpage>502</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1021/bi00727a022</pub-id><pub-id pub-id-type="pmid">4345806</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinclair</surname><given-names>RA</given-names></name><name><surname>Burns</surname><given-names>J</given-names></name><name><surname>Dunnill</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Immunoperoxidase staining of formalin-fixed, paraffin-embedded, human renal biopsies with a comparison of the peroxidase-antiperoxidase (PAP) and indirect methods</article-title><source>Journal of Clinical Pathology</source><volume>34</volume><fpage>859</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1136/jcp.34.8.859</pub-id><pub-id pub-id-type="pmid">7024314</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>SA</given-names></name><name><surname>Simoes-Spassov</surname><given-names>S</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Petsko</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer’s Disease</article-title><source>Trends in Neurosciences</source><volume>40</volume><fpage>592</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2017.08.003</pub-id><pub-id pub-id-type="pmid">28962801</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stawicki</surname><given-names>TM</given-names></name><name><surname>Owens</surname><given-names>KN</given-names></name><name><surname>Linbo</surname><given-names>T</given-names></name><name><surname>Reinhart</surname><given-names>KE</given-names></name><name><surname>Rubel</surname><given-names>EW</given-names></name><name><surname>Raible</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The zebrafish merovingian mutant reveals a role for pH regulation in hair cell toxicity and function</article-title><source>Disease Models &amp; Mechanisms</source><volume>7</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1242/dmm.016576</pub-id><pub-id pub-id-type="pmid">24973752</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strømme</surname><given-names>P</given-names></name><name><surname>Dobrenis</surname><given-names>K</given-names></name><name><surname>Sillitoe</surname><given-names>RV</given-names></name><name><surname>Gulinello</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>NF</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><name><surname>Stephney</surname><given-names>G</given-names></name><name><surname>Ellevog</surname><given-names>L</given-names></name><name><surname>Klungland</surname><given-names>A</given-names></name><name><surname>Walkley</surname><given-names>SU</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction</article-title><source>Brain</source><volume>134</volume><fpage>3369</fpage><lpage>3383</lpage><pub-id pub-id-type="doi">10.1093/brain/awr250</pub-id><pub-id pub-id-type="pmid">21964919</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>PM</given-names></name><name><surname>Mezdour</surname><given-names>H</given-names></name><name><surname>Aratani</surname><given-names>Y</given-names></name><name><surname>Knouff</surname><given-names>C</given-names></name><name><surname>Najib</surname><given-names>J</given-names></name><name><surname>Reddick</surname><given-names>RL</given-names></name><name><surname>Quarfordt</surname><given-names>SH</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>17972</fpage><lpage>17980</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.29.17972</pub-id><pub-id pub-id-type="pmid">9218423</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallquist</surname><given-names>MD</given-names></name><name><surname>Soriano</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function</article-title><source>Genesis</source><volume>26</volume><fpage>113</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1002/(sici)1526-968x(200002)26:2&lt;113::aid-gene3&gt;3.0.co;2-2</pub-id><pub-id pub-id-type="pmid">10686601</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trommsdorff</surname><given-names>M</given-names></name><name><surname>Gotthardt</surname><given-names>M</given-names></name><name><surname>Hiesberger</surname><given-names>T</given-names></name><name><surname>Shelton</surname><given-names>J</given-names></name><name><surname>Stockinger</surname><given-names>W</given-names></name><name><surname>Nimpf</surname><given-names>J</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2</article-title><source>Cell</source><volume>97</volume><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80782-5</pub-id><pub-id pub-id-type="pmid">10380922</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Acker</surname><given-names>ZP</given-names></name><name><surname>Bretou</surname><given-names>M</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors</article-title><source>Molecular Neurodegeneration</source><volume>14</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-019-0323-7</pub-id><pub-id pub-id-type="pmid">31159836</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Babu-Khan</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>S</given-names></name><name><surname>Mendiaz</surname><given-names>EA</given-names></name><name><surname>Denis</surname><given-names>P</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Amarante</surname><given-names>P</given-names></name><name><surname>Loeloff</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Edenson</surname><given-names>S</given-names></name><name><surname>Lile</surname><given-names>J</given-names></name><name><surname>Jarosinski</surname><given-names>MA</given-names></name><name><surname>Biere</surname><given-names>AL</given-names></name><name><surname>Curran</surname><given-names>E</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Louis</surname><given-names>JC</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title><source>Science</source><volume>286</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id><pub-id pub-id-type="pmid">10531052</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheijen</surname><given-names>J</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics</article-title><source>Trends in Genetics</source><volume>34</volume><fpage>434</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2018.02.007</pub-id><pub-id pub-id-type="pmid">29573818</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahrle</surname><given-names>S.E</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Legleiter</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Fryer</surname><given-names>JD</given-names></name><name><surname>Kowalewski</surname><given-names>T</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>40987</fpage><lpage>40993</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407963200</pub-id><pub-id pub-id-type="pmid">15269217</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahrle</surname><given-names>S.E</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Hartman</surname><given-names>RE</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>43236</fpage><lpage>43242</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508780200</pub-id><pub-id pub-id-type="pmid">16207708</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahrle</surname><given-names>SE</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Knoten</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Hirsch-Reinshagen</surname><given-names>V</given-names></name><name><surname>Wellington</surname><given-names>CL</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease</article-title><source>The Journal of Clinical Investigation</source><volume>118</volume><fpage>671</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1172/JCI33622</pub-id><pub-id pub-id-type="pmid">18202749</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Jing</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Beta-secretase/BACE1 promotes APP endocytosis and processing in the endosomes and on cell membrane</article-title><source>Neuroscience Letters</source><volume>685</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2018.08.016</pub-id><pub-id pub-id-type="pmid">30120949</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnick</surname><given-names>GR</given-names></name><name><surname>Mayfield</surname><given-names>C</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Hazzard</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3</article-title><source>Clinical Chemistry</source><volume>25</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">215348</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeber</surname><given-names>EJ</given-names></name><name><surname>Beffert</surname><given-names>U</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Christian</surname><given-names>JM</given-names></name><name><surname>Forster</surname><given-names>E</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>39944</fpage><lpage>39952</lpage><pub-id pub-id-type="doi">10.1074/jbc.M205147200</pub-id><pub-id pub-id-type="pmid">12167620</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>HL</given-names></name><name><surname>Rebeck</surname><given-names>GW</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease</article-title><source>Neuroscience Letters</source><volume>175</volume><fpage>46</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(94)91074-x</pub-id><pub-id pub-id-type="pmid">7970208</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wintersteiner</surname><given-names>O</given-names></name><name><surname>Abramson</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="1933">1933</year><article-title>The isoelectric point of insulin: Electrical properties of adsorbed and crystalline insulin</article-title><source>The Journal of Biological Chemistry</source><volume>99</volume><fpage>741</fpage><lpage>753</lpage></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wozniacka</surname><given-names>A</given-names></name><name><surname>Lesiak</surname><given-names>A</given-names></name><name><surname>Narbutt</surname><given-names>J</given-names></name><name><surname>McCauliffe</surname><given-names>DP</given-names></name><name><surname>Sysa-Jedrzejowska</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients</article-title><source>Lupus</source><volume>15</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1191/0961203306lu2299oa</pub-id><pub-id pub-id-type="pmid">16761500</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>X</given-names></name><name><surname>Pohlkamp</surname><given-names>T</given-names></name><name><surname>Durakoglugil</surname><given-names>MS</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Beck</surname><given-names>JK</given-names></name><name><surname>Lane-Donovan</surname><given-names>C</given-names></name><name><surname>Plattner</surname><given-names>F</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease</article-title><source>eLife</source><volume>7</volume><elocation-id>e40048</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.40048</pub-id><pub-id pub-id-type="pmid">30375977</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xinhan</surname><given-names>L</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Numaza</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Mitsui</surname><given-names>K</given-names></name><name><surname>Kanazawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Na + /H + exchanger isoform 6 (NHE6/SLC9A6) is involved in clathrin-dependent endocytosis of transferrin</article-title><source>American Journal of Physiology-Cell Physiology</source><volume>301</volume><fpage>C1431</fpage><lpage>C1444</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00154.2011</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Pescosolido</surname><given-names>MF</given-names></name><name><surname>Pruett</surname><given-names>BS</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Gamsiz Uzun</surname><given-names>ED</given-names></name><name><surname>Lizarraga</surname><given-names>SB</given-names></name><name><surname>Morrow</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of Christianson Syndrome</article-title><source>ENeuro</source><volume>4</volume><elocation-id>ENEURO.0388-17.2017</elocation-id><pub-id pub-id-type="doi">10.1523/ENEURO.0388-17.2017</pub-id><pub-id pub-id-type="pmid">29349289</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Guigard</surname><given-names>E</given-names></name><name><surname>Kay</surname><given-names>CM</given-names></name><name><surname>Ryan</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor</article-title><source>Biochemistry</source><volume>47</volume><fpage>11647</fpage><lpage>11652</lpage><pub-id pub-id-type="doi">10.1021/bi801117t</pub-id><pub-id pub-id-type="pmid">18847225</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><name><surname>Caulfield</surname><given-names>TR</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies</article-title><source>Nature Reviews. Neurology</source><volume>15</volume><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0228-7</pub-id><pub-id pub-id-type="pmid">31367008</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kozicky</surname><given-names>L</given-names></name><name><surname>Saferali</surname><given-names>A</given-names></name><name><surname>Fung</surname><given-names>S-Y</given-names></name><name><surname>Afacan</surname><given-names>N</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Falsafi</surname><given-names>R</given-names></name><name><surname>Gill</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Kollmann</surname><given-names>TR</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name><name><surname>Sly</surname><given-names>LM</given-names></name><name><surname>Turvey</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-inflammatory activity in phagocytic immune cells</article-title><source>Biomaterials</source><volume>111</volume><fpage>90</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.09.032</pub-id><pub-id pub-id-type="pmid">27728817</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanuck</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders</article-title><source>Frontiers in Psychiatry</source><volume>10</volume><elocation-id>712</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2019.00712</pub-id><pub-id pub-id-type="pmid">31632307</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Scholze</surname><given-names>AR</given-names></name><name><surname>O’Keeffe</surname><given-names>S</given-names></name><name><surname>Phatnani</surname><given-names>HP</given-names></name><name><surname>Guarnieri</surname><given-names>P</given-names></name><name><surname>Caneda</surname><given-names>C</given-names></name><name><surname>Ruderisch</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Liddelow</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Wu</surname><given-names>JQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex</article-title><source>The Journal of Neuroscience</source><volume>34</volume><fpage>11929</fpage><lpage>11947</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1860-14.2014</pub-id><pub-id pub-id-type="pmid">25186741</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhuo</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Can</surname><given-names>D</given-names></name><name><surname>Marten</surname><given-names>Y</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>C-C</given-names></name><name><surname>Du</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X-F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Author Correction: Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2923</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10950-2</pub-id><pub-id pub-id-type="pmid">31266955</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler-Waldkirch</surname><given-names>S</given-names></name><name><surname>Meyer-Luehmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimer’s Disease</article-title><source>Frontiers in Cellular Neuroscience</source><volume>12</volume><elocation-id>473</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2018.00473</pub-id><pub-id pub-id-type="pmid">30618627</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72034.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chin</surname><given-names>Jeannie</given-names></name><role>Reviewing Editor</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Morrow</surname><given-names>Eric</given-names></name><role>Reviewer</role><aff><institution>Brown University</institution></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper is of interest to a broad range of neuroscientists, particularly those interested in ApoE biology and Alzheimer's disease (AD), as it reveals a novel mechanism that counteracts AD-linked amyloid plaque burden and synapse dysfunction in mice. Overall, the methodology is sound, sophisticated, and employs animal models that more closely mimic human diseases, and the results are compelling.</p><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting your work entitled &quot;Endosomal Acidification by NHE6-depletion Corrects ApoE4-mediated Synaptic Impairments and Reduces Amyloid Plaque Load&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Eric Morrow (Reviewer #2).</p><p>We are sorry to say that, after consultation with the reviewers, we have decided that your work will not be considered further at this time for publication by <italic>eLife</italic>.</p><p>We would like to emphasize that all 3 reviewers found considerable strengths in your work, particularly the marked reductions in plaques in mice in which NHE6 was ablated or reduced. However, the lack of evidence that microglia and/or astrocytes are activated, take up Abeta, and mediate the plaque clearance in your studies leaves room for alternative explanations that were not addressed. Therefore, the data as they stand now do not strongly confirm the proposed mechanistic hypothesis put forward in your manuscript. This and other concerns listed below in the Reviewers' comments may take substantial time to satisfactorily address, which was the basis for our decision. If you decide to perform additional studies that address these concerns, we encourage you to consider submitting your thoroughly revised manuscript again to <italic>eLife</italic>.</p><p><italic>Reviewer #1:</italic></p><p>In this study, the authors confirm and extend their previous work demonstrating that ApoE4, a major risk for Alzheimer's disease, impairs endocytic recycling of membrane receptors, leading to synaptic dysfunction. Previously, the authors demonstrated in vitro that upon binding to ApoER2 at the plasma membrane and internalization, ApoE4 along with ApoER2 and glutamate receptors become trapped in the early endosome due to the similarity between the isoelectric point of ApoE4 and the pH of early endosomes. Enhancing acidification by inhibiting NHE6, a proton leak channel in the early endosome, restored vesicle recycling and improved synaptic plasticity in AD extract-treated hippocampal slices from ApoE4-KI mice. In the current study, the authors create and use novel NHE6 germline knockout and conditional knockout mouse lines to reduce NHE6 expression and enhance acidification of early endosomes. They confirm their previous findings and also extend their work by crossing NHE6 KO or cKO mice to a knockin, humanized APP mouse that expresses mutant human amyloid precursor protein under control of the endogenous APP promoter, alone or crossed with ApoE4-KI mice. In both cases, reduction of NHE6 resulted in increased Iba1-expressing microglia and GFAP-expressing astrocytes as well as a reduction in plaques. Together these findings highlight the importance of ApoE4's detrimental effect on endosomal recycling in vivo, with consequences for accumulation of AD-related pathology. While the studies presented are well-done and robust, some mechanistic links are missing, which make it difficult to fully support the conclusions drawn.</p><p>Major strengths of this paper include:</p><p>1. The creation of novel germline KO and conditional KO NHE6 mice allow for a number of in vivo investigations that would be difficult to complete otherwise. These mice represent a valuable resource to the field.</p><p>2. Use of the NHE6-KO and cKO mice to confirm the previous findings (that used pharmacological inhibition of NHE6) that enhancing endosomal acidification ameliorates ApoE4-induced deficits in vesicle cycling and synaptic plasticity in vivo. In addition, the finding that NHE6 ablation in APP and APP/ApoE4KI mice robustly reduced plaque accumulation is striking.</p><p>3. The demonstration that BACE-mediated production of APP CTFs is unaltered by NHE6 ablation supports the conclusion that the reduction in plaques is unlikely due to reduction in Abeta generation, but more likely due to clearance of Abeta.</p><p>Weaknesses of this paper include:</p><p>1. The authors conclude that reducing NHE6 clears plaques by activating resident microglia, shifting them from a dormant state to a damage-associated activated state that phagocytoses Abeta plaques. However, there is no data presented to demonstrate this. In a supplemental figure, the authors show there are more Iba1-expressing microglia and GFAP-expressing astroctyes in APP mice and in APP/ApoE4KI mice in which NHE6 has been ablated, but this does not prove that this is the mechanism by which plaques are cleared.</p><p>2. The mechanisms underlying the increase in Iba1 and GFAP are not clear. The authors cite a previous paper from another group that demonstrated in their own NHE6 KO mice, there was an increase in GFAP and in activated microglia expressing CD68, which may relate to the cell loss in hippocampus and other brain regions documented in those mice. However, in the current study, the authors indicate that in their NHE6 KO lines, there is no overt cell loss. It is therefore unclear how reductions in NHE6 expression lead to microglial/astrocyte activation. This is an important point to work out, since the authors conclude that it is microglial activation that is responsible for the reduction in Abeta plaques.</p><p>3. What might be some of the underlying explanations be for the differences between the published NHE6-KO mice, which has fairly widespread cell loss, and the current KO mice generated in this paper, which did not exhibit noticeable cell loss in brain regions other than the cerebellum?</p><p>4. There are a number of mechanistic links that have not been worked out, as indicated above. Until these links are identified and characterized, a number of the conclusions drawn by the authors are not yet supported.</p><p>Specific suggestions for authors:</p><p>1.To better assess whether the Iba1-expressing microglia are truly activated, CD68 should be stained. It would also be extremely compelling to stain for Abeta and demonstrate increased Abeta inside of microglia.</p><p>2. In order to conclude that NHE6 ablation clears plaques BY activating microglia, the authors should deplete microglia and then see whether there is still an effect on plaque load. If there is, that would firmly support their hypothesis; but if eliminating microglia has no effect on plaques, it would suggest that there are other mechanisms at play.</p><p>3. Careful assessment of cell viability/death in the NHE6 mice (and related crosses) should be done. It is puzzling why the NHE6 KO lines here would show such differences in level of cell loss, relative to the study by Xu et al. It is an important point though, because (1) it could help provide a mechanism by which microglia get activated. (2) it is necessary to fully appreciate the LTP studies – the Xu et al. paper indicated cell loss in the hippocampus, including the CA3-CA1 synapses, but there was no cell loss in KO or cKO described in this paper.</p><p>4. Some speculation is warranted to discuss the possible mechanisms that lead from loss of NHE6 to activation of microglia, since it is what the authors conclude is happening.</p><p><italic>Reviewer #2:</italic></p><p>This is a strong and interesting manuscript which examines innovative new hypotheses that have broad relevance to Alzheimer's disease pathophysiology as well as potential new therapeutics. Pohlkamp, Herz and colleagues study the role NHE6 in several orthogonal studies related to production and deposition of amyloid plaques. The use of various different experimental approaches as well as the use of advance mouse genetics is a strength.</p><p>The authors demonstrate several important findings that are robustly supported by the data including: late loss of NHE6 leads to Purkinje cell degeneration; recycling defects in surface receptors relevant to AD and APOE4, namely APOER2 and Glu receptors is improved by deletion of NHE6; NHE6 KO restores Reelin enhancement of LTP inhibited by APOE4; and profound decrease in plaque deposition due to NHE6 mutation.</p><p>The data are well presented in general and compelling. There are many strengths. The PC findings are important in the field of Christianson Syndrome. The reductions in plaque load in the NHE6 null brains are VERY interesting. The mouse genetics, including the conditional mutation -- presentation of a new cKO NHE6 mouse, the humanized Abeta and APOE4 alleles, are truly elegant. Some of the experiments are uniquely supported by the prior findings from the lab relating to Reelin effects on endocytosis and trafficking and effects on LTP, and this is a very important strength. I do not see major weaknesses with the experiments as presented.</p><p>I believe that this work will have broad interest and this work and prior work of the Herz lab in the area of NHE6 as it may relate to therapeutics in AD is developing into a unique niche with potential strong impact in AD therapeutics.</p><p><italic>Reviewer #3:</italic></p><p>In this manuscript, Pohlkamp, Xian, Wang et al. investigated the role of the sodium-hydrogen exchanger NHE6 in synaptic plasticity and Aβ plaque load in a mouse model of Alzheimer's disease (AD) in the presence or absence of Apolipoprotein E4 (APOE4), a major genetic risk factor for sporadic AD. They initially report that NHE6 deletion causes cerebellar neurodegeneration. They find that genetic deletion of NHE6 alleviates impairments in reelin-induced synaptic plasticity in mice expressing human APOE4. The main novelty of this study is that NHE6 suppression significantly reduced amyloid plaque load in a mouse model of AD expressing humanized Aβ, either in the presence or absence of ApoE4. This is interesting, as it potentially opens new roads to understand and control amyloid pathology in the AD brain. Although the data are intriguing and relevant for the community, some issues need to be addressed so that conclusions are justified by data:</p><p>1) The leading hypothesis of this work is that APOE4 impairs synapse function through prolonged association with endosomes, thereby making brain cells vulnerable to AD-related pathological changes. However, the positive effects of NHE6 in a mouse model of Aβ accumulation occurs regardless of APOE4. This suggests that NHE6 may contribute to pathology by mechanisms other than APOE4-mediated retention of endosomal trafficking.</p><p>2) With the current data, it is not possible to exclude possible nonspecific effects resulting from NHE6 genetic deletion. Additional experiments to measure the endosomal pH would add support to the hypothesis.</p><p>3) The authors attribute reduced amyloid plaque load in NHE6-deficient APP KI mice to increased glial responses, which would promote plaque clearance. This is a very interesting hypothesis, but it is not supported by the experimental data reported in Supplemental Figure 6. Additional experimentation is needed to more thoroughly characterize astrocytic and microglial phenotypes caused by NHE6 genetic depletion in APP KI mice. Functional assays, including cytokine release, nitric oxide production (Griess reaction), and Aβ uptake experiments would be desired to strengthen these conclusions.</p><p>4) The authors demonstrate that global or conditional NHE6 deletion causes severe Purkinje cell loss in the mouse cerebellum (Figure 2). Although the authors included representative images of H&amp;E staining indicating no gross histological abnormalities (Supplemental Figure 3), a more detailed investigation is required to assess neuronal survival in the hippocampus and cortex upon NHE6 suppression, given the relevance of these regions to AD pathology. Indeed, previous evidence (Xu et al., eNeuro, 2017) showed that NHE6 depletion leads to significant cortical and hippocampal atrophy, in addition to the cerebellum. Could the reductions in plaque load in NHE6 depleted mice (Figure 5, 6; Supplemental Figure 5) be somehow a reflection of neuronal loss? It is important that the authors discuss this issue in the manuscript.</p><p>5) Even though it is an important control assessment, data on cerebellar neurodegeneration (in addition to eventual new data on other brain regions to be included in the manuscript) could be moved to the supplementary file. Conversely, data on glial activation (in addition to eventual new data) could be moved to the main figures.</p><p>6) The authors should thoroughly revise their manuscript to make it more concise and straightforward. In particular, the Introduction and Discussion are excessively long and include several pieces of information that are not essential to understand the study.</p><p>7) It would be helpful to include a paragraph discussing the limitations of this study in the Discussion. In a revised Discussion section, it would also be relevant to comment on previous studies assessing potential behavioral, neuroinflammatory, and neurodegenerative phenotypes caused by NHE6 disruption (e.g. Xu et al., eNeuro, 2017; Petitjean et al., Pain, 2020) in mice. Authors should also comment on the apparently contradictory findings by Prasad and Rao, PNAS, 2018.</p><p>8) Statistical analyses need to be particularly revised for consistency. Data normality should be assessed, and suitable tests should be performed for each data set. Sample size description is often conflicting between graphs and figure legends, and the appropriate statistical tests have not been performed in all cases. For the sake of transparency, all bar graphs should be replaced by scatter dot plots.</p><p>9) A remaining question is whether NHE6 deletion does provide any cognitive benefit to APP KI mice.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;NHE6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque Load&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Jonathan Cooper (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.</p><p>The manuscript has been improved by the inclusion of new experiments and toning down of the text and conclusions drawn to better reflect what the data demonstrate. However, there are some remaining issues that need to be addressed, without additional experiments, as outlined below.</p><p>1. The new experiments that co-stained Abeta and Iba1 indicate that loss of NHE6 does not increase microglia around plaques, nor does it increase Abeta inside of microglia. The authors state that the results suggest increased efficiency of microglia in degrading Abeta. However, those results are also consistent with a lack of a role of microglia in the reduction of plaques in this case. Results from other studies have demonstrated that microglia can clear plaques, so this might be the most logical conclusion here as well, but no data to support this conclusion is presented in this manuscript. Therefore, the following is suggested:</p><p>1a. Further toning down of the manuscript; for example, at the end of the last Results section (page 20). The authors should remove the last statement that the mechanisms that lead to reduced plaque load in NHE6 deficient APP mice may involve increased catabolic rate, brought about by accelerated acidification and vesicular trafficking of early endosomes. There are two statements there for which the authors have not presented evidence – (1) that there is an increased catabolic rate, and (2) that accelerated acidification and endosomal trafficking increased catabolic rate. If the authors wish, they can discuss these possibilities in the discussion, and clearly state that these are speculations, but these statements should not be in the Results section.</p><p>1b. Clearer summary and discussion of the relative effects of NHE6 in neurons vs microglia or astrocytes.</p><p>1c. In the first paragraph of the discussion, the authors state that loss of NHE6 &quot;suppressed&quot; amyloid deposition. However, the data do not clearly distinguish whether there is reduction of deposition or enhancement of clearance. Perhaps saying that &quot;loss of NHE6 reduces Abeta accumulation&quot; may be more appropriate.</p><p>2. The Results sections describing the new data for (lack of) neuronal loss and co-staining of Abeta and Iba1/GFAP need to be edited and streamlined. There seems to be some inconsistency in the references to figures. Either the references are not in the right order, or the way they are referred to is not as streamlined as it could be.</p><p>3. The new discussion of the contradictory results related to Prasad and Rao 2018 highlights the difference between tissue culture versus genetically engineered mice as a possible reason underlying the discrepant results, but how about the difference of astrocyte vs neurons? Prasad an Rao overexpressed NHE6 in astrocytes, whereas the current manuscript manipulated primary neurons or mice. Such discussion would also enhance the readers' understanding of the relative roles of NHE6 in neurons vs microglia and astrocytes.</p><p>4. The authors state: &quot;Xu et al. (2017) reported neuronal loss in the cortex and hippocampus of NHE6-KO mice, which we were able to reproduce in our germline NHE6-KO model (Supplemental Figure S3).&quot;</p><p>Xu et al. (2017) examined tissue area. Xu et al. (2017) did not examine &quot;neuronal loss&quot; in cortex and hippocampus. The authors might agree that neuronal loss would reflect an observation wherein there is a measurable loss of neurons, ie counts of neurons are reduced. Instead, the studies reflect measurements of tissue area.</p><p>This underscores another new and important finding in the manuscript as stated: &quot;We measured brain size, cortical thickness, hippocampal area, and CA1 thickness. In contrast to germline NHE6-KO mice (Supplemental Figure S3) none of the analyzed parameters differed significantly between NHE6- cKO and controls (Figure 5 E-I).&quot;</p><p>These results could argue that the decrease tissue area in NHE6-KO, that is not seen in the NHE6-cKO, is due to undergrowth of cortex and hippocampus, ie the reduced tissue area in the NHE6-KO is a developmental effect due to loss of NHE6 during development. This would be predicted by the postnatal microcephaly seen in patients. This was also predicted by modeling in the Xu et al. paper: &quot;The cerebrum data do fit an undergrowth-only model, with a similar degenerative rate as wild-type animals. The cerebellum strongly supports a mixed scenario of both undergrowth and enhanced neurodegeneration…&quot; Further, Xu et al. describe that ventricle size is not vastly enlarged which might be predicted by neurodegeneration.</p><p>If the authors agree, the authors should consider editing their writing to reflect that Xu et al. did not look at &quot;neuronal loss&quot;, and further, they may consider adding this interpretation of the difference between the tissue area in the NHE6-KO vs their NHE6-cKO to the discussion, ie that this may be a developmental effect.</p><p>5. Introduction: The authors may wish to consider shortening the first paragraph of the introduction, which is quite long (lines 2-43).</p><p>6. Abstract (line 13): change &quot;amyloid&quot; to &quot;plaque load&quot;.</p><p>7. Experimental procedures:</p><p>7a. page 7, line 28: change &quot;for primer&quot; to &quot;forward primer&quot;.</p><p>7b. page 8, lines 12-13: details (i.e. host, dilution, and catalog number) of antibodies raised against GFAP, IBA1, and Aβ should be provided.</p><p>7c. More details on the pH measurements should be provided. How many fields on each coverslip were quantified? How many vesicles per field were quantified? What was considered an experimental &quot;n&quot; (Supplemental Figure S1E-F)?</p><p>8. Results: In page 19 (lines 4-5) the conclusion is not related to the results presented in this paragraph. Results related to glial activation are only presented in the following paragraph.</p><p>9. Figure legends:</p><p>9a. Figure 2B: please specify the sample size.</p><p>9b. Figure 4: the phrase &quot;Conditional knockout of NHE6 in ApoE4-KI mice attenuates reelin-enhanced long-term potentiation&quot; is confusing and should be clarified.</p><p>9c. Supplemental Figure S1-E-F: statistical tests should be specified.</p><p>9d. Supplemental Figure S3: the reported sample sizes differ between the figure and the legend, which needs to be reconciled for accuracy.</p><p>10. Discussion: In page 20, lines 19-20: the phrase &quot;hyper acidification of early endosomes occludes the effect of all ApoE forms on amyloid plaque formation&quot; would be more accurate and easier to read if written as &quot;hyper acidification of early endosomes prevents amyloid plaque formation independently of ApoE4&quot;.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72034.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…]</p><p>Weaknesses of this paper include:</p><p>1. The authors conclude that reducing NHE6 clears plaques by activating resident microglia, shifting them from a dormant state to a damage-associated activated state that phagocytoses Abeta plaques. However, there is no data presented to demonstrate this. In a supplemental figure, the authors show there are more Iba1-expressing microglia and GFAP-expressing astroctyes in APP mice and in APP/ApoE4KI mice in which NHE6 has been ablated, but this does not prove that this is the mechanism by which plaques are cleared.</p></disp-quote><p>We apologize for the overstatement. We agree, we have not evaluated whether NHE6 depletion causes a signature of damage-associated microglia. Thus, we have removed this comment from the manuscript (abstract).</p><disp-quote content-type="editor-comment"><p>2. The mechanisms underlying the increase in Iba1 and GFAP are not clear. The authors cite a previous paper from another group that demonstrated in their own NHE6 KO mice, there was an increase in GFAP and in activated microglia expressing CD68, which may relate to the cell loss in hippocampus and other brain regions documented in those mice. However, in the current study, the authors indicate that in their NHE6 KO lines, there is no overt cell loss. It is therefore unclear how reductions in NHE6 expression lead to microglial/astrocyte activation. This is an important point to work out, since the authors conclude that it is microglial activation that is responsible for the reduction in Abeta plaques.</p></disp-quote><p>We agree that identifying the mechanism how NHE6 depletion causes glial activation is crucial. We and others show that germline NHE6 depletion causes glial activation. Moreover, our current data suggest that genetic deletion of NHE6 in both germline and from adulthood on causes glial activation. Neuronal cell loss is a potential explanation for glial activation. We found cerebellar Purkinje cell loss in both of our NHE6 mutant lines. As stated in the old version of our manuscript we find “Normal Gross Anatomical Brain Structure in Both NHE6-KO and NHE6cKO Mice” (Supplementary Figure S3). To address whether neuronal loss occurs in the hippocampus or cortex, as described for NHE6-KO mice in Xu et al., 2017, we measured neuronal loss in both NHE6 mutant lines. Comparable to Xu et al., in the NHE6-KO line we detect a reduction in total brain area, HC area, cortical thickness and CA1 thickness. By contrast, in our NHE6-cKO;APP-KI;ApoE4-KI mice we do not observe any neuronal loss when compared to NHE6-floxed,APP<sup>NL-F</sup>,ApoE4-KI littermate controls; however, we detect similar glial activation in the NHE6-cKO;APP<sup>NL-F</sup>;ApoE4-KI mice as compared to the germline NHE6KO,APP<sup>NL-F</sup> mice. This suggests that the neuronal loss in the germline NHE6-KO model does not mediate glial activation. Lastly, we have removed the statement that the microglial activation is the reason why we detect Aβ reduction and included a discussion of our new findings.</p><disp-quote content-type="editor-comment"><p>3. What might be some of the underlying explanations be for the differences between the published NHE6-KO mice, which has fairly widespread cell loss, and the current KO mice generated in this paper, which did not exhibit noticeable cell loss in brain regions other than the cerebellum?</p></disp-quote><p>Our previous manuscript stated that there are no gross anatomical abnormalities in the NHE6KO mice. However, we appreciate the reviewer’s concerns as it prompted us to analyze neuronal loss in NHE6-KO versus NHE6-cKO mice. Besides Purkinje cell loss in both lines, and as stated above, we do detect cell loss in the hippocampus and cortex in our germline NHE6KO mouse model, but not in the tamoxifen induced NHE6-cKO mice.</p><disp-quote content-type="editor-comment"><p>4. There are a number of mechanistic links that have not been worked out, as indicated above. Until these links are identified and characterized, a number of the conclusions drawn by the authors are not yet supported.</p></disp-quote><p>We thank the reviewer for the constructive feedback. We have removed these conclusions.</p><disp-quote content-type="editor-comment"><p>Specific suggestions for authors:</p><p>1.To better assess whether the Iba1-expressing microglia are truly activated, CD68 should be stained. It would also be extremely compelling to stain for Abeta and demonstrate increased Abeta inside of microglia.</p></disp-quote><p>We thank the reviewer for this suggestion. Whereas we had too much non-specific background with the CD68 staining (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>), we successfully co-stained Aβ with Iba1 and GFAP similar to others (Feng, W., et al., Alzheimers Res. Ther., 2020; Monasor, L., et al., <italic>ELife</italic>, 2020; Pomilio, C., et al., Geroscience, 2020; Parhizkar, S., Nat. Neurosci., et al., 2019; Zhon, L., et al., Nat. Commun., 2019). We did not detect a significant difference between genotypes in Aβ inside microglia. In addition, we quantified the amount of microglia and astrocytes surrounding plaques, with no significant differences between genotypes (NHE6-KO;APP<sup>NL-F</sup> and APP<sup>NL-F</sup>). As NHE6-KO mice show less plaque/Aβ-staining while having increased immunoreactivity for GFAP and Iba1, the fact that the proportion of microglia containing Aβ is equal to control indirectly suggests that the microglia are indeed more efficient in Aβ uptake and degradation. This hypothesis will be tested in future studies to evaluate Aβ uptake in primary microglia derived from NHE6-KO mice. We discussed our findings in the manuscript accordingly.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72034-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2. In order to conclude that NHE6 ablation clears plaques BY activating microglia, the authors should deplete microglia and then see whether there is still an effect on plaque load. If there is, that would firmly support their hypothesis; but if eliminating microglia has no effect on plaques, it would suggest that there are other mechanisms at play.</p></disp-quote><p>We thank the reviewer for this suggestion. We are currently in the process of obtaining the animal approval for depleting the microglia in our mouse model. Future experiments will allow us to evaluate whether depleting the activated microglial affects the reduction of Aβ plaques.</p><disp-quote content-type="editor-comment"><p>3. Careful assessment of cell viability/death in the NHE6 mice (and related crosses) should be done. It is puzzling why the NHE6 KO lines here would show such differences in level of cell loss, relative to the study by Xu et al. It is an important point though, because (1) it could help provide a mechanism by which microglia get activated. (2) it is necessary to fully appreciate the LTP studies – the Xu et al. paper indicated cell loss in the hippocampus, including the CA3-CA1 synapses, but there was no cell loss in KO or cKO described in this paper.</p></disp-quote><p>As stated above, we evaluated cell loss in both the NHE6-KO and NHE6-cKO lines. In contrast to germline NHE6-KO mice, we did not detect cell loss in the cortex or hippocampus of the tamoxifen induced NHE6-cKO line, which was used in the electrophysiological studies. We agree with the reviewer that these novel data are crucial to better understand if NHE6-loss is a primary or secondary factor to induce glia activation.</p><disp-quote content-type="editor-comment"><p>4. Some speculation is warranted to discuss the possible mechanisms that lead from loss of NHE6 to activation of microglia, since it is what the authors conclude is happening.</p></disp-quote><p>We have added more potential mechanism in the discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>In this manuscript, Pohlkamp, Xian, Wang et al. investigated the role of the sodium-hydrogen exchanger NHE6 in synaptic plasticity and Aβ plaque load in a mouse model of Alzheimer's disease (AD) in the presence or absence of Apolipoprotein E4 (APOE4), a major genetic risk factor for sporadic AD. They initially report that NHE6 deletion causes cerebellar neurodegeneration. They find that genetic deletion of NHE6 alleviates impairments in reelin-induced synaptic plasticity in mice expressing human APOE4. The main novelty of this study is that NHE6 suppression significantly reduced amyloid plaque load in a mouse model of AD expressing humanized Aβ, either in the presence or absence of ApoE4. This is interesting, as it potentially opens new roads to understand and control amyloid pathology in the AD brain. Although the data are intriguing and relevant for the community, some issues need to be addressed so that conclusions are justified by data:</p><p>1) The leading hypothesis of this work is that APOE4 impairs synapse function through prolonged association with endosomes, thereby making brain cells vulnerable to AD-related pathological changes. However, the positive effects of NHE6 in a mouse model of Aβ accumulation occurs regardless of APOE4. This suggests that NHE6 may contribute to pathology by mechanisms other than APOE4-mediated retention of endosomal trafficking.</p></disp-quote><p>We agree with the reviewer that NHE6 depletion plays a protective role in AD both by protecting against synaptic impairments in ApoE4-KI mice and Aβ toxicity in an Aβ overproducing mouse model. This may reflect a beneficial effect of endosomal compartment acidification through NHE6 depletion. Our current work and studies by others (Fagan, A.M., et al., Neurobio. of Dis. 2002) show that human Aβ-overproducing ApoE4-KI mice generate plaques at a much later age than mice with wildtype, mouse ApoE, but the mechanism is unknown. Since both of our mouse models, NHE6-KO and NHE6-cKO;ApoE4-KI show a comparable reduction in plaque load, this might be the result of a maximally accelerated early endosomal maturation and cargo transport in the absence of NHE6. We elaborated on this in topic in the discussion of our manuscript.</p><disp-quote content-type="editor-comment"><p>2) With the current data, it is not possible to exclude possible nonspecific effects resulting from NHE6 genetic deletion. Additional experiments to measure the endosomal pH would add support to the hypothesis.</p></disp-quote><p>We agree with the reviewer’s concern and addressed this in the discussion accordingly.</p><disp-quote content-type="editor-comment"><p>3) The authors attribute reduced amyloid plaque load in NHE6-deficient APP KI mice to increased glial responses, which would promote plaque clearance. This is a very interesting hypothesis, but it is not supported by the experimental data reported in Supplemental Figure 6. Additional experimentation is needed to more thoroughly characterize astrocytic and microglial phenotypes caused by NHE6 genetic depletion in APP KI mice. Functional assays, including cytokine release, nitric oxide production (Griess reaction), and Aβ uptake experiments would be desired to strengthen these conclusions.</p></disp-quote><p>We thank the reviewer for this valuable feedback. In our revised manuscript, we evaluated whether there is a change of microglial Ab content in the NHE6 depletion mouse model. We also quantified the immunoreactivity of Iba1 and GFAP in plaque areas. We found no change between NHE6-KO or control littermate APP<sup>NL-F</sup> controls when we co-stained with Aβ and Iba1 (microglia) or GFAP (astrocyte). However, when considering a massively reduced Aβ signal in NHE6-KO brains overall, yet the proportion of microglia containing Aβ is comparable to control, this indirectly indicates that NHE6 deficient microglia are more efficient in Aβ uptake and degradation. We agree with the reviewers that future studies will be required to evaluate Aβ uptake in primary microglia derived from NHE6-KO mice to properly conclude that the reduction of Aβ is mediated by enhance glial activation. Thus, we have adjusted our conclusions in the manuscript accordingly.</p><disp-quote content-type="editor-comment"><p>4) The authors demonstrate that global or conditional NHE6 deletion causes severe Purkinje cell loss in the mouse cerebellum (Figure 2). Although the authors included representative images of H&amp;E staining indicating no gross histological abnormalities (Supplemental Figure 3), a more detailed investigation is required to assess neuronal survival in the hippocampus and cortex upon NHE6 suppression, given the relevance of these regions to AD pathology. Indeed, previous evidence (Xu et al., eNeuro, 2017) showed that NHE6 depletion leads to significant cortical and hippocampal atrophy, in addition to the cerebellum. Could the reductions in plaque load in NHE6 depleted mice (Figure 5, 6; Supplemental Figure 5) be somehow a reflection of neuronal loss? It is important that the authors discuss this issue in the manuscript.</p></disp-quote><p>We thank the reviewer for this suggestion. We have now measured brain area, hippocampal area, cortical and CA1 thickness. Comparable to Xu et al., we detect a reduction in total brain area, HC area, cortical thickness and CA1 thickness. Contrary, in our NHE6-cKO;APP<sup>NFL</sup>;ApoE4-KI mice we do not see any neuronal loss; however, we detect similar plaque reduction and glial activation in the NHE6-KO;APP<sup>NL-F</sup> mice. These findings suggest that the neuronal loss does not mediate the reduction in plaque load or glial activation. We discussed our findings in our manuscript accordingly.</p><disp-quote content-type="editor-comment"><p>5) Even though it is an important control assessment, data on cerebellar neurodegeneration (in addition to eventual new data on other brain regions to be included in the manuscript) could be moved to the supplementary file. Conversely, data on glial activation (in addition to eventual new data) could be moved to the main figures.</p></disp-quote><p>We thank the reviewer for the suggestion. We included new data on neuronal loss in additional brain regions of the NHE6 mutant mice. As specific findings on germline NHE6-KO mice are already published by others (and now reproduced by us), we decided to keep our results on NHE6-KO in the supplements, while keeping the novel results on NHE6-cKO in the main figures. Our novel data on glia and Aβ co-labeling are now included in the main manuscript, Figure 7.</p><disp-quote content-type="editor-comment"><p>6) The authors should thoroughly revise their manuscript to make it more concise and straightforward. In particular, the Introduction and Discussion are excessively long and include several pieces of information that are not essential to understand the study.</p></disp-quote><p>We thank the reviewer for this comment and shortened the introduction. While adding several points to our discussion, based on reviewers’ suggestions and novel findings, we also shortened it by removing the paragraph addressing NHE6 C-terminal interactions, since it is not relevant to understand the study.</p><disp-quote content-type="editor-comment"><p>7) It would be helpful to include a paragraph discussing the limitations of this study in the Discussion. In a revised Discussion section, it would also be relevant to comment on previous studies assessing potential behavioral, neuroinflammatory, and neurodegenerative phenotypes caused by NHE6 disruption (e.g. Xu et al., eNeuro, 2017; Petitjean et al., Pain, 2020) in mice. Authors should also comment on the apparently contradictory findings by Prasad and Rao, PNAS, 2018.</p></disp-quote><p>We thank the reviewer for this suggestion and have added new paragraphs to our discussion that also address limitations of our study. We also discussed the findings by Prasad and Rao (Prasad, H. and Rao, R., PNAS 2018).</p><disp-quote content-type="editor-comment"><p>8) Statistical analyses need to be particularly revised for consistency. Data normality should be assessed, and suitable tests should be performed for each data set. Sample size description is often conflicting between graphs and figure legends, and the appropriate statistical tests have not been performed in all cases. For the sake of transparency, all bar graphs should be replaced by scatter dot plots.</p></disp-quote><p>We thank the reviewer for pointing this out. We carefully went through the statistics and the numbers. Corrections have been made for figure legends 6, S5, and S6. Scatter dot plots have been provided for Figure 3 and 7.</p><disp-quote content-type="editor-comment"><p>9) A remaining question is whether NHE6 deletion does provide any cognitive benefit to APP KI mice.</p></disp-quote><p>We agree with the reviewer that behavioral insights would be compelling. However, APP<sup>NL-F</sup> mice do not show behavioral abnormalities until at least 18 months of age (Saito et al., 2014). In addition, when we bred APP<sup>NL-F</sup> with ApoE4 and ApoE3 mice, we were not able to detect differences in the Morris Water Maze test between ApoE genotype, either. Thus, we are unable to determine whether NHE6 depletion provides any cognitive benefits in the APP<sup>NL-F</sup> mouse line. We addressed this in our revised discussion.</p><p>[Editors’ note: what follows is the authors’ response to the second round of review.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved by the inclusion of new experiments and toning down of the text and conclusions drawn to better reflect what the data demonstrate. However, there are some remaining issues that need to be addressed, without additional experiments, as outlined below.</p><p>1. The new experiments that co-stained Abeta and Iba1 indicate that loss of NHE6 does not increase microglia around plaques, nor does it increase Abeta inside of microglia. The authors state that the results suggest increased efficiency of microglia in degrading Abeta. However, those results are also consistent with a lack of a role of microglia in the reduction of plaques in this case. Results from other studies have demonstrated that microglia can clear plaques, so this might be the most logical conclusion here as well, but no data to support this conclusion is presented in this manuscript. Therefore, the following is suggested:</p><p>1a. Further toning down of the manuscript; for example, at the end of the last Results section (page 20). The authors should remove the last statement that the mechanisms that lead to reduced plaque load in NHE6 deficient APP mice may involve increased catabolic rate, brought about by accelerated acidification and vesicular trafficking of early endosomes. There are two statements there for which the authors have not presented evidence – (1) that there is an increased catabolic rate, and (2) that accelerated acidification and endosomal trafficking increased catabolic rate. If the authors wish, they can discuss these possibilities in the discussion, and clearly state that these are speculations, but these statements should not be in the Results section.</p></disp-quote><p>We agree that this last statement should be removed from our Results section and added to the discussion (Page 24).</p><disp-quote content-type="editor-comment"><p>1b. Clearer summary and discussion of the relative effects of NHE6 in neurons vs microglia or astrocytes.</p></disp-quote><p>We have added a detailed discussion (Page 25) on the effects of NHE6 in various cell types (neurons, microglia or astrocytes).</p><disp-quote content-type="editor-comment"><p>1c. In the first paragraph of the discussion, the authors state that loss of NHE6 &quot;suppressed&quot; amyloid deposition. However, the data do not clearly distinguish whether there is reduction of deposition or enhancement of clearance. Perhaps saying that &quot;loss of NHE6 reduces Abeta accumulation&quot; may be more appropriate.</p></disp-quote><p>We have adjusted this statement in our discussion (Page 20).</p><disp-quote content-type="editor-comment"><p>2. The Results sections describing the new data for (lack of) neuronal loss and co-staining of Abeta and Iba1/GFAP need to be edited and streamlined. There seems to be some inconsistency in the references to figures. Either the references are not in the right order, or the way they are referred to is not as streamlined as it could be.</p></disp-quote><p>We apologize for any confusion and have made the requested modifications to help streamline the figures and text, which is located on page 18 and 19.</p><disp-quote content-type="editor-comment"><p>3. The new discussion of the contradictory results related to Prasad and Rao 2018 highlights the difference between tissue culture versus genetically engineered mice as a possible reason underlying the discrepant results, but how about the difference of astrocyte vs neurons? Prasad an Rao overexpressed NHE6 in astrocytes, whereas the current manuscript manipulated primary neurons or mice. Such discussion would also enhance the readers' understanding of the relative roles of NHE6 in neurons vs microglia and astrocytes.</p></disp-quote><p>We apologize for any confusion, and we made corrections to this paragraph. Previously, we referred to astrocytes when in fact Prasad and Rao used HEK293 cells (Prasad and Rao, 2015) to look at Ab generation. We have added additional text to explain the discrepant results (page 23) and included section for the readers about the relative roles of NHE6 in neurons versus microglia and astrocytes (Page 25, see Reviewer Comment 1b).</p><disp-quote content-type="editor-comment"><p>4. The authors state: &quot;Xu et al. (2017) reported neuronal loss in the cortex and hippocampus of NHE6-KO mice, which we were able to reproduce in our germline NHE6-KO model (Supplemental Figure S3).&quot;</p><p>Xu et al. (2017) examined tissue area. Xu et al. (2017) did not examine &quot;neuronal loss&quot; in cortex and hippocampus. The authors might agree that neuronal loss would reflect an observation wherein there is a measurable loss of neurons, ie counts of neurons are reduced. Instead, the studies reflect measurements of tissue area.</p><p>This underscores another new and important finding in the manuscript as stated: &quot;We measured brain size, cortical thickness, hippocampal area, and CA1 thickness. In contrast to germline NHE6-KO mice (Supplemental Figure S3) none of the analyzed parameters differed significantly between NHE6- cKO and controls (Figure 5 E-I).&quot;</p><p>These results could argue that the decrease tissue area in NHE6-KO, that is not seen in the NHE6-cKO, is due to undergrowth of cortex and hippocampus, ie the reduced tissue area in the NHE6-KO is a developmental effect due to loss of NHE6 during development. This would be predicted by the postnatal microcephaly seen in patients. This was also predicted by modeling in the Xu et al. paper: &quot;The cerebrum data do fit an undergrowth-only model, with a similar degenerative rate as wild-type animals. The cerebellum strongly supports a mixed scenario of both undergrowth and enhanced neurodegeneration…&quot; Further, Xu et al. describe that ventricle size is not vastly enlarged which might be predicted by neurodegeneration.</p><p>If the authors agree, the authors should consider editing their writing to reflect that Xu et al. did not look at &quot;neuronal loss&quot;, and further, they may consider adding this interpretation of the difference between the tissue area in the NHE6-KO vs their NHE6-cKO to the discussion, ie that this may be a developmental effect.</p></disp-quote><p>We thank the reviewer for this valuable discussion of our findings and the important point clarifying Xu et al. We have revised discussion accordingly and included detailed discussion of the Xu et al. findings in the context of our results (Page 18, 19, and 25).</p><disp-quote content-type="editor-comment"><p>5. Introduction: The authors may wish to consider shortening the first paragraph of the introduction, which is quite long (lines 2-43).</p></disp-quote><p>We appreciate this comment and we have accordingly introduced line breaks into the first paragraph (Page 3).</p><disp-quote content-type="editor-comment"><p>6. Abstract (line 13): change &quot;amyloid&quot; to &quot;plaque load&quot;.</p></disp-quote><p>We’ve changed this text in the abstract.</p><disp-quote content-type="editor-comment"><p>7. Experimental procedures:</p><p>7a. page 7, line 28: change &quot;for primer&quot; to &quot;forward primer&quot;.</p><p>7b. page 8, lines 12-13: details (i.e. host, dilution, and catalog number) of antibodies raised against GFAP, IBA1, and Aβ should be provided.</p><p>7c. More details on the pH measurements should be provided. How many fields on each coverslip were quantified? How many vesicles per field were quantified? What was considered an experimental &quot;n&quot; (Supplemental Figure S1E-F)?</p></disp-quote><p>We have added these experimental details to the experimental procedures.</p><disp-quote content-type="editor-comment"><p>8. Results: In page 19 (lines 4-5) the conclusion is not related to the results presented in this paragraph. Results related to glial activation are only presented in the following paragraph.</p></disp-quote><p>We have adjusted the text accordingly.</p><disp-quote content-type="editor-comment"><p>9. Figure legends:</p><p>9a. Figure 2B: please specify the sample size.</p><p>9b. Figure 4: the phrase &quot;Conditional knockout of NHE6 in ApoE4-KI mice attenuates reelin-enhanced long-term potentiation&quot; is confusing and should be clarified.</p><p>9c. Supplemental Figure S1-E-F: statistical tests should be specified.</p><p>9d. Supplemental Figure S3: the reported sample sizes differ between the figure and the legend, which needs to be reconciled for accuracy.</p></disp-quote><p>We apologize for the oversight and typos. We have adjusted the text accordingly.</p><disp-quote content-type="editor-comment"><p>10. Discussion: In page 20, lines 19-20: the phrase &quot;hyper acidification of early endosomes occludes the effect of all ApoE forms on amyloid plaque formation&quot; would be more accurate and easier to read if written as &quot;hyper acidification of early endosomes prevents amyloid plaque formation independently of ApoE4&quot;.</p></disp-quote><p>We have changed this text.</p></body></sub-article></article>